

RFP Number: S14-199
Subcontract Number: 14X262
Washington University in St. Louis

Systematic Reviews to Inform Research and Treatment for Multi-Morbidities

660 S. Euclid Avenue, Campus Box 8100
St. Louis, Missouri, 63110-8109
314-454-7939

Final Systematic Review Report
October 23, 2015

PI: Graham A. Colditz, MD, DrPH

Report Submitted By: Carolyn Stoll, MPH, MSW
Period covered by report: 9/25/2014-9/25/2015

Contents

| | |
|---|-----|
| Final Report Instructions..... | 3 |
| A. Executive Summary, including objectives and main findings..... | 4 |
| B. Key Personnel | 6 |
| C. Background, including information on the relevance of multiple chronic conditions in behavioral and psychosocial intervention research | 6 |
| D. Research question(s) and study objectives..... | 8 |
| E. Methods..... | 9 |
| F. Main results of the review in answering the initial research question(s)..... | 15 |
| G. Discussion and Conclusions..... | 28 |
| H. Implications for further research..... | 30 |
| I. References | 32 |
| Appendix A: Deliverables..... | 36 |
| Appendix B: Additional Information..... | 39 |
| 1. Protocol..... | 39 |
| 2. Differences between protocol and report..... | 46 |
| 3. Search Strategy | 47 |
| 4. Reader training materials | 59 |
| 5. Extraction codebook | 61 |
| 6. Included studies | 81 |
| 7. Key informant information | 119 |

Final Report Instructions

Use the template below as a guide for producing the Systematic Review Report. The sections and information requested follow the Deliverables description from the Agreement Statement of Work. If any information requested below was not included in the project, include a brief description of why it was omitted. Additional results or conclusions produced during performance of the agreement may also be included.

Please submit the Final Report in electronic format to the following individuals:

| Name | E-Mail Address |
|------------------|--|
| Elisa Ahmanson | elisa.ahmanson@fnlcr.nih.gov |
| Christen Osburn | christen.osburn@fnlcr.nih.gov |
| Becky Pastorella | pastorellarj@mail.nih.gov |

A. Executive Summary, including objectives and main findings

Background:

As the population with multiple chronic conditions (MCC) increases, it is essential that randomized controlled trials (RCTs) include MCC to ensure the appropriateness of applying trial results to the broader population. However, previous reviews of RCTs not limited by intervention type have found that individuals with MCC are often excluded, and when MCC are reported in participant characteristics, details are sparse. A thorough systematic review of the inclusion of MCC in RCTs of behavioral and/or psychosocial interventions is needed to provide important insight into the applicability of results and to identify gaps in the design and implementation of behavioral and/or psychosocial interventions in prevention and control of chronic conditions.

Objectives:

With this review we seek to test the hypothesis that individuals with multiple chronic conditions are underrepresented in RCTs of behavioral and psychosocial interventions published in general medical, behavioral medicine, behavioral science, health psychology, social science, and public health journals.

The goals of the review are to: (1) conduct a systematic review to assess the frequency with which research participants with MCC are represented in all or a representative subset of RCTs of behavioral and psychosocial interventions published in general medical and specialized journals, published within the last decade or decade and a half, that focus on behavioral medicine and behavioral science, health psychology, social science, and public health; (2) determine whether there are significant differences by type of journal or over time in the frequency with which research participants with MCC are represented in RCTs of behavioral and psychosocial interventions.

Chronic conditions:

This review considered 20 chronic conditions. The selected conditions were taken from a list compiled by an MCC working group at the Office of the Assistant Secretary of Health (OASH) within the US Department of Health and Human Services (HHS). These chronic conditions meet the definition for chronicity, are prevalent and have potential to be modifiable by public health and/or clinical interventions.

Search methods:

A certified MLS librarian with expertise in searching for systematic reviews designed to retrieve all reported RCTs in adults regarding chronic illness in PubMed MEDLINE and EMBASE. Database supplied limits were used to limit by three year clusters, 2000-2004, 2005-2009, and 2010-2014. Searches were completed in February 2015.

Selection criteria:

Within each 5-year time period, search results were randomly ordered and selection criteria was applied by two independent reviewers until 200 articles meeting inclusion criteria were selected per time period. Selection criteria were primary reports of RCTs of behavioral and/or psychosocial interventions targeting adults with at least one specified chronic conditions of interest.

Data collection and analysis:

Data were extracted independently by two trained readers using a standardized form. Risk of bias was assessed using a modified version of the Cochrane Collaboration tool for assessing risk of bias. After extraction by each reader, records were compared and differences were adjudicated by a third party. Data was managed in REDCap.

Main results:

600 RCTs testing behavioral and/or psychosocial interventions were included. Studies were mostly from specialty journals (83.8%), and about half of studies were from North America (51.5%). The most common intervention focuses were psychological well-being (35.5%) and weight management/diet/physical activity (27.5%). Mean risk of bias score improved over time ($p < 0.001$).

Targeting MCC directly was rare (4.3%). The most commonly targeted individual conditions were cancer (17.0%) and diabetes (13.0%). Exclusion criteria related to MCC were categorized as specific (naming specific conditions), general (using general terms for chronic conditions), or vague (criteria without clear definition that is likely to result in exclusion of MCC). Overall, 68.3% of trials included general, specific, or vague exclusion criteria for MCC. This did not change over time ($p = 0.87$). The most common specific conditions excluded were substance abuse disorders (19.0%), dementia (16.9%), and schizophrenia (14.1%). Using a maximum age as exclusion criteria was common (27.8%), and in these trials the median maximum age was 65.0. When exclusions for MCC were reported, only 15.9% of trials identified the number of individuals excluded for these reasons during screening.

The inclusion of MCC could be identified in 35.8% of trials. Condition specific descriptions were more common than general descriptions (28.7% vs 11.3%). Of those trials that reported including MCC, the prevalence of MCC was reported in 59.5% of trials. Of trials reporting specific comorbidities of the index conditions, the mean number of additional conditions reported was 2.1. Comorbidities were considered in analysis in 5.2% of all trials, and 12.1% of trials reporting inclusion of MCC.

Authors' conclusions:

In a representative sample of RCTs testing behavioral and/or psychosocial interventions for participants with at least one chronic condition published over the last 15 years (2000–2014), trials rarely target individuals with MCC. Additionally, they frequently exclude individuals with MCC due to specific, general, or vague exclusion criteria, and exclusion criteria based on factors correlated with MCC, such as age. When MCC are used as exclusion criteria, information regarding to what extent potential participants were excluded for having MCC is usually not provided. When trials indicated that some participants did have MCC, the prevalence of MCC either by general measure or by individual conditions is often not specified. Although our results suggest that individuals with MCC are not appropriately represented in RCTs of behavioral and/or psychosocial interventions, perhaps of bigger concern is that it is often difficult to determine if and to what extent MCC are included due to the poor reporting quality of relevant information in trials. Collectively these factors limit the ability to judge the appropriateness of applying trial results to the broader population. Additionally this review identifies possible areas for further study to address the shortcomings of existing evidence of the representation of individuals with MCC in RCTs.

B. Key Personnel

| Name | Title | Role |
|--------------------------|--|------------------------|
| Graham Colditz, MD, DrPH | Niess-Gain Professor of Surgery; Chief, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine; Associate Director Prevention and Control, Alvin J. Siteman Cancer Center | Principal Investigator |
| Carolyn Stoll, MPH, MSW | Staff Scientist, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine | Study Director |
| Sonya Izadi, BA | Senior Public Health Research Coordinator, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine | Database Manager |

C. Background, including information on the relevance of multiple chronic conditions in behavioral and psychosocial intervention research

Roughly 75 million people in the United States have multiple chronic conditions (MCC) and 65% of total health care spending in the nation is used for this quarter of the population.¹ In 2013, 17.6% of people age 18-64 and 60.8% of those 65 and older in the United States had more one chronic condition.² As the United States is experiencing considerable growth in its older population, the proportion of people with MCC will undoubtedly expand.³

However, randomized controlled trials (RCTs) frequently exclude participants with MCC.^{1,4-8} In a systematic sampling of high impact general medical journals, 81% of RCTs reviewed excluded participants with MCC. Additionally, 38.5% of those trials excluded potential participants older than 65 years of age.⁸ By excluding older participants, these trials are likely to exclude participants with MCC. A similar review sampling both general and specialized high impact medical journals found that participants with MCC were excluded from 63% of all RCTs and 90% of RCTs that explicitly or implicitly mentioned MCC. They also found that only 2% of RCTs explicitly included participants with MCC.⁶ Furthermore, when these participants are not excluded, reporting of co-occurring chronic conditions is limited.^{4,5,9} A survey of clinical trials revealed only a 44% reporting rate of participant comorbidities.⁴ This inconsistency between the characteristics of eligible participants in RCTs and the characteristics of the actual population with the disease reduces confidence in applying trial results to the patient population.^{4,7} Consequently, the knowledge base for multiple chronic conditions is largely limited by the reliance on clinical trials that strive to maximize internal validity by excluding participants with comorbidities.¹

The challenge of treating patients who have MCC is further exacerbated by the large variance in how the term *chronic condition* is defined, which is problematic when comparing results across studies and attaining accurate prevalence rates. Among peer reviewed literature and public information sources, there is much

inconsistency in several dimensions of the definition, such as the duration, effect on function and well-being, and need for medical attention.¹⁰ There is currently no standard list of diseases considered to epitomize universal chronic conditions.¹¹⁻¹³

It is well established that behavioral and psychological factors play a large role in outcomes for numerous chronic conditions, such as cancer, cardiovascular disease, and diabetes.¹⁴ In an analysis of actual causes of US deaths in the year 2000, the three leading causes were behavioral-based and largely modifiable: tobacco use (18.1%), poor diet and physical inactivity (15.2%), and alcohol consumption (3.5%).¹⁵ These figures illuminate the importance of testing behavioral/psychosocial interventions within RCTs. Yet, the inclusion of MCC patients specifically in such trials has not been studied. As these patients account for roughly 25% of the US population, this is an area that warrants further examination.

Existing evidence

Several reviews^{4,6,8,16,17} have attempted to assess the inclusion of individuals with MCC in RCTs. These reviews vary slightly in aims, focus, and methods, but all considered the generalizability of eligibility criteria in RCTs as related to MCC or to factors correlated with MCC.

In a review of 284 RCTs published in high impact journals from 1995 to 2010, Jadad found that individuals with MCC were excluded in 63% of trial reports.⁶ There was no significant difference in exclusion over time.

Boyd (2012) reviewed 161 trials sampled from 11 Cochrane Reviews summarizing the effectiveness of various interventions for four major chronic diseases (diabetes, heart failure, COPD, and stroke) and assessed the inclusion of people with comorbidities as well as the reporting of comorbidities and whether comorbidities were considered as modifiers of treatment effects. This review also considered the reporting and replicability of eligibility criteria. In these 161 trials, the proportion of exclusions for comorbidities ranged from 0% to 55% for each of the four major chronic diseases they assessed, and people with common comorbidities of the index condition were frequently excluded. Additionally, 21% of all trials had an upper age exclusion of age greater than 65, 75, or 80 years. Only 43.5% of trials described the prevalence of comorbidities among participants, and among this subgroup of trials, the median number of reported comorbidities was 3. Trials rarely used comorbidities as a subgroup variable to examine comorbidities as a potential effect modifier (3.1%). In addition, replicability of eligibility criteria was only moderate, which affects the ability to adequately assess the eligibility criteria of a trial.⁴

Van Spall (2007) considered the nature and extent of exclusion criteria and the contribution of exclusion criteria to the representation of certain patient populations in 283 RCTs published between 1994 and 2006 in high impact general medical journals. Trials were not limited by condition of interest. Of those sampled, 12% of trials did not report exclusion criteria. Medical comorbidities were used in exclusion of 81.3% of trials. A third (31%) of trials did not use specific medical conditions in exclusion criteria but instead used more general terms such as “illness,” or “comorbidity.” Additionally, age was used in exclusion criteria in 72.1% of RCTs, which Van Spall concluded may impair the generalizability of RCT outcomes and result in exclusion of participants with MCC.⁸

Zulman (2011) assessed the inclusion of complex, older adults in RCTs by considering eligibility based on age as well as eligibility criteria that might disproportionately affect older adults (i.e., exclusion based on inability to give informed consent or decreased life expectancy) in 109 clinical trials published in high-

impact journals.¹⁷ Of these trials, 20% excluded participants above a certain age. Among trials that did not exclude based on age, 46% used exclusion criteria that could disproportionately impact older adults.¹⁷

Schmidt (2014) considered the justification of exclusion criteria in cardiovascular trials and to what extent exclusion affected generalizability of study results.¹⁶ Of 113 RCTs on secondary prevention of cardiovascular events, many used ambiguous exclusion criteria such as exclusion due to the opinion of the physician (25%) or physical disability (11%). Only 1 trial provided a rationale for its exclusion criteria.¹⁶

Contribution of the current review

Although there have been multiple reviews on this topic as summarized above, these reviews varied on the index conditions considered, the sampling techniques used, and the aspects of eligibility and inclusion of MCC assessed. Most reviews did not limit by intervention type, and there has not been a comprehensive review assessing the inclusion of individuals with MCC specifically in trials of behavioral and psychosocial interventions. Additionally, many previous reviews limited their sample to trials published in high-impact journals.^{6,8,17} These trials may have a different quality of trial design or reporting, and may not be representative of the inclusion and reporting of MCC in RCTs among trials that encompass the current literature.

The current review differs from previous reviews by (a) focusing solely on RCTs testing behavioral and/or psychosocial interventions; (b) considering a previously defined list of 20 chronic conditions chosen for their chronicity, prevalence, and potential to be modifiable by public health and/or clinical interventions; (c) using a comprehensive search strategy and sampling technique to produce a large representative subset of the literature across 15 years (2000-2014); (d) evaluating a wide range of variables related to trial design, trial quality, eligibility criteria, participant selection, and consideration of comorbidities in analysis; and (e) using best practices for systematic reviews including review of search results and selection of included studies and extraction of data by two independent readers.

D. Research question(s) and study objectives

With this review we seek to test the hypothesis that individuals with multiple chronic conditions are underrepresented in RCTs of behavioral and psychosocial interventions published in general medical, behavioral medicine, behavioral science, health psychology, social science, and public health journals.

This review has the following goals:

Goal 1: Conduct a systematic review to assess the frequency with which research participants with MCC are represented in all or a representative subset of RCTs of behavioral and psychosocial interventions published in general medical and specialized journals, published within the last decade or decade and a half, that focus on behavioral medicine and behavioral science, health psychology, social science, and public health.

Goal 2: Determine whether there are significant differences by type of journal or over time in the frequency with which research participants with MCC are represented in RCTs of behavioral and psychosocial interventions.

E. Methods

Methods were specified in advance and documented in a protocol (Appendix B.1), along with a description of any changes from the original protocol (Appendix B.2).

Eligibility criteria

Eligibility criteria was designed with the goal of creating a representative sample of RCTs published in peer-reviewed literature from 2000-2014 designed to develop and/or test the efficacy or effectiveness of behavioral and psychosocial interventions to modify health behaviors, improve health-related quality of life, psychosocial functioning, and/or health outcomes. Eligibility criteria were designed to be fairly broad to produce a heterogeneous sample of the literature in terms of populations, interventions, and outcomes.

The following eligibility criteria was used for this review:

1. RCT with original data
2. Primary report (not protocols, posttrial follow-up studies, secondary or subgroup analyses, etc.)
3. Published in English
4. Targeting at least one of the chronic conditions of interest (i.e. all enrolled participants must have at least one of the 20 specified chronic conditions)
5. Had a primary goal to develop and/or test efficacy or effectiveness of a behavioral or psychosocial intervention
6. Enrolled participants and applied eligibility criteria at the individual level
7. Enrolled only adult subjects (18+)

Types of studies

All randomized controlled trials testing the efficacy or effectiveness of behavioral or psychosocial interventions to modify health behaviors, improve health-related quality of life, psychosocial functioning, and/or health outcomes. If trials included a non-randomized portion alongside an RCT, we considered only the RCT cohort.

Types of participants

Human adults (18+) with at least one chronic condition.

Types of conditions

The following 20 chronic conditions were considered as potential targets of the interventions: arthritis, asthma, autism spectrum disorder, cancer, cardiac arrhythmias, chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, dementia (including Alzheimer's and other senile dementias), depression, diabetes, hepatitis, human immunodeficiency virus, hyperlipidemia, hypertension, osteoporosis, schizophrenia, stroke, substance abuse disorders (drug and alcohol) (Table 1).

There is much inconsistency in several dimensions of the definition of chronic condition.¹⁰ Therefore, in order to establish consistency, the selected conditions were taken from a list compiled by an MCC working group at the Office of the Assistant Secretary of Health (OASH) within the US Department of Health and Human Services (HHS). These chronic conditions meet the definition for chronicity, are prevalent and have

potential to be modifiable by public health and/or clinical interventions. Specifically, OASH defined chronic illnesses as conditions that last a year or more and require ongoing medical attention and/or limit activities of daily living.¹⁰

Additionally, interventions that targeted chronic conditions in general (using such terms as “chronic condition” or “chronic illness”) were included.

| TABLE 1. Chronic conditions of interest* |
|---|
| Arthritis |
| Asthma |
| Autism spectrum disorder |
| Cancer |
| Cardiac arrhythmias |
| Chronic kidney disease |
| Chronic obstructive pulmonary disease |
| Congestive heart failure |
| Coronary artery disease |
| Dementia (including Alzheimer’s and other senile dementias) |
| Depression |
| Diabetes |
| Hepatitis |
| Human immunodeficiency virus (HIV) |
| Hyperlipidemia |
| Hypertension |
| Osteoporosis |
| Schizophrenia |
| Stroke |
| Substance abuse disorders (drug and alcohol) |

*OASH list of chronic conditions¹⁰

Types of interventions

For the purpose of this review, “behavioral or psychosocial intervention” was defined as any intervention that is non-pharmacological and non-surgical and includes at least one behavior change technique.¹⁸ Additionally, there must be some aspect of direct communication with an individual (or small group) whether this is in person, by phone, by internet, etc. This ensured that participants were enrolled at the individual level, and interventions are not performed at the level of a community, campus, etc.

Comparison groups could be usual care, pharmacological interventions, surgical interventions, or a lesser dose of the treatment. Interventions could include a behavioral or psychosocial intervention in addition to a drug or surgery, as long as the comparison group did not receive the same behavioral or psychosocial intervention.

Types of outcome measures

Eligibility was not limited by outcome measure.

Search methods for identification of studies

The librarian designed search strategies to retrieve, as thoroughly as possible, all reported randomized controlled trials in adults regarding chronic illness in PubMed Medline and Embase. Database supplied limits were used to limit by three year clusters, 2000-2004, 2005-2009, and 2010-2014. Chronic illness was defined using general terms for chronic conditions and specific conditions specified by the Centers for Disease Control including arthritis, asthma, autism spectrum disorder, all cancer except non-melanoma skin, cardiac arrhythmias, chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, dementia including Alzheimer's and other senile dementias, depression, all non-gestational diabetes, hepatitis, human immunodeficiency virus, hyperlipidemia, hypertension, osteoporosis, schizophrenia, stroke, and drug and alcohol related substance abuse disorders. Searches were completed in February 2015. Results were sent to EndNote and the software-provided duplicate finder was used and assumed to correctly identify duplicates. Full search strategies are available in Appendix B.3.

Data collection and analysis

Selection of studies

Sampling strategy

Three separate literature searches (using identical keywords and in the same databases) were performed within the defined time periods (2000-2004, 2005-2009, 2010-2014). Within each time period, search results were randomly ordered using the RAND function in Microsoft Excel (2013). The study selection process (application of eligibility criteria onto each article) was performed on the randomly ordered results until studies meeting selection criteria were identified for extraction (200 per time period for a total of 600 articles). Selection was stratified by time period to ensure that an adequate number of studies per time period were selected to allow for analysis over time.

Selection process

Two reviewers performed study selection to reduce the possibility that relevant reports were missed.¹⁹ Titles were examined for eligibility criteria and more obviously irrelevant results were removed. Abstracts of remaining results were then screened for eligibility. Finally, full text of the potentially eligible results were retrieved and examined for eligibility criteria. At each level of screening, excluded articles and one reason for exclusion were documented. Once full texts were selected, results were compared between the two reviewers, and any disagreement was resolved by discussion. Reviewers assessing study eligibility were not blinded to the names of the authors, journals, and other publication details. Reviewers performed study selection independently on at least 1250 citations before comparing results. The number of search results screened in each time period was kept even (i.e., the first 5000 results from each time period were screened before screening the second 5000 results from each time period) to ensure that any potential drift in application of eligibility criteria by reviewers throughout the selection process would not bias results over time periods.

Data extraction and management

Data management

Study data were collected and managed using REDCap electronic data capture tools hosted in the Biostatistics Division of Washington University School of Medicine. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing:

1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources.²⁰

REDCap was chosen because it is uniquely suited to meet the needs of an effective and efficient data extraction process. It allows form creators to require specific entry formats for individual questions (ensuring reviewers input data in a consistent format), allows for multiple types of response formats (dropdown menus, select all, select only one, open-ended text entry, etc), and performs data validation to improve accuracy of extraction. In addition, REDCap has a built in “Data Comparison Tool” feature, which allows for the differences in two records to be identified automatically.

Development of extraction form

The extraction form was designed to ensure consistency, accuracy, and efficiency of the data extraction process. The extraction form was tested for item clarity, item comprehensiveness, and form usability. Additionally, throughout the data extraction process the form was constantly evaluated to make sure it was performing as planned. The structure of REDCap allowed for easy editing of the form, such as adding variables, adding answer options, combining answer options, changing entry formats, etc.

Reader training

Readers were Master of Public Health students or had equivalent experience. Their previous experience included managing behavioral research projects, delivering behavioral and/or psychosocial interventions, and clinical experience treating chronic conditions. Readers went through an extensive training process before they began extracting data. Training focused on relevant background material and important concepts such as background information on MCC, systematic review methods, RCT methods, RCT reporting, and assessment of bias in RCTs, as well as the specific extraction items and process for this review. Readers were assessed for accuracy and completeness of extraction on multiple test articles before beginning to extract included articles so that any learning curve did not affect the quality of the data. Further details of reader training materials are included in Appendix B.4.

Extraction of data

Each article was extracted independently by two reviewers. This method was chosen as systematic review best practices recommend that independent data extraction by more than one reader can minimize errors and reduce potential biases being introduced by readers.²¹⁻²³ After both extractions were complete, any differences were identified using the REDCap Data Comparison Tool. Disagreements were resolved by a third party with graduate training in public health and four years of experience and expertise in extraction of data from published reports, the design and implementation of systematic reviews, and the goals and objectives of this review. This continuous comparison reduced error in the database, and allowed the monitoring of any systematic errors by readers, which helped to ensure the high quality of the extraction process and of the data.

Order of extraction

Readers were assigned articles to extract and the order of extraction was designed to ensure that number of articles extracted was kept constant within time periods to minimize any bias created by extraction over a long period of time. Additionally, as two readers were required per article for double extraction, readers were shuffled in regards to which additional reader they were matched with in order to better identify inconsistencies across readers.

Study measures and variables extracted

The variables extracted were designed to assess inclusion and reporting of MCC in all phases of a trial—eligibility criteria, participant screening, participant selection and reporting of characteristics, and study analysis. A thorough review of relevant peer-reviewed literature, including reviews of a similar nature or those that assessed the inclusion criteria of RCTS, was performed to identify key variables previously used to evaluate inclusion of specific populations in RCTS.^{4,8,16,17,24-28}

For each trial, the items extracted were intended to determine if participants with MCC were represented. This determination for each trial was complex and involved answering several more specific questions (Table 2).

TABLE 2. Key questions to be answered for each trial

| |
|---|
| <p>Does the RCT explicitly exclude MCC? Is the RCT likely to have excluded MCC due to exclusion criteria regarding other factors? To what extent are potential participants excluded for MCC? Does the RCT select participants with MCC? What is the prevalence of MCC among participants? Are MCC considered in analysis?</p> |
|---|

A final version of the extraction form codebook is in Appendix B.5.

Briefly, the items extracted consisted of basic study characteristics (author, title, journal, journal type, year, region, study registration, sample size), intervention details, eligibility information, participant selection details, study outcomes, and risk of bias assessment.

Assessment of risk of bias in included studies

The risk of bias of each included study was assessed for the purposes of describing and evaluating the body of evidence that conclusions are based on, and assessing if study quality and inclusion of MCC are associated. This risk of bias was assessed using a modified version of the Cochrane Collaboration’s Risk of Bias tool.²⁹ The Risk of Bias tool (Table 3) includes six domains: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias.²¹ For each item the reader categorizes the article as low risk of bias, high risk of bias, or unclear risk of bias. The unclear risk of bias option allows the reader to indicate when the article has not provided enough information to make a judgement, which helps to separate out issues of study reporting quality from actual study quality.

The Cochrane Collaboration’s Risk of Bias tool was adapted slightly for use in this review. Specifically, the “other bias” domain was removed as this element was unnecessary under the scope of this review. The inclusion of this domain is beneficial when considering more specialized studies, therefore it was not necessary for our generalized approach. For attrition bias, readers made judgements on whether attrition was appropriately reported and explained but they did not assess the actual amount of attrition. As this review encompassed studies on a wide variety of populations, interventions, and outcomes, it was not feasible for readers to have enough domain specific knowledge to adequately assess how the amount of attrition in each study may have affected the outcome.

| TABLE 3. Cochrane Collaboration's Risk of Bias tool | | |
|---|--|---|
| Domain | Support for judgment | Review authors' judgement |
| <i>Selection bias.</i> | | |
| Random sequence generation. | Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. | Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence. |
| Allocation concealment. | Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrollment. | Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment. |
| <i>Performance bias.</i> | | |
| Blinding of participants and personnel | Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective. | Performance bias due to knowledge of the allocated interventions by participants and personnel during the study. |
| <i>Detection bias.</i> | | |
| Blinding of outcome assessment | Describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective. | Detection bias due to knowledge of the allocated interventions by outcome assessors. |
| <i>Attrition bias.</i> | | |
| Incomplete outcome data | Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors. | Attrition bias due to amount, nature or handling of incomplete outcome data. |
| <i>Reporting bias.</i> | | |
| Selective reporting. | State how the possibility of selective outcome reporting was examined by the review authors, and what was found. | Reporting bias due to selective outcome reporting. |
| <i>Other bias.</i> | | |
| Other sources of bias. | State any important concerns about bias not addressed in the other domains in the tool. | Bias due to problems not covered elsewhere in the table. |

Often in a systematic review it is more useful to use a quality measure adapted for the specific review topic that takes into account which quality domains are likely to actually affect the outcomes being assessed in the review. However, for this review, the goal was to see how overall trial quality as measured using a broad tool was related to inclusion of MCC or reporting regarding MCC. The GRADE scoring process³⁰⁻³³ was determined to be inappropriate for this review, as it is intended for evaluating the strength of a body of evidence for specific recommendations. GRADE classifies the quality of evidence into four levels (high, moderate, low, and very low) and the strength of the recommendation as strong or weak. Since the purpose of this review was to describe the existing literature, the Cochrane Collaboration's Risk of Bias tool was more suitable for our heterogeneous sample.

We created a risk of bias score (range -6 to 6) for each article by combining the six risk of bias items (low risk of bias = -1, unclear risk of bias = 0, high risk of bias = 1).

Dealing with missing data and duplicate studies

As a key part of this review was to assess the reporting of information regarding MCC, no attempts were made to contact authors for additional information. For each extraction item there was an option to list it as "not reported." Duplicate studies were not included, and only one primary report of trials was used.

Data synthesis

Analyses performed were determined by specifics of data extracted (both type and volume) from selected studies. Basic study characteristics were summarized to describe the studies, populations, interventions, and outcomes reported and to verify that a representative sample was created. Exploratory data analysis using summary statistics such as mean, proportion, and frequency was performed to assess inclusion of participants with MCC and based on summarizing the key questions for each trial (Table 3). Statistical tests (ANOVA or t-tests) were performed to assess the impact of time period or journal type on key outcomes. No meta-analyses were performed, thus statistical measures of heterogeneity were unnecessary.³⁴ The potential impact of publication bias was considered.³⁵

Analysis was performed using SAS 9.4 (SAS Institute, Cary, NC).

F. Main results of the review in answering the initial research question(s)

Description of studies

Results of the search

In total we identified 343,123 records through database searching (PubMed, Embase). After removing all duplicate records we were left with 190,554 records to assess for eligibility. We conducted a two-phase screening process. The first screening phase involved reading the titles/abstracts of these records, which left us with 41,186 articles that could proceed to the full-text screening phase. During this phase we identified 39,728 articles that were not eligible, which left 1,458 articles to enter the final screening phase. After this 858 were excluded, which left 600 articles included in our study, with 200 from each intended time period. Our study flow is presented in Figure 1.




Figure 1 Flow Diagram

Excluded studies

In total there were 40,586 studies excluded during the screening process and extraction processes. 39,728 of these were excluded during the first phase of screening with the majority of articles excluded because they were not testing behavioral/psychosocial interventions (29,313) or they were not targeting at least one of our 20 chronic conditions (6,143). In many cases, these were trials testing drugs or surgery. During the second phase of screening, which occurred during full-text article assessment, 858 articles were excluded predominantly for the article not being the primary report (201) or the intervention assessed in the article was not behavioral/psychosocial in nature (184). All exclusions are listed in Figure 1. Although all included and excluded articles were confirmed by two reviewers, the reasons for exclusion were not adjudicated and the flow diagram represents only one reviewer's reasons for exclusion.

Included studies

A list of the 600 included studies can be found in Appendix B.6. A summary of the basic study characteristics of all 600 included studies is presented in Table 4 with each category stratified by time period. We found that while registration reporting generally increased over time, only 97 out of our 600 trials were registered on clinicaltrials.gov or some other registry. We also found that the number of trials with interventions related to weight management/diet/physical activity increased over time with 27.5% of all trials focusing on this intervention. Sample size of included trials varied greatly (from 8-8,517) and the median was 104.5 participants.

We examined how study quality varied over time based on the Cochrane risk of bias tool (Table 5). Surprisingly, we found that only allocation sequence concealment and selective outcome reporting increased in the number of trials with low risk of bias in these categories and decreased in the number of trials with high risk of bias. Additionally, random sequence generation and incomplete outcome data quality assessments showed an increase in the number of trials with a high risk of bias and a decrease in the number of trials with a low risk of bias between the 2005-2009 and the 2010-2014 categories. Furthermore, overall mean risk of bias score (range -6 to 6, with a lower score indicating lower risk of bias) changed from -2.2 (1.7) in the first time period to -2.8 (1.8) in the final time period, which was a significant decrease in risk of bias over time ($p < 0.001$). In all time periods a large percentage of trials were categorized as unclear risk of bias in various risk categories, indicating that the trial did not report adequate information to assess the risk of bias.

We speculated that trial registration and mean risk of bias score may vary by journal type (general vs specialty). Reporting of trial registration occurred in 14.3% of specialty journals and 25.8% of general medical journals and risk of bias score was higher in specialty journals (-2.6 (1.7)) compared to general medical journals (-2.8 (1.7)) (Table 6). However, this result was not significant ($p = 0.92$).

We also explored intervention focus by the top targeted conditions (Tables 7-10).

TABLE 4. Study characteristics

| | 2000-2004 (N=200) | 2005-2009 (N=200) | 2010-2014 (N=200) | Total (N=600) |
|---|----------------------|----------------------|----------------------|------------------|
| Journal Type^a | | | | |
| General Medicine | 29 (14.5) | 38 (19.0) | 30 (15.0) | 97 (16.2) |
| Specialty | 171 (85.5) | 162 (81.0) | 170 (85.0) | 503 (83.8) |
| Funding Source^b | | | | |
| Industry | 23 (11.6) | 13 (6.5) | 12 (6.0) | 48 (8.0) |
| Non-Industry | 145 (72.9) | 153 (76.5) | 160 (80.0) | 458 (76.5) |
| Not reported | 31 (15.6) | 34 (17.0) | 28 (14.0) | 93 (15.5) |
| Region | | | | |
| North America | 121 (60.5) | 101 (50.5) | 87 (43.5) | 309 (51.5) |
| Europe | 50 (25.0) | 55 (27.5) | 61 (30.5) | 166 (27.7) |
| Middle East | 2 (1.0) | 1 (0.5) | 6 (3.0) | 9 (1.5) |
| Asia/Pacific | 23 (11.5) | 34 (17.0) | 41 (20.5) | 98 (16.3) |
| Latin America | 4 (2.0) | 5 (2.5) | 3 (1.5) | 12 (2.0) |
| Africa | 0 (0.0) | 4 (2.0) | 2 (1.0) | 6 (1.0) |
| Registered^c | | | | |
| No | 200 (100.0) | 174 (87.0) | 129 (64.5) | 503 (83.8) |
| Yes - clinicaltrials.gov | 0 (0.0) | 14 (7.0) | 47 (23.5) | 61 (10.2) |
| Yes - other registry | 0 (0.0) | 12 (6.0) | 24 (12.0) | 36 (6.0) |
| Intervention focus | | | | |
| Weight management/ diet/physical activity | 49 (24.5) | 57 (28.5) | 59 (29.5) | 165 (27.5) |
| Tobacco habits | 4 (2.0) | 3 (1.5) | 5 (2.5) | 12 (2.0) |
| Adherence to disease management | 45 (22.5) | 52 (26.0) | 41 (20.5) | 138 (23.0) |
| Psychological well-being | 82 (42.0) | 66 (33.0) | 63 (31.5) | 213 (35.5) |
| Other | 18 (9.0) | 22 (11.0) | 32 (16.0) | 72 (12.0) |
| Sample size (N=596) median (range) | 112 (8 – 2957) | 110 (14 – 3522) | 96.5 (10 – 8517) | 104.5 (8 – 8517) |

TABLE 5. Study quality

| Risk of Bias | 2000-2004 (N=200) | 2005-2009 (N=200) | 2010-2014 (N=200) | Total (N=600) |
|--|----------------------|----------------------|----------------------|------------------|
| Random sequence generation (selection bias) | | | | |
| Low risk of bias | 81 (40.5) | 105 (52.5) | 100 (50.0) | 286 (47.7) |
| High risk of bias | 11 (5.5) | 6 (3.0) | 12 (6.0) | 29 (4.8) |
| Unclear risk of bias | 108 (54.0) | 89 (44.5) | 88 (44.0) | 285 (47.5) |
| Allocation sequence concealment (selection bias) | | | | |
| Low risk of bias | 50 (25.0) | 61 (30.5) | 86 (43.0) | 197 (32.8) |
| High risk of bias | 8 (4.0) | 5 (2.5) | 7 (3.5) | 20 (3.3) |
| Unclear risk of bias | 142 (71.0) | 134 (67.0) | 107 (53.5) | 383 (63.8) |
| Blinding of participants and personnel (performance bias) | | | | |
| Low risk of bias | 16 (8.0) | 20 (10.0) | 48 (24.0) | 84 (14.0) |
| High risk of bias | 36 (18.0) | 35 (17.5) | 38 (19.0) | 109 (18.2) |
| Unclear risk of bias | 148 (74.0) | 145 (72.5) | 114 (57.0) | 407 (67.8) |
| Blinding of outcome assessment (detection bias) | | | | |
| Low risk of bias | 78 (39.0) | 103 (51.5) | 114 (57.0) | 295 (49.2) |
| High risk of bias | 17 (8.5) | 8 (4.0) | 25 (12.5) | 50 (8.3) |
| Unclear risk of bias | 105 (52.5) | 89 (44.5) | 61 (30.5) | 255 (42.5) |
| Incomplete outcome data (attrition bias) | | | | |
| Low risk of bias | 153 (76.5) | 169 (84.5) | 154 (77.0) | 476 (79.3) |
| High risk of bias | 30 (15.0) | 20 (10.0) | 34 (17.0) | 84 (14.0) |
| Unclear risk of bias | 17 (8.5) | 11 (5.5) | 12 (6.0) | 40 (6.7) |
| Selective outcome reporting (reporting bias) | | | | |
| Low risk of bias | 181 (90.5) | 187 (93.5) | 189 (94.5) | 557 (92.8) |
| High risk of bias | 18 (9.0) | 12 (6.0) | 11 (5.5) | 41 (6.8) |
| Unclear risk of bias | 1 (0.5) | 1 (0.5) | 0 (0.0) | 2 (0.4) |
| Mean risk of bias score | -2.2 (1.7) | -2.8 (1.7) | -2.8 (1.8) | -2.6 (1.7) |

TABLE 6. Trial registration and mean risk of bias score by time

| | General Medicine N (%) | Specialty N (%) |
|--------------------------|---------------------------|--------------------|
| Registered | | |
| No | 72 (74.2) | 431 (85.7) |
| Yes – clinicaltrials.gov | 12 (12.4) | 49 (9.7) |
| Yes – other registry | 13 (13.4) | 23 (4.6) |
| Mean quality score | -2.8 (1.7) | -2.6 (1.7) |

TABLE 7. Targeted condition and intervention focus, 2000-2004

| | Cancer | Diabetes | Depression | CVD ^a |
|---------------------------------|-----------|----------|------------|------------------|
| Weight/diet/PA | 4 | 15 | 0 | 12 |
| Tobacco habits | 1 | 0 | 0 | 0 |
| Adherence to disease management | 1 | 2 | 8 | 4 |
| Psychological well-being | 27 | 0 | 19 | 2 |
| Other | 5 | 1 | 1 | 3 |
| Total | 38 (19.0) | 18 (9.0) | 28 (14.0) | 21 (10.5) |

^acomposite of hypertension, CAD, and CHF

TABLE 8. Targeted condition and intervention focus, 2005-2009

| | Cancer | Diabetes | Depression | CVD ^a |
|---------------------------------|-----------|-----------|------------|------------------|
| Weight/diet/PA | 9 | 16 | 1 | 13 |
| Tobacco habits | 0 | 0 | 1 | 1 |
| Adherence to disease management | 0 | 11 | 4 | 8 |
| Psychological well-being | 20 | 1 | 15 | 6 |
| Other | 5 | 3 | 0 | 2 |
| Total | 34 (17.0) | 31 (15.5) | 21 (10.5) | 30 (15.0) |

^acomposite of hypertension, CAD, and CHF

TABLE 9. Targeted condition and intervention focus, 2010-2014

| | Cancer | Diabetes | Depression | CVD ^a |
|---------------------------------|-----------|-----------|------------|------------------|
| Weight/diet/PA | 7 | 13 | 2 | 11 |
| Tobacco habits | 0 | 0 | 1 | 0 |
| Adherence to disease management | 1 | 8 | 3 | 7 |
| Psychological well-being | 17 | 2 | 16 | 1 |
| Other | 5 | 6 | 1 | 2 |
| Total | 30 (15.0) | 29 (14.5) | 23 (11.5) | 21 (10.5) |

^acomposite of hypertension, CAD, and CHF

TABLE 10. Targeted condition and intervention focus, 2000-2014

| | Cancer | Diabetes | Depression | CVD ^a |
|---------------------------------|-------------------|------------------|------------------|------------------|
| Weight/diet/PA | 20 | 44 | 3 | 36 |
| Tobacco habits | 1 | 0 | 2 | 1 |
| Adherence to disease management | 2 | 21 | 15 | 19 |
| Psychological well-being | 64 | 3 | 50 | 9 |
| Other | 15 | 10 | 2 | 7 |
| Total | 102 (17.0) | 78 (13.0) | 72 (12.0) | 72 (12.0) |

^acomposite of hypertension, CAD, and CHF

Eligibility

Inclusion criteria

Exploratory data analysis was performed to assess inclusion of participants with MCC and to determine the frequency with which each condition was targeted based on time period (Table 11; Table 128). We found that 95.7% of trials only targeted one condition. Targeting MCC directly was rare (4.3%), and most of these trials that targeted MCC focused on a specific set of chronic conditions. No included trials targeted MCC generally. In considering which specific conditions were targeted, cancer was the condition of interest in 17.0% of all trials over all time periods and was the condition most targeted in each time period. The second most targeted condition was diabetes, which was the condition of interest in 13.0% of all trials. Of the 20 chronic conditions considered (Table 1), only hepatitis and autism spectrum disorders were not represented as index conditions in our sample.

TABLE 11. MCC inclusion

| Do studies target MCC? | N (%) |
|---|------------|
| No (target only 1 condition) | 574 (95.7) |
| Yes | 26 (4.3) |
| Specific set of chronic conditions | 22 (3.7) |
| Any combination of chronic conditions within a specific set of conditions | 4 (0.7) |
| Multiple chronic conditions | 0 (0.0) |

TABLE 12. Specific conditions targeted*

| | 2000-2004 (N=200) | 2005-2009 (N=200) | 2010-2014 (N=200) | Total (N=600) |
|---------------------------------------|----------------------|----------------------|----------------------|------------------|
| Cancer | 38 (19.0) | 34 (17.0) | 30 (15.0) | 102 (17.0) |
| Diabetes | 18 (9.0) | 31 (15.5) | 29 (14.5) | 78 (13.0) |
| Depression | 28 (14.0) | 21 (10.5) | 23 (11.5) | 72 (12.0) |
| Substance abuse disorders | 30 (15.0) | 20 (10.0) | 19 (9.5) | 69 (11.5) |
| Arthritis | 16 (8.0) | 16 (8.0) | 14 (7.0) | 46 (7.7) |
| Human Immunodeficiency Virus (HIV) | 13 (6.5) | 13 (6.5) | 10 (5.0) | 36 (6.0) |
| Schizophrenia | 13 (6.5) | 8 (4.0) | 12 (6.0) | 33 (5.5) |
| Chronic Obstructive Pulmonary Disease | 5 (2.5) | 9 (4.5) | 13 (6.5) | 27 (4.5) |
| Hypertension | 4 (2.0) | 11 (5.5) | 11 (5.5) | 26 (4.3) |
| Coronary Artery Disease | 9 (4.5) | 10 (5.0) | 5 (2.5) | 24 (4.0) |
| Congestive Heart Failure | 8 (4.0) | 9 (4.5) | 5 (2.5) | 22 (3.7) |
| Asthma | 6 (3.0) | 6 (3.0) | 5 (2.5) | 17 (2.8) |
| Stroke | 3 (1.5) | 5 (2.5) | 9 (4.5) | 17 (2.8) |
| Dementia | 3 (1.5) | 3 (1.5) | 7 (3.5) | 13 (2.2) |
| Chronic Kidney Disease | 0 (0.0) | 1 (0.5) | 4 (2.0) | 5 (0.8) |
| Hyperlipidemia | 2 (1.0) | 0 (0.0) | 2 (1.0) | 4 (0.7) |
| Osteoporosis | 2 (1.0) | 2 (1.0) | 0 (0.0) | 4 (0.7) |
| Chronic condition (General) | 0 (0.0) | 1 (0.5) | 2 (1.0) | 3 (0.5) |
| Cardiac arrhythmias | 2 (1.0) | 0 (0.0) | 0 (0.0) | 2 (0.3) |

*OASH list of chronic conditions¹⁰

Exclusion criteria

Exploratory analyses were also performed to evaluate exclusion criteria of participants with MCC by specific or general criteria, presence of exclusion justification, specific conditions excluded, and exclusion based on age.

Chronic conditions

We assessed exclusion criteria for all 600 trials and categorized criteria related to chronic conditions as specific (mentioned individual conditions by name or diagnostic criteria), general (used a general term), or vague (criteria that likely resulted in exclusion of specific conditions) (Table 13). Over all time periods, 68.3% of trials used a general, specific, or vague exclusion criteria (Table 14). This did not change over time ($p=0.87$). Although the overall use of specific, general, or vague exclusions did not change, general exclusions increased over time (from 4.5% in 2000-2004 to 8.5% in 2010-2014) and vague exclusions have decreased over time (from 51.5% in 2000-2004 to 43.5% in 2010-2014). Of those trials that mentioned specific, general or vague exclusion criteria, we considered if a justification was provided. We found that over all time periods 31.2% of trials with exclusions for specific, general, or vague exclusions justified these exclusions by citing an individual's ability to perform the intervention or otherwise mentally or physically participate in the trial (Table 15).

TABLE 13. Definitions and examples of exclusion categories

| Type of exclusion | Definition | Examples |
|-------------------|--|---|
| <i>Specific</i> | exclusion of individual conditions by name or diagnostic criteria | Type 2 diabetes, HbA1c > 7% |
| <i>General</i> | exclusion of MCC by general term | chronic disease, additional comorbidities |
| <i>Vague</i> | exclusion criteria that is likely to result in exclusion of specific conditions, but do not provide enough information to determine which conditions would be excluded | serious medical problems, acute medical complications, unstable medical conditions, mental illness, too ill |

TABLE 14. Exclusion of MCC

| | 2000-2004 N=200 | 2005-2009 N=200 | 2010-2014 N=200 | All years N=600 |
|--|--------------------|--------------------|--------------------|--------------------|
| Specific exclusion | 82 (41) | 89 (44.5) | 84 (42.0) | 255 (42.5) |
| General exclusion | 9 (4.5) | 14 (7.0) | 17 (8.5) | 40 (6.7) |
| Vague exclusion | 103 (51.5) | 99 (49.5) | 86 (43.0) | 288 (48.0) |
| Specific OR general exclusion | 85 (42.5) | 94 (47.0) | 91 (45.5) | 270 (45.0) |
| Specific OR general OR vague exclusion | 137 (68.5) | 134 (67.0) | 139 (69.5) | 410 (68.3) |

TABLE 15. Exclusions justified by ability to perform/participate

| | 2000-2004 | 2005-2009 | 2010-2014 | All years |
|--|-----------|-----------|-----------|------------|
| Specific exclusion | 14 (17.1) | 10 (11.2) | 14 (16.7) | 38 (14.9) |
| General exclusion | 3 (33.3) | 3 (21.4) | 4 (23.5) | 10 (25.0) |
| Vague exclusion | 39 (37.9) | 37 (37.4) | 31 (36.0) | 107 (37.2) |
| Specific OR general exclusion | 15 (17.6) | 12 (12.8) | 15 (16.5) | 42 (15.6) |
| Specific OR general OR vague exclusion | 44 (32.1) | 44 (32.8) | 40 (28.8) | 128 (31.2) |

Additionally, we assessed which conditions were excluded most often when conditions were named specifically (Table 16). We found that substance abuse disorders (19.0%), dementia (16.9%), and schizophrenia (14.1%) were the most common specific exclusions named explicitly.

We considered if specific exclusions were for a narrowed version of that condition. For example, a trial could specifically exclude any form of hypertension, or could only exclude class II hypertension. We characterized specific exclusions as narrowed by severity when the exclusion specified or suggested that only certain levels of that condition were excluded. In all, 37.9% of exclusions for specific conditions were narrowed by severity. Trials sometimes used specific diagnostic criteria to narrow by severity (such as *class II hypertension*) but often times used more general terms to narrow (such as *severe dementia*). This created difficulty in assessing what levels of the condition were likely to be excluded.

TABLE 16. Specific conditions excluded

| | Trials exclude this condition | Exclusions for this condition narrowed by severity N=94 |
|--|----------------------------------|---|
| Substance Abuse Disorders | 47 (19.0) | 3 (9.0) |
| Dementia | 42 (16.9) | 7 (87.5) |
| Schizophrenia | 35 (14.1) | 0 (0.0) |
| Stroke | 21 (8.5) | 1 (10.0) |
| Congestive Heart Failure | 20 (8.1) | 6 (66.7) |
| Chronic Kidney Disease | 18 (7.3) | 20 (74.1) |
| Cancer | 16 (6.5) | 10 (41.7) |
| Chronic Obstructive Pulmonary Disease | 13 (5.2) | 2 (66.7) |
| Coronary Artery Disease | 12 (4.8) | 6 (26.1) |
| Depression | 10 (4.0) | 13 (81.3) |
| Diabetes | 8 (3.2) | 3 (42.9) |
| Cardiac Arrhythmias | 1 (0.4) | 1 (14.3) |
| Asthma | 1 (0.4) | 3 (75.0) |
| Arthritis | 1 (0.4) | 1 (33.3) |
| Hepatitis | 1 (0.4) | 1 (50.0) |
| Human Immunodeficiency Virus (HIV) | 1 (0.4) | 1 (100.0) |
| Hyperlipidemia | 1 (0.4) | 0 (0.0) |
| Hypertension | 0 (0.0) | 16 (84.2) |
| Autism Spectrum Disorder | 0 (0.0) | 0 (0.0) |
| Osteoporosis | 0 (0.0) | 0 (0.0) |
| All conditions | 255 (42.5) | 94 (36.9) |

Age

We evaluated the use of a maximum age as exclusion in trials, as the prevalence of MCC increases with age,² so excluding by age may indirectly exclude MCC. We found that 27.8% of trials had exclusions based on a maximum age and in these trials the median age used for exclusions was only 65.0 years (Table 17). The use of a maximum age in exclusion decreased very slightly over time with 26.5% of trials in 2010-2014 excluding participants over a certain age, compared to 28.5% of trials published in both 2000-2004 and 2005-2009 excluding participants based on a maximum age (Table 18). This difference was not significant (p=0.15).

TABLE 17. Age exclusion

| N= 600 | N (%) |
|---------------------|------------|
| Maximum age | |
| No | 433 (72.2) |
| Yes | 167 (27.8) |
| Maximum age (years) | |
| Mean | 66.8 |
| Median | 65.0 |
| Range | 25 - 89 |

TABLE 18. Age exclusion over time

| | 2000-2004 | 2005-2009 | 2010-2014 |
|------------------------|------------|------------|------------|
| Maximum age | | | |
| No | 143 (71.5) | 143 (71.5) | 147 (73.5) |
| Yes | 57 (28.5) | 57 (28.5) | 53 (26.5) |
| Mean age limit (years) | 65.8 | 66.1 | 68.8 |

Behavioral risk factors

We also examined behavioral risk factors or conditions used in exclusion criteria that may have resulted in exclusion of MCC. Specifically, 86 (14.3%) of trials used any behavioral factor for exclusion criteria, with 36 trials excluding participants based on criteria related to physical activity (Table 19). Exclusions based on these risk factors may have been likely to exclude people at higher risk for MCC (e.g., smoked >10 packs a year) but also in some cases excluded those with lower risk of MCC (e.g., “already performing >150 min of moderate vigorous exercise per week”).

TABLE 19. Behavioral risk factor exclusion

| Exclusions for behavioral factors | N (%) |
|-----------------------------------|-----------|
| Any behavioral factor | 86 (14.3) |
| Physical activity | 36 (6.0) |
| Smoking or tobacco use | 24 (4.0) |
| Weight | 23 (3.8) |
| Other substance abuse | 17 (2.9) |
| Alcohol use | 10 (1.7) |
| Diet | 2 (0.3) |

Participant screening

As we found that some trials were reporting general or specific exclusion criteria related to MCC, we questioned if the number of potential participants excluded for having MCC was reported. Only 15.9% of

trials that excluded participants using either general or specific criteria actually reported the number of people excluded for this reason (Table 20). This could be because the trial did not report the number of people excluded during screening, or because numbers given were only for combined eligibility criteria (such as number of people meeting exclusion criteria overall).

TABLE 20. Participant screening

| General OR specific exclusions (N=270) | N (%) |
|--|-----------|
| General exclusions, # reported | 8 (3.0) |
| Specific exclusions, # reported | 35 (13.0) |
| General OR specific exclusions, # reported | 43 (15.9) |

Participant characteristics

We considered MCC information reported in participant characteristics to determine if trials actually included participants with MCC, and if so, could the prevalence of MCC in the trial be determined. We categorized a trial as reporting the presence of MCC if there was any information given from which it could be determined that conditions additional to the index condition existed. This was further categorized into general description (a measure related to chronic conditions in general, such as mean number of comorbidities, percentage of participants with specific number of comorbidities, etc.) or specific description (a measure related to a specific comorbidity). Overall, 35.8% of trials reported the presence of comorbidities through a specific or general description. There was no significant change in this over time ($p=0.07$) (Table 21). Condition specific descriptions were more common than general descriptions (28.7% vs. 11.3%).

Of those trials that reported including MCC, the prevalence of MCC (by general measure or by prevalence of specific conditions) was reported in 59.5% of trials. Of trials reporting specific comorbidities of the index conditions, the mean number of additional conditions reported was 2.1 (Table 22).

TABLE 21. Trials reporting presence of MCC (specific conditions or general measure)

| | 2000-2004 | 2005-2009 | 2010-2014 | Total |
|---------------------------------|-----------|-----------|-----------|------------|
| Condition specific description | 47 (23.5) | 57 (28.5) | 68 (34.0) | 172 (28.7) |
| General description | 22 (11.0) | 20 (10.0) | 26 (13.0) | 68 (11.3) |
| Specific OR general description | 61 (30.5) | 71(35.5) | 83 (80.7) | 215 (35.8) |

TABLE 22. Additional specific conditions are reported

| | N (%) |
|--|------------|
| Report prevalence of MCC (general or specific) | 128 (59.5) |
| Number of conditions reported (N=179) | |
| Mean | 2.1 |
| Median | 2 |
| Range | 0 - 7 |

Of the 68 trials that gave a general description of the presence of MCC, 95.6% reported some measure of MCC (Table 23). These measures were most often the mean number of MCC per participant (44.6%) or the number of or percentage of participants with MCC (43.1%). The Charlson Comorbidity Index (CCI), which predicts the ten-year mortality for a patient who may have a range of comorbid conditions,³⁶ provides a standardized way to report a general measure of MCC and may be more useful than reporting individual specific conditions. However, the CCI was reported less often than other general measures of MCC (15.4%).

TABLE 23. General measures of MCC

| General description reported (n=68) | N (%) |
|--------------------------------------|-----------|
| Any type of measure used | 65 (95.6) |
| Mean number of MCC per participant | 29 (44.6) |
| Number or percentage of participants | 28 (43.1) |
| Charlson Comorbidity Index | 10 (15.4) |

Study analysis

We assessed if presence of comorbidities was considered in the analysis of the trial outcomes. Comorbidities were considered in analysis in only 5.2% of all trials (n=600). Of trials that reported including MCC, any information related to comorbidities was used in analysis in 12.1% of trials. (Table 24).

TABLE 24. Considering comorbidities in analysis

| Use in analysis | N (%) |
|---------------------------------|------------|
| All trials (n=600) | |
| Yes | 31 (5.2) |
| No | 569 (94.8) |
| Trials that include MCC (n=215) | |
| Yes | 26 (12.1) |
| No | 189 (87.9) |

Reported challenges of recruiting individuals with MCC

We initially anticipated summarizing reported challenges of recruiting individuals with MCC; however, we did not find any relevant comments in any of our included trials.

Discussions with key informants

We consulted key informants with particular expertise to provide insight on prioritizing the shaping of analysis, as well as, reporting and presenting the data. While we requested their multifaceted feedback, we also specifically wanted to gather their reactions to our key variables and issues we planned to address with the data, have them evaluate if any items were omitted from this top level summary, and provide feedback both in general and regarding the potential informative nature of the summary. The key informants provided beneficial comments and criticisms, with the majority of their remarks suggesting consideration of the effect of varied reporting methods regarding MCC, redefining or specifying certain eligibility and selection criteria, and proposing particular analysis measures. While many of their comments were not within the scope of this

report or were suggestions we had already incorporated, we did take their additional remarks under advisement and pursued the feasibility of incorporating them into our analysis and report. Moreover, their comments confirmed that we were on the right track in our report strategy and that we were considering measures and analyses that would be the most informative to researchers. For a list of our key informants, their positions and affiliations, and a summary of their comments, see Appendix B.7.

G. Discussion and Conclusions

In this review, we found that in a representative sample of RCTs testing behavioral and/or psychosocial interventions published over the last 15 years (2000-2014), trials rarely target individuals with MCC. Additionally, they frequently exclude individuals with MCC due to specific, general, or vague exclusion criteria, and exclusion criteria based on factors correlated with MCC, such as age. When MCC are used as exclusion criteria, information regarding to what extent potential participants were excluded for having MCC is usually not provided. When trials indicated that some participants did have MCC, the prevalence of MCC either by general measure or by individual conditions is often not specified.

Our ability to answer the key questions for each trial (Table 2) was complicated by an overall lack of information given regarding MCC. When information about MCC was reported, either in eligibility criteria or participant characteristics, the level of detail given varied greatly.

We categorized MCC information as specific, general, or vague. Vague descriptions were the least informative, as it was impossible to determine how these related to MCC, and more specifically, which chronic conditions were likely to have been excluded by vague exclusion criteria.

General descriptions and specific descriptions could be more or less informative depending on their use. For example, when general exclusion criteria were used, occasionally examples of specific conditions that would meet the criteria were given, but in most cases a definition of how that criteria was used in the trial was not provided. Given that there is not an agreed upon definition of chronic condition,¹⁰ assumptions about which conditions would be excluded under that criteria would need to be made. Specific exclusion criteria may be more informative than general exclusion criteria, but overall when information was given by specific conditions only, it was difficult to consider the relationship of conditions to each other. Particularly in participant characteristics, when information was given by individual specific conditions only, it was impossible to gain an overall picture of the presence and extent of MCC in the population. The CCI may be a more informative measure when describing the included population, but it is rarely used.

In view of the risk of bias assessment, we can see that quality of trial reporting is an overall issue not just related to MCC information. Unclear risk of bias, which suggests that the report did not provide appropriate information to judge the risk, was common and seemed to be indicative of the lack of important details given in reports of trials. Improving standards for reporting and increasing trial registration may help to standardize and improve trial performance and reporting.

Publication bias³⁵ must be considered in the context of this review. Given that our sample of trials is from published literature, we must assume that our sample is biased towards larger positive trials and that smaller null studies may not be appropriately represented. It is difficult to assess how this may have affected our results in terms of the inclusion of MCC. For example, if MCC were included and represented a significant portion of the trial population, for certain outcomes a larger effect may be shown as people with MCC may

start out sicker and have more room to improve. With a larger effect, the trial may be more likely to get published. Alternatively, the presence of MCC within the trial population may act as a confounder and reduce the likelihood of an intervention showing an effect if it is not accounted for appropriately, which would reduce the likelihood of the trial getting published.

Our review confirms results from previous reviews that comorbidities are often used as exclusion criteria in trials.^{4,6,8} Maximum age limits are common.^{4,17} General terms rather than specific conditions are used in eligibility often,⁸ and vague or ambiguous terms are used as well.¹⁶ Trials often do not describe the presence of comorbidities in the population, and consideration of comorbidities in analysis is rare.⁴

The strengths of this review include the large volume of RCTs assessed (n=600). This is a much larger sample size than previous reviews. Our sample was created from a comprehensive search performed in multiple databases with extensive search terms performed by a medical librarian with expertise in systematic reviews. By not limiting inclusion to higher impact journals as previous reviews have done, we ensured that our sample was representative of the literature. Our sampling strategy resulted in a broad sample of the literature over the past 15 years that varied in population addressed, conditions considered, intervention component, and study risk of bias, which gave us a wide view of behavioral and/or psychosocial interventions. Additionally, we considered a defined list of 20 conditions instead of limiting to a smaller number of conditions as previous reviews have done. In all aspects of this review we followed established best methods for systematic reviews.²¹ This included an appropriate and replicable search strategy, screening of results for inclusion by two independent reviewers to ensure no relevant reports were missed, and extraction of data from each article by two independent reviewers to ensure quality of data. We assessed the inclusion of MCC in a new population of trials by focusing on behavioral and/or psychosocial interventions specifically, and confirmed that our results were similar to reviews of other intervention types. We extracted a large volume of information from each trial and developed a framework for assessing the inclusion and reporting of MCC in eligibility, screening, selection, and analysis.

Limitations of our review include the fact that we focused on trials targeting a chronic condition. In order to evaluate inclusion based on multiple conditions, it was necessary to first know that all participants had at least one conditions and then assess for presence of further conditions due to the fact that trials so often report information of exclusion or inclusion only by individual specific conditions. Many behavioral and/or psychosocial interventions are often focused on prevention and may therefore include populations that are only at risk of chronic conditions. Our requirement that trials include participants with a chronic condition may limit the generalizability of our results to the broader behavioral and/or psychosocial intervention literature.

Although focusing on a specific list of 20 chronic conditions was a strength of our review, it may have resulted in the inability to consider information from trials presented in ways that did not correspond with our conditions. For example, if trials reported participant characteristics using more broad or vague categories of conditions that we could not link to the 20 conditions or to an overall measure of MCC, we may have missed relevant information. However, we believe that this was a rare occurrence. Additionally, we were limited in the analyses that we were able to perform. We were limited to broad sample statistics rather than more sophisticated analyses or meta-analysis due to the variation in the amount and format of relevant information in these trials.

Based on the results of this review, trials of behavioral and/or psychosocial interventions often exclude MCC, and this has not improved over time. Although our results suggest that individuals with MCC are not

appropriately represented in RCTs of behavioral and/or psychosocial interventions, perhaps of bigger concern is that it is often difficult to determine if and to what extent MCC are included due to the poor reporting quality of relevant information in trials. Collectively these factors make it difficult to judge the appropriateness of applying trial results to the broader population. We recommend that behavioral and psychosocial research that both considers individuals with MCC and reports the involvement of MCC appropriately should emerge as an NCI priority.

H. Implications for further research

In the process of this review, several additional research questions were identified as necessary to address the shortcomings of existing evidence of the representation of individuals with MCC in RCTs. We suggest that the following topics would be among the next steps in evaluating the inclusion of MCC in behavioral and psychosocial trials.

Developing recommendations for reporting MCC and other relevant characteristics in the literature

This review found that even when MCC or other relevant participant characteristics are reported, they are reported in heterogeneous ways that are not always helpful in understanding to what sort of population the results are applicable. An exploration of the most informative ways of reporting this information and development of recommendations for trial reporting would help to address the shortcomings of existing evidence of the representation of MCC in RCTs of behavioral and/or psychosocial interventions.

Potential impact of race/ethnicity

Additional variables considered to be correlated with the presence of MCC were evaluated in this review (age, behavioral risk factors) to determine if inclusion related to these factors may have impacted inclusion of MCC. While this review did not consider race or ethnicity, significant differences in the prevalence of MCC stratified by race/ethnicity have been shown.³⁷ Evaluating reporting of race/ethnicity information in participant characteristics of these trials may provide further information regarding the inclusion of MCC.

Inclusion of MCC in specific condition populations

This review encompasses trials targeting a broad range of chronic conditions; however, it is likely that the inclusion of MCC differs based on the targeted population of each trial. Therefore, it would be important to consider inclusion of MCC within specific areas of study. For example, conducting a similar review of only trials including cancer survivors would allow for a better and more specific understanding of the current state of behavioral research for cancer survivors than the current review allows. A more focused review could include the measures of inclusion used here, but may also necessitate additional considerations regarding factors of particular importance to cancer survivors.

Effect of MCC clustering

Certain combinations of MCC are more prevalent than others,^{37,38} and a focus on these clusters is a key component of the HHS MCC framework.³⁹ It would be of particular concern if trials considering one condition are excluding additional conditions that are often seen alongside the target condition. This would greatly limit the external validity of the trial and make it difficult for practitioners to know how the results may apply to their patients. Inclusion of MCC in trials must be explored in the context of these most

prevalent clusters to understand to what extent individuals with common clusters of MCC are being excluded from trials.

Inclusion of MCC in trials not targeting one condition

All trials included this review are targeting at least one chronic condition, meaning that every participant in the trial has at least one condition. However, many behavioral and/or psychosocial interventions are targeted at people who are at risk for conditions. A similar review should be performed on RCTs of behavioral and/or psychosocial interventions not limited to trials targeting participants with at least one chronic condition to provide a better understanding of the current state inclusion of MCC in behavioral/psychosocial research.

Inclusion of MCC in trials of specific intervention types

Inclusion of MCC may differ by intervention focus. As exclusions for MCC are often justified by limiting the ability of the individual to physically participate in the trial, it would be expected that physical activity trials may exclude MCC more often due to the physical requirements of the interventions. A more focused review on trials testing physical activity interventions would evaluate the impact of such eligibility criteria, consider if these exclusions are appropriately justified, and describe how the generalizability of the trials are affected. Similar reviews could be performed for other intervention types.

Relationship between efficacy/effectiveness of interventions and inclusion of MCC

It is unclear how inclusion of MCC may be related to efficacy and/or effectiveness of trials of behavioral and/or psychosocial interventions. A Mann-Whitney meta-analysis⁴⁰ was proposed for this review to address this relationship, but these methods were determined to not be feasible for this review due to the limited number of articles that provided sufficient outcome data for analysis and reporting of MCC. Narrowing down the sample to articles that provide appropriate information for this analysis or developing new methodology as needed would allow for an evaluation of the relationship between efficacy and/or effectiveness of interventions and inclusion of MCC. This would be essential for understanding how the inclusion of MCC is affecting the current evidence base of behavioral and/or psychosocial interventions. Additionally, describing the relationship between efficacy/effectiveness and inclusion of MCC could also help to clarify the impact of publication bias on this review.

Trial funding source correlation to inclusion of MCC

An original goal of this review was to provide evidence of research that considers individuals with MCC in order to establish if this type of research should emerge as a NCI priority. Accordingly, by assessing the inclusion of MCC in trials funded by the NCI in comparison to trials funded by the NIH as a whole or other funding sources, it would be possible to better evaluate the current state of MCC inclusion in NCI funded research.

Impact factor of journal and inclusion of MCC

Previous reviews considered trials from high impact journals only, but the current review did not limit by impact factor. It is possible that impact factor of journal may be correlated with the likelihood of the trial including MCC or with the reporting quality of the trial regarding MCC. However it may be difficult to measure over time, as impact factor changes and would be most appropriate to consider the impact factor of a journal at time of publication.

Consideration of pragmatic-explanatory trials and MCC

Exclusion of MCC may be more common in explanatory trials due to the emphasis on internal validity, while it would be expected that pragmatic trials would have less restrictive eligibility criteria. In order to confirm this hypothesis, there needs to be a way to assess where a trial falls on the pragmatic-explanatory continuum based on published reports. The PRECIS⁴¹ and PRECIS-2⁴² tools provide a framework for considering the position of a trial on the pragmatic-explanatory continuum. However, when we attempted to use a selection of these measures to evaluate trials in this review, we found that trials often did not provide appropriate information to adequately assess their position on this continuum. The development of a better method for using these measures or new measures to assess trial reports would allow for the relationship between the pragmatic-explanatory continuum and MCC to be explored. Additionally, considering reporting of participant characteristics in these trials would allow for the confirmation that broader eligibility criteria actually leads to a trial population more reflective of the general population.

Assessing general reporting of RCTs with CONSORT

A major challenge in this review was the lack of reported information regarding MCC in trials. It would be useful to consider the quality of reporting in trials in general and consider the reporting of information regarding MCC in this context. For example, CONSORT⁴³⁻⁴⁵ provides a framework for reporting of trial findings and is endorsed by many journals. However, the iterations of CONSORT over time (1996, 2001, 2010) make it difficult to analyze the use of CONSORT longitudinally, as would be necessary in this review. Even when considering the same issues of reporting, the versions of CONSORT can differ in number of items and exactly what is being assessed. Additionally, it is difficult to determine at what point in time each version of CONSORT should be used, as there is no simple way to determine precisely when it was formally endorsed by individual journals. Nevertheless, the development of a framework to use CONSORT over time would contribute to the understanding of inclusion of MCC by providing a methodology for assessing overall reporting quality of RCTs.

Specific aims of trials compared to trial report

The poor reporting of primary outcomes, eligibility criteria, and additional trial information in RCTs was a major challenge in this review. It may be useful to consider the original specific aims of NIH funded research and compare those to the trial report, as well as to assess if the population included and primary outcome is reported as planned, if eligibility criteria has been altered, or if other significant differences exist.

I. References

1. Parekh AK, Barton MB. The challenge of multiple comorbidity for the US health care system. *JAMA : the journal of the American Medical Association*. Apr 7 2010;303(13):1303-1304.
2. National Center for Health Statistics. Health, United States, 2014: With Special Feature on Adults Aged 55–64. 2015.
3. Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. *Washington, DC: US Census Bureau*. 2014:25-1140.

4. Boyd CM, Vollenweider D, Puhan MA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. *PLoS One*. 2012;7(8):e41601. PMC3411714:
5. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? *Annals of family medicine*. Mar-Apr 2006;4(2):104-108. PMC1467012:
6. Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. *JAMA: the journal of the American Medical Association*. 2011;306(24):2670-2672.
7. Ritchie CS, Zulman DM. Research priorities in geriatric palliative care: multimorbidity. *Journal of palliative medicine*. Aug 2013;16(8):843-847. PMC3717194:
8. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. *JAMA : the journal of the American Medical Association*. Mar 21 2007;297(11):1233-1240.
9. Kenning C, Coventry PA, Bower P. Self-management interventions in patients with long-term conditions: a structured review of approaches to reporting inclusion, assessment, and outcomes in multimorbidity. *2014*. 2014-08-28 2014;4(1):9.
10. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and Measuring Chronic Conditions: Imperatives for Research, Policy, Program, and Practice. *Preventing Chronic Disease*. 2013;10:E66.
11. Weiss CO, Boyd CM, Yu Q, Wolff JL, Leff B. Patterns of prevalent major chronic disease among older adults in the united states. *JAMA : the journal of the American Medical Association*. 2007;298(10):1158-1162.
12. Weiss CO, Varadhan R, Puhan MA, et al. Multimorbidity and evidence generation. *Journal of general internal medicine*. 2014;29(4):653-660.
13. Guralnik JM. Assessing the impact of comorbidity in the older population. *Annals of epidemiology*. 1996;6(5):376-380.
14. Trask PC, Schwartz SM, Deaner SL, et al. Behavioral medicine: the challenge of integrating psychological and behavioral approaches into primary care. *Effective clinical practice : ECP*. Mar-Apr 2002;5(2):75-83.
15. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA : the journal of the American Medical Association*. Mar 10 2004;291(10):1238-1245.
16. Schmidt AF, Groenwold RH, van Delden JJ, et al. Justification of exclusion criteria was underreported in a review of cardiovascular trials. *Journal of clinical epidemiology*. Jun 2014;67(6):635-644.
17. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. *Journal of general internal medicine*. 2011;26(7):783-790.
18. Michie S, Richardson M, Johnston M, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*. Aug 2013;46(1):81-95.
19. Edwards P, Clarke M, DiGiuseppi C, Pratap S, Roberts I, Wentz R. Identification of randomized controlled trials in systematic reviews: accuracy and reliability of screening records. *Statistics in medicine*. 2002;21(11):1635-1640.
20. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow process for providing translational

- research informatics support. *Journal of biomedical informatics*. Apr 2009;42(2):377-381. Pmc2700030:
21. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2008.
 22. Buscemi N, Hartling L, Vandermeer B, Tjosvold L, Klassen TP. Single data extraction generated more errors than double data extraction in systematic reviews. *Journal of clinical epidemiology*. 2006;59(7):697-703.
 23. Jones AP, Remington T, Williamson PR, Ashby D, Smyth RL. High prevalence but low impact of data extraction and reporting errors were found in Cochrane systematic reviews. *Journal of clinical epidemiology*. Jul 2005;58(7):741-742.
 24. Lugtenberg M, Burgers JS, Clancy C, Westert GP, Schneider EC. Current Guidelines Have Limited Applicability to Patients with Comorbid Conditions: A Systematic Analysis of Evidence-Based Guidelines. *PLoS ONE*. 2011;6(10):e25987.
 25. To MJ, Jones J, Emara M, Jadad AR. Are reports of randomized controlled trials improving over time? A systematic review of 284 articles published in high-impact general and specialized medical journals. *PLoS One*. 2013;8(12):e84779. Pmc3877340:
 26. Mundi S, Chaudhry H, Bhandari M. Systematic review on the inclusion of patients with cognitive impairment in hip fracture trials: a missed opportunity? *Canadian journal of surgery. Journal canadien de chirurgie*. Aug 2014;57(4):E141-145. Pmc4119128:
 27. Ronconi JM, Shiner B, Watts BV. Inclusion and exclusion criteria in randomized controlled trials of psychotherapy for PTSD. *Journal of psychiatric practice*. Jan 2014;20(1):25-37.
 28. Paek T, Ferreira ML, Sun C, Lin CW, Tiedemann A, Maher CG. Are older adults missing from low back pain clinical trials? A systematic review and meta-analysis. *Arthritis care & research*. Aug 2014;66(8):1220-1226.
 29. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ: British Medical Journal*. 2011;343.
 30. Guyatt GH, Oxman AD, Vist GE, et al. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ: British Medical Journal*. 2008;336(7650):924.
 31. Oxman AD, Group GW. Grading quality of evidence and strength of recommendations. *BMJ (Clinical research ed.)*. 2004;328(19):1490-1494.
 32. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. *American journal of respiratory and critical care medicine*. 2006;174(5):605-614.
 33. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? *BMJ (Clinical research ed.)*. 2008;336(7651):995-998.
 34. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in medicine*. 2002;21(11):1539-1558.
 35. Sterne JA, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. *BMJ (Clinical research ed.)*. 2001;323(7304):101-105.
 36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases*. 1987;40(5):373-383.
 37. Ward BW, Schiller JS. Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From the National Health Interview Survey, 2010. *Preventing Chronic Disease*. 2013;10:E65.

38. Sinnige J, Braspenning J, Schellevis F, Stirbu-Wagner I, Westert G, Korevaar J. The Prevalence of Disease Clusters in Older Adults with Multiple Chronic Diseases—A Systematic Literature Review. 2013.
39. Parekh AK, Goodman RA, Gordon C, Koh HK, Conditions HIWoMC. Managing multiple chronic conditions: a strategic framework for improving health outcomes and quality of life. *Public health reports*. 2011;126(4):460.
40. Colditz GA, Miller JN, Mosteller F. Measuring gain in the evaluation of medical technology. The probability of a better outcome. *International journal of technology assessment in health care*. 1988;4(4):637-642.
41. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *Journal of clinical epidemiology*. 2009;62(5):464-475.
42. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ (Clinical research ed.)*. 2015;350:h2147.
43. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Journal of clinical epidemiology*. 2010;63(8):e1-e37.
44. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. *Controlled clinical trials*. 1995;16(1):62-73.
45. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Annals of internal medicine*. 2001;134(8):663-694.

| Appendix A: Deliverables | | |
|--|--|----------------------|
| Milestones/Deliverables | | |
| Major Milestones/Deliverables | Time Period / Due Date | Date competed |
| Phase 1: Topic refinement, sampling and analysis plan development, protocol writing | Month 1- Month 3 (October 2014 – December 2014) | |
| Milestone 1: Project kick-off call | Month 1 – Month 2 (November 2014) | November 2014 |
| Milestone 1.1.4: Finalization of PICOT topic and key questions | Month 2 (November 2014) | December 2014 |
| Milestone 1.1.5: Finalization of inclusion/exclusion criteria | Month 2 (November 2014) | December 2014 |
| Milestone 1.2.2: Finalization of sampling strategy | Month 1 – Month 2 (October 2014 - November 2014) | November 2014 |
| Milestone 1.4.1: Finalization of protocol | Month 1 – Month 2 (October 2014 - November 2014) | December 2014 |
| Phase 1 Deliverables: | | |
| A. Monthly interim report | As indicated on cover page | |
| B. Background on the relevance of multiple chronic conditions in behavioral and psychosocial intervention research; process for further refinement of key scientific questions as deemed necessary and with justification | October 2014 – November 2014 | October 2014 |
| C. Summary of the discussions held with the key informants and the outcomes/impact on the project, including the list of questions asked of each informant | To be included in the Systematic Review Report, due 10/25/2015 | September 2015 |
| D. Study protocol to include key scientific questions and study objectives; methodology (search strategy for sources of evidence including databases and resources used); selection criteria (detailed study inclusion/exclusion criteria); data collection, coding schema, and analytical plans | November 2014 – December 2014 | December 2014 |

| | | |
|---|--|---------------|
| Phase 2: Extraction forms development, development of quality assessment plan, literature search | Months 2 – 3 (November 2014 – December 2014) | |
| Milestone 2.1.2: Finalization of extraction form | Month 2 – Month 3 (November 2014 – December 2014) | December 2014 |
| Milestone 2.2.4: Finalize quality assessment tool | Month 2 – Month 3 (November 2014 – December 2014) | December 2014 |
| Milestone 2.3.1.3: Finalization of search strategy | Month 2 – Month 3 (November 2014 – December 2014) | January 2015 |
| Milestone 2.3.1.4: Performance of literature search | Month 2 – Month 3 (November 2014 – December 2014) | January 2015 |
| Phase 2 Deliverables: | | |
| A. Monthly interim report | As indicated on cover page | |
| B. Extraction sheet to include examples of what and how information will be extracted | December 2014 | December 2014 |
| Phase 3: Study selection, data extraction, and quality assessment | Months 4-8 (January 2015 – May 2015) | |
| Milestone 3.2.3: Log of excluded studies with reasons for exclusion | Month 4 – Month 5 (January 2015 – February 2015) | July 2015 |
| Milestone 3.2.4: Finalized list of selected studies | Month 4 – Month 5 (January 2015 – February 2015) | July 2015 |
| Milestone 3.2.5.2: Completed database of extracted data | Month 5 – Month 8 (February 2015 – May 2015) | August 2015 |
| Phase 3 Deliverables: | | |
| A. Included list to reflect articles being captured by methodology and selection criteria | To be included in the Systematic Review Report, due 10/25/2015 | August 2015 |
| Phase 4: Data Synthesis and analysis | Months 8 – 10 (May 2015 – July 2015) | |
| Milestone 4.1.2: Table of study and patient characteristics | Month 8 – Month 10 (May 2015 – July 2015) | August 2015 |

| | | |
|---|--|----------------|
| Milestone 4.1.3: Table summarizing reported challenges of recruiting individuals with MMCs | Month 8 – Month 10 (May 2015 – July 2015) | August 2015 |
| Milestone 4.2.6: Tables of figures key outcomes | Month 8 – Month 10 (May 2015 – July 2015) | August 2015 |
| Milestone 4.3.1: Summary of study quality including GRADEing of evidence | Month 8 – Month 10 (May 2015 – July 2015) | August 2015 |
| Phase 4 Deliverables: | | |
| A. Monthly interim reports | As indicated on cover page | |
| B. Tables including GRADEing of the evidence | July 2015 | July 2015 |
| Phase 5: Formation of conclusions and reporting of recommendations | | |
| Phase 5 Deliverables: | | |
| A. Database publication per submitted plan including: <ul style="list-style-type: none"> • Database • Data Dictionary • Codebook • FAQ document • Hosting of Database and documents on WUSTL website | Month 12 (September 2015) | September 2015 |
| B. Monthly interim reports | As indicated on cover page | |
| C. Presentation of preliminary systematic review report | July 27, 2015 | July 2015 |
| D. Draft of the systematic review report | 9/4/2015 | September 2015 |
| E. Final Systematic Review Report, including responses to questions posed during NCI review | No later than 10/25/2015 | October 2015 |

Appendix B: Additional Information

1. Protocol

BACKGROUND

There are roughly 75 million people in the United States with multiple chronic conditions (MCC), and 65% of total health care spending in the nation is used for this quarter of the population.¹ In 2010 only 32% of Medicare fee-for-service beneficiaries had zero or one chronic condition, while 32% had two or three, 25% had four or five, and 14% had six or more chronic conditions.²

However, randomized controlled trials (RCTs) frequently exclude patients with MCC.^{1,3-7} In a systematic sampling of high impact general medical journals, 81% of RCTs reviewed excluded patients with MCC.⁷ A similar review sampling both general and specialized high impact medical journals found patients with MCC were excluded from 63% of all RCTs and 90% of RCTs that explicitly or implicitly mentioned MCC. Only 2% of RCTs explicitly included patients with MCC.⁵ Furthermore, when these patients are not excluded, reporting of co-occurring chronic conditions is limited.^{3,4,8} An in-depth survey of clinical trials revealed only a 44% reporting rate of participant comorbidities.³ This inconsistency between the characteristics of eligible patients in RCTs and the characteristics of the actual patient population with the disease reduces confidence in applying trial results to the patient population.^{3,6} Consequently, the knowledge base for multiple chronic conditions is largely limited by the reliance on clinical trials that strive to maximize internal validity by excluding patients with comorbidities.¹

It is well established that behavioral and psychological factors play a large role in outcomes for numerous chronic conditions, such as cancer, cardiovascular disease, and diabetes.⁹ In an in depth analysis of actual causes of US deaths in the year 2000, the three leading causes were behavioral based and largely modifiable: tobacco use (18.1%), poor diet and physical inactivity (15.2%), and alcohol consumption (3.5%).¹⁰ These figures illuminate the importance of testing behavioral/psychosocial interventions within RCTs. Yet, the inclusion of MCC patients specifically in such trials has not been studied. As these patients account for roughly 25% of the US population, this is an area that warrants further examination.

Description of the condition

The challenge of treating patients who have MCC is further exacerbated by the large variance in how chronic condition is defined, which is problematic when comparing results across studies and attaining accurate prevalence rates. Among peer reviewed literature and public information sources, there is much inconsistency in several dimensions of the definition, such as the duration, effect on function and well-being, and need for medical attention.¹¹ To address this issue, an MCC working group at the Office of the Assistant Secretary of Health (OASH) within the US Department of Health and Human Services (HHS) compiled a list chronic conditions that met the definition for chronicity, are prevalent and have potential to be modifiable by public health and/or clinical interventions. The definition OASH used defined chronic illnesses as conditions that last a year or more and require ongoing medical attention and/or limit activities of daily living. This resulted in a compilation of 20 conditions (Table 1).¹¹

| Table 1: OASH List of Chronic Conditions |
|--|
| Arthritis |
| Asthma |
| Autism spectrum disorder |
| Cancer |
| Cardiac arrhythmias |

| |
|---|
| Chronic kidney disease |
| Chronic obstructive pulmonary disease |
| Congestive heart failure |
| Coronary artery disease |
| Dementia (including Alzheimer's and other senile dementias) |
| Depression |
| Diabetes |
| Hepatitis |
| Human immunodeficiency virus (HIV) |
| Hyperlipidemia |
| Hypertension |
| Osteoporosis |
| Schizophrenia |
| Stroke |
| Substance abuse disorders (drug and alcohol) |

Why it is important to do this review

The evaluation of representation of individuals with MCC in RCTs over the past 15 years is necessary in order to determine if behavioral and psychosocial intervention research that considers individuals with multiple chronic conditions should emerge as a research priority. We aim to perform the review, evaluation and summarization of data regarding the representation of individuals with multiple chronic conditions in RCTs of behavioral and psychosocial interventions published in general medical, behavioral medicine, behavioral science, health psychology, social science, and public health journals.

OBJECTIVES

With this review we seek to test the hypothesis that individuals with multiple chronic conditions are underrepresented in RCTs of behavioral and psychosocial interventions published in general medical, behavioral medicine, behavioral science, health psychology, social science, and public health journals. The overall goals of the project are as follows:

Goal 1: Conduct a systematic review to assess the frequency with which research participants with MCC are represented in all or a representative subset of RCTs of behavioral and psychosocial interventions published in general medical and specialized journals, published within the last decade or decade and a half, that focus on behavioral medicine and behavioral science, health psychology, social science, and public health.

Goal 2: Determine whether there are significant differences by type of journal or over time in the frequency with which research participants with MCC are represented in RCTs of behavioral and psychosocial interventions.

These goals will be accomplished with the following objectives:

Objective 1: Perform a systematic review of a representative sample of the peer-reviewed literature over the past 15 years (2000-2014) to describe, quantify, and critically appraise the inclusion of individuals with MCC in RCTs designed to develop and/or test the efficacy or effectiveness of behavioral and psychosocial interventions to modify health behaviors, improve health-related quality of life, psychosocial functioning, and/or health outcomes.

Objective 2: Describe and analyze how inclusion/exclusion of individuals with MCC in RCTs differs across time and by journal type. As appropriate, consider other factors such as components of intervention.

METHODS

Criteria for selecting studies for this review

Types of studies

All randomized controlled trials testing the efficacy or effectiveness of behavioral or psychosocial interventions to modify health behaviors, improve health-related quality of life, psychosocial functioning, and/or health outcomes.

Types of participants

All human adults (18+) with at least one chronic condition.

Types of conditions

For purposes of selecting studies, we will consider the following 20 chronic conditions as potential targets of the interventions: arthritis, asthma, autism spectrum disorder, cancer, cardiac arrhythmias, chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, dementia (including Alzheimer's and other senile dementias), depression, diabetes, hepatitis, human immunodeficiency virus, hyperlipidemia, hypertension, osteoporosis, schizophrenia, stroke, substance abuse disorders (drug and alcohol).

Types of interventions

For the purpose of this review, we define "behavioral or psychosocial intervention" to mean any intervention that is non-pharmacological and non-surgical. Additionally, there must be some aspect of direct communication with an individual (or small group) whether this is in person, by phone, by internet, etc. This ensures that participants are enrolled at the individual level, meaning that we will not include interventions that are only performed at a community, campus, etc level.

Comparison groups can be usual care, pharmacological interventions, surgical interventions, or a lesser dose of the treatment. Interventions may include a behavioral or psychosocial intervention in addition to a drug or surgery, as long as the comparison group is not receiving the same behavioral or psychosocial intervention.

Types of outcome measures

Primary outcomes

- Exclusion of individuals with multiple chronic conditions
 - Whether exclusion used names of specific conditions or used general terms such as comorbidities or coexisting disease explicitly
 - Proportion of participants excluded due to MCC
- Inclusion of individuals with multiple chronic conditions
 - Proportion of participants included with multiple chronic conditions
 - Which specific conditions were included

Secondary outcomes

- Additional details of each trial that could potentially be used in the meta-analyses, including year, type of journal (general or specialized), components of intervention, and quality of trial.

Search methods for identification of studies

The search strategy will be developed by an MLIS clinical librarian with expertise in searching for systematic reviews. We anticipate searching multiple databases (MEDLINE, EMBASE, etc) for English-language trials published from 2000 to 2014. Hand-searching will not be performed.

We will then apply our sampling strategy (see *Sampling plan* below) in order to create a representative sample of the peer-reviewed literature on RCTs designed to develop and/or test efficacy or effectiveness of behavioral and psychosocial interventions over the past 15 years.

Data collection and analysis

Sampling plan

We expect our search strategy to produce an extremely large number of results that would not be possible to manage in a reasonable amount of time. In order to reduce the number of trials to be screened we have developed a sampling plan. This will result in a project that is manageable in the allotted time frame and provides meaningful results without imposing unnecessary restrictions on study selection and inclusion criteria that would reduce the representativeness of our sample.

Three separate literature searches (using identical keywords and in the same databases) will be done within defined time periods (2000-2004, 2005-2009, 2010-2014). Within each time-period group, search results will be randomly ordered. The study selection process (application of inclusion/exclusion onto each article) will be performed on the randomly ordered results until the desired number of studies for extraction meeting inclusion/exclusion criteria have been identified (200 per time period for a total of 600 articles).

Selection of studies

Two independent reviewers will screen the titles and the abstracts based on the following exclusion criteria:

1. Not an RCT with original data
2. Not a primary report (will not include protocols, posttrial follow-up studies, secondary subgroup analyses, etc)
3. Not published in English
4. Not targeting at least one of chronic conditions of interest (see *Types of conditions*)
5. Not testing a behavioral or psychosocial intervention or not including an accepted comparison group (see *Types of interventions*)
6. Not including patients with at least one chronic condition
7. Not enrolling participants at the individual level
8. Not human adult subjects (18+)

Excluded articles and a reason for exclusion will be carefully documented. Any disagreement between the two authors will be resolved by a third party. If the title and the abstract is not clear to determine to reject, or disagreement is not resolved by discussion, the full-text of the article will be retrieved. Reviewers assessing study eligibility will not be blinded to the names of the authors, journals, and other publication details.

Data extraction and management

Characteristics of included studies and data will be extracted independently by two reviewers using a standard abstraction form. The abstraction form will be created and used in REDCap. REDCap is uniquely suited to meet the needs of an effective and efficient data extraction process. It allows form creators to require specific entry formats for individual questions (ensuring reviewers input data in a consistent format), allows for multiple types of response formats (dropdown menus, select all, select only one, open-ended text entry, etc), and performs data validation to improve accuracy of extraction. In addition REDCap has a built in “Double Data Entry” feature, which allows multiple users to input data from a single source and automatically compares the entries and identifies differences. Disagreements that are identified by the “Double Data Entry” feature will be resolved by a third party (project manager).

Data extracted will include the following:

- Basic study characteristics (journal, journal type, journal impact factor, publication year, funding source, article title, author, country/region, trial registration, and study protocol access)
- Intervention details (enrollment/intervention duration timeframes, condition(s) targeted, number of study arms, description of comparison group including number/age/sex etc, description of intervention group including number/age/sex etc, studywide characteristics/sample size, and type/description of intervention components)
- Eligibility details (reporting of eligibility, general/specific/vague exclusion criteria, proportion of excluded patients with MCC, and justifications for exclusions)
- Patient selection details (CONSORT participant flow, MCC inclusion implicitly or explicitly, proportion of included participants with MCC, specific MCC mentioned, and how information regarding targeted and other MCC was obtained)
- Quality assessment (selection bias, performance bias, detection bias, attrition bias, and reporting bias)
- Outcomes (presence of primary outcome, type of primary outcome, how primary outcome is measured, result of primary outcome, author conclusions, subgroup analyses, and effect modification)

Assessment of methodological quality in included studies

Two reviewers will independently assess methodological quality of the trials independently. Disagreements will be resolved by a third party. The quality of the RCTs will be assessed using a modified version of the Cochrane Collaboration’s Risk of Bias tool, which evaluates seven domains including selection bias, performance bias, detection bias, attrition bias, reporting bias, and ‘other bias.’¹² For each domain, the trial is given a rating of low risk of bias, high risk of bias, or unclear risk of bias. We will use this information in analysis in several ways, by using individual items, domains, or overall quality. For this review we will remove the “other bias” domain as it is unnecessary for the scope of this generalized report and is better suited for more specialized studies.

Dealing with missing data and duplicate studies

As a key part of this review is to assess the reporting of information regarding MCC, no attempts will be made to contact authors for additional information. For each extraction item there will be an option to list as “not reported.” Duplicate studies will not be included, and only one article will be used for each trial.

Data synthesis

Analyses will be determined by specifics of data extracted (both type and volume) from selected studies; however, we anticipate that the large scope of this review will provide enough data to perform the following analyses.

We will summarize and describe the studies, populations, interventions, and outcomes included to verify that we have a representative sample. Assessment of inclusion of patients with MCC will greatly depend on how the information is presented in included studies, but we intend to perform such analyses as (1) calculating the proportion of studies explicitly excluding patients with MCC, (2) synthesizing a list of and frequency of each chronic condition present in patients in trials, (3) performing a proportions meta-analysis to estimate average proportion of patients within a trial that have MCC when they are included.

Key outcomes regarding inclusion of patients with MCC can be stratified by time category, journal type (general vs specialized), quality of study (as measured by our original quality tool and the GRADE process) and by other key variables identified throughout the process. Additionally time can be used as continuous variables in a meta-regression.^{13,14} Study quality overall score can be used in a meta-regression or individual quality categories can be used to explore relationship with inclusion of patients with MCC and address issues of bias. Study quality data will also be used to descriptively assess the body of evidence.

We will also descriptively synthesize and report any challenges of recruiting as described by the primary authors of the RCTs included in this SRMA.

Additionally, publication bias will be explored.¹⁵

We anticipate all meta-analyses performed will be done so with a random effects model. Data analysis will be performed using STATA 12.0 (College Station, TX), which provides a comprehensive set of meta-analysis routines, with additional analysis in R (3.1.0) as needed.

Assessment of heterogeneity

If any meta-analyses are performed, statistical heterogeneity will be assessed with the Cochran's Q and Higgins I² statistic.¹⁶ We anticipate that the amount of heterogeneity will suggest that the random effects model is appropriate.

Subgroup analysis and investigation of heterogeneity

Key outcomes regarding inclusion of patients with MCC can be stratified by time category, journal type (general vs specialized), quality of study and by other key variables identified throughout the process. If meta-analyses are performed, time can be used as a continuous variable in a meta-regression.^{13,14} Study quality overall score can be used in a meta-regression or individual quality categories can be used to explore relationship with inclusion of patients with MCC and address issues of bias.

References

1. Parekh AK, Barton MB. The challenge of multiple comorbidity for the US health care system. *JAMA : the journal of the American Medical Association*. Apr 7 2010;303(13):1303-1304.
2. Agency for Healthcare Research and Quality. National Healthcare Disparities Report, 2013. Rockville, MD May 2014.

3. Boyd CM, Vollenweider D, Puhan MA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. *PLoS One*. 2012;7(8):e41601. PMC3411714:
4. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? *Annals of family medicine*. Mar-Apr 2006;4(2):104-108. PMC1467012:
5. Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. *JAMA: the journal of the American Medical Association*. 2011;306(24):2670-2672.
6. Ritchie CS, Zulman DM. Research priorities in geriatric palliative care: multimorbidity. *Journal of palliative medicine*. Aug 2013;16(8):843-847. PMC3717194:
7. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. *JAMA : the journal of the American Medical Association*. Mar 21 2007;297(11):1233-1240.
8. Kenning C, Coventry PA, Bower P. Self-management interventions in patients with long-term conditions: a structured review of approaches to reporting inclusion, assessment, and outcomes in multimorbidity. *2014*. 2014-08-28 2014;4(1):9.
9. Trask PC, Schwartz SM, Deaner SL, et al. Behavioral medicine: the challenge of integrating psychological and behavioral approaches into primary care. *Effective clinical practice : ECP*. Mar-Apr 2002;5(2):75-83.
10. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA : the journal of the American Medical Association*. Mar 10 2004;291(10):1238-1245.
11. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and Measuring Chronic Conditions: Imperatives for Research, Policy, Program, and Practice. *Preventing Chronic Disease*. 2013;10:E66.
12. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2008.
13. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics*. Jul 1995;96(1 Pt 1):29-35.
14. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA : the journal of the American Medical Association*. Mar 2 1994;271(9):698-702.
15. Sterne JA, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. *BMJ (Clinical research ed.)*. 2001;323(7304):101-105.
16. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in medicine*. 2002;21(11):1539-1558.

2. Differences between protocol and report

This section summarizes the main changes in methods for our review. We found that some aspects included in our original protocol were impractical based on the scope of our report, the time restraint for completing the project, and/or another unexpected factor. For example, in our original objectives we planned to analyze how inclusion of individuals with MCC in RCTs differed across journal impact factor and if this was associated with the efficacy or effectiveness of interventions. We also planned to describe the challenges of recruiting individuals with MCC to participate in trials and identify improvements for future studies regarding reporting and inclusion of individuals with MCC. After beginning extraction we determined that we would have only a very small number of articles from high impact journals and a very large number from low/average impact journals given that we did not use impact factor in our inclusion criteria. Although previous reviews purposefully chose high impact journals, we wanted a more representative sample of RCTs. Additionally, we addressed the possibility of looking into journal impact factor, efficacy/effectiveness of interventions, challenges of recruiting individuals with MCC, and improvements for future studies regarding reporting and inclusion of individuals with MCC in our implications for future research section as these topics were better suited for a more in depth and extended review. Furthermore, we also anticipated conducting an exploratory analysis regarding the primary outcome of the trial as one of our secondary outcomes. Again, we found that this aspect would be better suited for comprehensive report, and we identified this in our future directions section.

Another change that was made was extending and specifying our data extraction parameters. Through more extensive research and input from key informants, we narrowed our criterion for data extraction to be more specific to our primary and secondary outcomes. Additionally, we originally anticipated assessing the quality of the RCTs using a modified version of the Cochrane Collaboration's Risk of Bias tool, which evaluates seven domains including selection bias, performance bias, detection bias, attrition bias, reporting bias, and 'other bias.' However, before beginning extraction we removed the "other bias" domain as this element was an unnecessary consideration under the scope of this review and is better suited for more specialized studies. This determination was also addressed in the "Assessment of risk of bias in included studies" section of our report.

We planned to stratify our key outcomes by journal impact factor and intervention components (outcomes targeted, index disease targeted, type of intervention). As stated previously, we found that these factors were not pertinent to the scope and aim of this generalized report and would be better suited in a more expansive research paper focusing on these aspects of reporting in RCTs. The possibility of including these components was addressed in our future directions section.

A Mann-Whitney meta-analysis to explore the relationship between efficacy/effectiveness of interventions and inclusion of MCC was not feasible given the small amount of trials that reported outcome information in the necessary format for this analysis.

Ultimately we determined that the changes made from our original protocol did not impact the strength of our report, and, in addition, these differences are addressed in our future directions section as aspects that should be considered in a more comprehensive report.

3. Search Strategy

PubMed

("Young Adult"[Mesh] OR "Adult"[Mesh] OR "Middle Aged"[Mesh] OR "Aged"[Mesh] OR "Aged, 80 and over"[Mesh] OR "Frail Elderly"[Mesh] OR "adult" OR "adults" OR Middle age*[tiab] OR Geriatric* OR Aged OR Elder* OR Nonagenarian* OR Octogenarian* OR Centenarian* OR "senior citizen" OR "senior citizens" OR senium OR "very old" OR "oldest old" OR "older patient" OR "older patients" OR "older people") AND ("Controlled Clinical Trial"[Publication Type] OR "Randomized Controlled Trial"[Publication Type]) AND ("Chronic Disease"[Mesh] OR "Chronic Disease" OR "chronic illness" OR "chronic Diseases" OR "Chronic Illnesses" OR "Chronically Ill" OR "Arthritis"[Mesh] OR "Arthritis" OR "Arthritides" OR "articular tuberculosis" OR "bone joint tuberculosis" OR "joint tuberculosis" OR "osteo-articular tuberculosis" OR "osteoarticular tuberculosis" OR "tuberculosis joint" OR "osteoarticular tuberculosis" OR "Psoriasis Arthropathica" OR "Caplan's Syndrome" OR "Felty Syndrome" OR "Rheumatoid Nodule" OR "Rheumatoid Nodules" OR "Rheumatoid Nodulosis" OR "Rheumatoid Vasculitis" OR "Sjogren Syndrome" OR "Sjogrens Syndrome" OR "Sjogren's Syndrome" OR "Sicca Syndrome" OR "Adult-Onset Still's Disease" OR "Adult Onset Still's Disease" OR "Adult-Onset Stills Disease" OR "Adult-Onset Still Disease" OR "Adult Onset Still Disease" OR "Chondrocalcinosis" OR "Calcium Pyrophosphate Dihydrate Deposition" OR "Pseudogout" OR "Chondrocalcinosis" OR "Gout" OR "Gouts" OR "gouty" OR "Osteoarthritis" OR "Osteoarthritis" OR "Osteoarthrosis" OR "Osteoarthroses" OR "Periarthritis" OR "Periarthritides" OR "Rheumatic Fevers" OR "Inflammatory Rheumatism" OR "Rheumatic Fever" OR "Rheumatic Nodule" OR "Rheumatic Nodules" OR "Aschoff Bodies" OR "Aschoff Bodies" OR "Wissler's Syndrome" OR "Wissler-Fanconi Syndrome" OR "Wissler Fanconi Syndrome" OR "Subsepsis Allergica" OR "Subsepsis Hyperergica" OR "Sacroiliitis" OR "Spondylarthropathies" OR "Spondylarthropathy" OR "Bechterew Disease" OR "Bechterew's Disease" OR "Bechterews Disease" OR "Ankylosing Spondyloarthritis" OR "Rheumatoid Spondylitis" OR "Spondylarthritis Ankylopoietica" OR "Ankylosing Spondylarthritis" OR "Ankylosing Spondylarthritis" OR "Ankylosing Spondylitis" OR "Marie-Struempell Disease" OR "Marie Struempell Disease" OR "Coxarthrosis" OR "Coxarthroses" OR "hip arthrosis" OR "hip joint arthrosis" OR "cox arthrosis" OR "malum coxae senilis" OR "arthrosynovitis" OR "joint inflammation" OR "oligoarthritis" OR "antisynthetase syndrome" OR "Behcet disease" OR "Behcet's syndrome" OR "Behcet syndrome" OR "Behcets disease" OR "Behcets syndrome" OR "Blau syndrome" OR "Blau's syndrome" OR "systemic granulomatosis" OR "Jabs syndrome" OR "inflammatory joint disease" OR "polyarthritis" OR "Asthma"[Mesh] OR Asthma* OR "Child Development Disorders, Pervasive"[Mesh] OR "Pervasive Child Development Disorders" OR "Pervasive Development Disorders" OR "Pervasive Development Disorder" OR "PDD"[tiab] OR "PDDNOS"[tiab] OR Autis* OR Asperger* OR "Kanner syndrome" OR "kanner's syndrome" OR "childhood disintegrative disorder" OR "Rett syndrome" OR "rett disease" OR "Rett's syndrome" OR "Retts syndrome" OR "Neoplasms"[Mesh] OR neoplas* OR tumor OR tumors OR tumour OR tumours OR cancer OR cancers OR cancerous OR leukemia* OR mycosis OR leukaemi* OR Leucocythaemia* OR Leucocythemia* OR Chloroma* OR incidentaloma* OR "Myeloid Sarcoma" OR "Myeloid Sarcomas" OR "Granulocytic Sarcoma" OR "Granulocytic Sarcomas" OR "blast cell crisis" OR "blast crisis" OR "blastic crisis" OR carcinoma OR adenocarcinoma OR carcinomatous OR carcinosis OR choriocarcinoma OR "chorio epithelioma" OR chorioepithelioma OR "chorion epithelioma" OR "chorioncarcinoma" OR "chorionepithelioma" OR trophocarcinoma OR cystadenocarcinoma OR cystosarcoma OR "cysto sarcoma" OR "giant fibroadenoma" OR teratocarcinoma OR lymphoma* OR "Hodgkin disease" OR "hodgkin's disease" OR "hodgkins disease" OR "lymphogranuloma malignum" OR lymphogranulomatosis OR "malignant lymphogranuloma" OR "morbus hodgkin" OR "adenolymphoma" OR "cystadenoma lymphomatosum" OR "lymphoid malignancies" OR "lymphoid malignancy" OR immunocytoma OR lymphosarcoma OR "granuloma fungoides" OR "Sezary

syndrome” OR “Sezary disease” OR “syndrome sezary” OR astrocytoma OR astroglioma OR oligoastrocytoma OR “pleomorphic xanthoastrocytoma” OR cholangiocarcinoma OR “malignant cholangioma” OR carcinogenesis OR neoplasmogenesis OR oncogenesis OR tumorigenesis OR “tumorigenic effect” OR “tumourigenesis” OR “tumourigenic effect” OR osteosarcoma OR glioma OR ependymblastoma OR ependymoma OR glioblastoma OR gliosarcoma OR medulloblastoma OR oligodendroglioma OR subependymoma OR blastoma OR blastomere OR blastomeres OR oligodendrocytosis OR carcinoid* OR microcarcinoma OR “childhood malignancy” OR “paediatric malignancy” OR “pediatric malignancy” OR melanoma* OR “malignant lentigo” OR “dubreuilh melanosis” OR “hutchinson melanotic freckle” OR “hutchinson's melanotic freckle” OR “lentigo maligna” OR “melanosis circumscripta praecancerosa” OR “melanosis circumscripta precancerosa” OR “melanotic freckle” OR nevocarcinoma OR “melano ameloblastoma” OR “melanotic adamantinoma” OR “melanotic ameloblastoma” OR “melanotic progonoma” OR progonoma OR retinoblastoma OR neuroblastoma OR ganglioneuroblastoma OR sympathicoblastoma OR sympathicogonioma OR sympathoblastoma OR neuroepithelioma OR neurocytoma OR retinocytoma OR hepatoma OR hepatoblastoma OR hepatocarcinogenesis OR hepatocarcinoma OR “schneeberg disease” OR “Pancoast syndrome” OR “Pancoast's syndrome” OR macroglobulinemia OR mesothelioma OR celothelioma OR mesotheliomatosis OR myeloma OR myeloplaxoma OR esthesioneuroblastoma OR “nasal glial heterotopia” OR dysgerminoma OR “call exner body” OR gynandroblastoma OR “demons meigs syndrome” OR rhinopharyngioma OR pheochromocytoma OR “medullary paraganglioma” OR phaeochromocytoma OR pinealoblastoma OR pinealocytoma OR pinealoma OR pineocytoma OR “hypophyseal adenoma” OR “pituitary adenoma” OR “pituitary gland adenoma” OR “pituitary microadenoma” OR rhabdomyosarcoma OR thymoma OR leiomyosarcoma OR nephroblastoma OR "Arrhythmias, Cardiac"[Mesh] OR Arrhythmia* OR Arrhythmia* OR “cardiac dysrhythmia” OR proarrhythmia OR “ectopic rhythm” OR “heart dysrhythmia” OR “heart rhythm disorder” OR tachycardia OR bradycardia OR “nodal rhythm” OR “nodal rhythms” OR brachycardia OR bradyarrhythmia OR bradycardia OR “low heart rate” OR “carotid sinus syndrome” OR “sinus reflex” OR “cardiac channelopathy” OR “cardiac channelopathies” OR “Brugada syndrome” OR “Brugada's syndrome” OR “long QT syndrome” OR “Andersen syndrome” OR “Andersen Tawil syndrome” OR “Andersen's syndrome” OR “Jervell and Lange-Nielsen syndrome” OR “Jervell Lange Nielsen syndrome” OR “Jervell Lange Nielson syndrome” OR “Jervell-Lange Nielsen syndrome” OR “Romano-Ward syndrome” OR “progressive cardiac conduction defect” OR “Lenegre disease” OR “Lenegre's disease” OR “short QT syndrome” OR “short QT interval syndrome” OR “cardiopulmonary arrest” OR “sinus node disease” OR “sinus node dysfunction” OR “sick sinus syndrome” OR “sinus arrest” OR “atrial arrest” OR “atrial asystole” OR “atrial standstill” OR “cardiac sinus arrest” OR “sinoatrial arrest” OR “sinus node arrest” OR “sinus node syndrome” OR “heart fibrillation” OR “cardiac fibrillation” OR “atrium fibrillation” OR “atrial fibrillation” OR “auricular fibrillation” OR “auricular fibrillation” OR “conduction defect” OR “conduction defects” OR “conduction disease” OR “conduction diseases” OR “conduction disorder” OR “conduction disorders” OR “conduction disturbance” OR “conduction disturbances” OR cardiopalmus OR palpitation OR proarrhythmia OR parasystole OR “hyperkinetic heart syndrome” OR "Renal Insufficiency, Chronic"[Mesh] OR “chronic kidney disorder” OR “chronic nephropathy” OR “chronic renal disease” OR “chronic kidney failure” OR “End Stage Kidney Disease” OR “End Stage Renal Disease” OR “End Stage Renal Failure” OR “Chronic Renal Failure” OR “ESRD”[tiab] OR “Frasier Syndrome” OR “Chronic Renal Insufficiencies” OR “Chronic Renal Insufficiency” OR “Chronic Kidney Insufficiency” OR “Chronic Kidney Diseases” OR “Chronic Kidney Disease” OR “Chronic Renal Diseases” OR "Pulmonary Disease, Chronic Obstructive"[Mesh] OR “COPD”[tiab] OR “Chronic Obstructive Pulmonary Disease” OR “COAD”[tiab] OR “Chronic Obstructive Airway Disease” OR “Chronic Obstructive Lung Disease” OR “Chronic Airflow Obstructions” OR “Chronic Airflow Obstruction” OR “chronic obstructive bronchitis” OR

“chronic obstructive bronchopulmonary disease” OR “chronic obstructive pulmonary disorder” OR “chronic obstructive respiratory disease” OR “Chronic Bronchitis” OR “Pulmonary Emphysema” OR “pulmonary Emphysemas” OR “Focal Emphysema” OR “Panacinar Emphysema” OR “Panlobular Emphysema” OR “Centriacinar Emphysema” OR “Centrilobular Emphysema” OR “Edema, Cardiac”[Mesh] OR “Heart Failure, Diastolic”[Mesh] OR “Heart Failure, Systolic”[Mesh] OR “cardiac congestive failure” OR “congestive cardiac failure” OR “congestive heart insufficiency” OR “congestive heart failure” OR “cor pulmonale” OR “pulmonary cardiac disease” OR “pulmonary heart disease” OR “diastolic heart failure” OR “heart failure with preserved ejection fraction” OR “heart edema” OR “cardiac edema” OR “cardiac oedema” OR “heart oedema” OR “systolic heart failure” OR “Coronary Artery Disease”[Mesh] OR “Coronary Artery Diseases” OR “Coronary Artery Disease” OR “Coronary Arteriosclerosis” OR “Coronary Atherosclerosis” OR “coronary disease” OR “Dementia”[Mesh] OR Dementia* OR Amentia* OR Alzheimer* OR CADASIL OR “Lewy body” OR “DNTC”[tiab] OR “diffuse neurofibrillary tangles with calcification” OR “frontotemporal lobar degeneration” OR “FTD”[tiab] OR “FTLD”[tiab] OR “Pick's complex”[tiab] OR “Pick complex”[tiab] OR fvFTD[tiab] OR bvFTD[tiab] OR “primary progressive aphasia” OR “Mesulam syndrome” OR “PPA”[tiab] OR tvFTD[tiab] OR “progressive nonfluent aphasia” OR “non-fluent progressive aphasia” OR “nonfluent progressive aphasia” OR “PNFA”[tiab] OR “progressive non-fluent aphasia” OR “AIDS encephalopathy” OR “HIV 1 associated cognitive motor complex” OR “HIV associated cognitive motor complex” OR “HIV associated neurocognitive disorder” OR “HIV encephalopathy” OR “HIV Encephalopathies” OR “Huntington Disease” OR “Huntington chorea” OR “chorea Huntington” OR “chronic progressive chorea” OR “hereditary chorea” OR “Huntington's chorea” OR “Huntington's disease” OR “Kluver Bucy”[tiab] OR “Kluever Bucy”[tiab] OR “Kluver-Bucy”[tiab] OR “mental deterioration” OR “cognitive deterioration” OR “mental regression” OR “neuronal ceroid lipofuscinosis” OR “amaurotic familial idiocy” OR “amaurotic idiocy” OR “Batten disease” OR “batten mayou disease” OR “familial amaurotic idiocy” OR “neuronal ceroid-lipofuscinoses” OR “neuronal ceroid-lipofuscinosis” OR “neuronal ceroidosis” OR “Pick disease” OR “pick syndrome” OR “prion disease” OR “bovine spongiform encephalopathy” OR “chronic wasting disease” OR “Creutzfeldt Jakob disease” OR “fatal familial insomnia” OR “Gerstmann Straussler Scheinker syndrome” OR “kuru” OR “scrapie” OR “transmissible mink encephalopathy” OR “transmissible neurodegenerative disease” OR “subacute spongiform” OR “transmissible spongiform encephalopathy” OR “pseudodementia” OR “Rett syndrome” OR “rett disease” OR “Retts syndrome” OR senility OR “senile confusion” OR “senile psychosis” OR tauopathy OR tauopathies OR “Kohlschutter-Tonz Syndrome” OR “Depressive Disorder”[Mesh] OR “Depression”[Mesh] OR depression* OR “depressive disease” OR “depressive disorder” OR “depressive episode” OR “depressive illness” OR “depressive personality disorder” OR “depressive state” OR “depressive symptom” OR “depressive symptoms” OR “depressive syndrome” OR Melancholia OR “depressive Disorders” OR “Depressive Neuroses” OR “Depressive Neurosis” OR “Depressive Syndrome” OR “Depressive Syndromes” OR “Involutional Psychoses” OR “Involutional Psychosis” OR “Treatment Resistant Depressive” OR “treatment Resistant Depressives” OR “Dysthymic Disorders” OR “Dysthymic Disorder” OR “Premenstrual Dysphoric Disorder” OR “Premenstrual Dysphoric Syndrome” OR “Seasonal Affective Disorder” OR “Seasonal Mood Disorder” OR “Seasonal Mood Disorders” OR “Seasonal Affective Disorders” OR “bipolar disorder” OR “bipolar affective disorder” OR “bipolar illness” OR “bipolar psychosis” OR “manic depressive” OR “bipolar mania” OR cyclothymia OR “cyclothymic depressive” OR “cyclothymic disorder” OR “cyclothymic personality” OR “rapid cycling mood disorder” OR “depressive psychosis” OR dysphoria OR dysthymia OR “depressive reaction” OR “dysthymic disorder” OR “mental anorexia” OR “mental fatigue” OR melancholy OR “unipolar disorder” OR “Perry syndrome” OR “Diabetes Mellitus, Type 1”[Mesh] OR “Diabetes Mellitus, Type 2”[Mesh] OR “insulin-Dependent Diabetes Mellitus” OR “Juvenile Onset Diabetes” OR “Type 1 Diabetes” OR “Sudden-Onset Diabetes Mellitus” OR “Diabetes

Mellitus Type I” OR “IDDM”[tiab] OR “Insulin Dependent Diabetes” OR “Brittle Diabetes” OR “Ketosis-Prone Diabetes Mellitus” OR “Autoimmune Diabetes” OR “DIDMOAD”[tiab] OR “Wolfram Syndrome” OR “NIDDM” OR “Maturity Onset Diabetes” OR “Adult Onset Diabetes” OR “Ketosis Resistant Diabetes Mellitus” OR “Non Insulin Dependent Diabetes Mellitus” OR “Stable Diabetes Mellitus” OR “MODY”[tiab] OR “Type 2 Diabetes” OR “Noninsulin Dependent Diabetes” OR “Lipoatrophic Diabetes” OR diabetic* OR “diabetes mellitus type I” OR “early onset diabetes” OR “iddm”[tiab] OR “juvenile diabetes” OR “ketoacidotic diabetes” OR “labile diabetes mellitus” OR “type I diabetes” OR “diabetes mellitus type 2” OR “diabetes mellitus type ii” OR “diabetes type 2” OR “diabetes type II” OR “insulin independent diabetes” OR “ketosis resistant diabetes” OR “type II diabetes” OR "Hepatitis, Chronic"[Mesh] OR “Chronic Hepatitis” OR “Chronic Active Hepatitis” OR “Chronic Persistent Hepatitis” OR “Chronic Delta Hepatitis” OR “Autoimmune Hepatitides” OR “Chronic Hepatitides” OR “Autoimmune Hepatitis” OR “chronic hepatopathy” OR "HIV"[Mesh] OR “AIDS Virus” OR “AIDS Viruses” OR HTLV-III OR “Human Immunodeficiency Virus” OR “Human Immunodeficiency Viruses” OR “Human T Cell Lymphotropic Virus Type III” OR “Human T Lymphotropic Virus Type III” OR “Human T-Cell Leukemia Virus Type III” OR “Human T Cell Leukemia Virus Type III” OR “Human T-Cell Lymphotropic Virus Type III” OR “Human T-Lymphotropic Virus Type III” OR “LAV-HTLV-III” OR “Lymphadenopathy-Associated Virus” OR “Lymphadenopathy Associated Virus” OR “Acquired Immune Deficiency Syndrome Virus” OR “Acquired Immunodeficiency Syndrome Virus” OR “HIV-1” OR “HIV-2” OR “aids associated retrovirus” OR “aids associated virus” OR “aids related virus” OR “immunodeficiency viruses” OR “lymphadenopathy associated retrovirus” OR "Hyperlipidemias"[Mesh] OR Hyperlipemia OR Hyperlipemias OR Hyperlipidemia OR Lipidemia OR Lipemia OR Hypercholesterolemia OR “Elevated Cholesterol” OR “Hypercholesteremia” OR hyperlipaemia OR hyperlipidaemia OR hyperlipidemias OR hyperlipidemic OR lipaemia OR lipidaemia OR cholesterolemia OR hypercholesterolaemia OR “Burger Grutz syndrome” OR hyperbetalipoproteinaemia OR hyperbetalipoproteinemia OR hypercholesterolemic OR “familial hyperlipoproteinaemia type ii” OR “familial hyperlipoproteinemia type ii” OR “hyper low density lipoproteinaemia” OR “hyper low density lipoproteinemia” OR “hypercholesterolaemic xanthomatosis” OR “hyperlipoproteinaemia type ii” OR “hyperlipoproteinemia type 2” OR “hyperlipoproteinemia type ii” OR “ldl receptor disorder” OR “tendinous xanthomatosis” OR “xanthoma tendinosum” OR “xanthoma tuberosum” OR hypertriglyceridemia OR hypertriglyceridaemia OR “triglyceride storage disease” OR triglyceridemia OR “hypertriglyceridemic waist” OR Hyperlipoproteinemias OR "Hypertension"[Mesh] OR Hypertension* OR Hypertensive OR “High Blood Pressure” OR “High Blood Pressures” OR “Goldblatt Syndrome” OR “apparent mineralocorticoid excess syndrome” OR “Gordon syndrome” OR “Gordon’s syndrome” OR “Liddle syndrome” OR “Liddle’s syndrome” OR “metabolic syndrome” OR “insulin resistance syndrome” OR “ocular ischaemic syndrome” OR “ocular ischemic syndrome” OR “orthostatic hypertension” OR “posterior encephalopathy” OR “posterior leucoencephalopathy” OR “posterior leucoencephalopathy” OR “posterior leucoencephalopathy” OR “posterior reversible encephalopathy” OR “posterior reversible leucoencephalopathy” OR “posterior reversible leucoencephalopathy” OR “PRES”[tiab] OR “RPLS”[tiab] OR pre-hypertension OR “goldblatt kidney” OR nephrosclerosis OR “renal arteriosclerosis” OR “renal atherosclerosis” OR "Osteoporosis"[Mesh] OR Osteoporosis OR Osteoporoses OR “Age-Related Bone Loss” OR “Age-Related Bone Losses” OR “female athlete triad” OR “Perimenopausal Bone Loss” OR “Postmenopausal Bone Loss” OR “posttraumatic osteopenia” OR “Sudeck atrophy” OR “sudeck dystrophy” OR “Sudeck Leriche syndrome” OR “Sudeck syndrome” OR “Sudeck’s atrophy” OR "Schizophrenia"[Mesh] OR Schizophrenia* OR Schizophrenic* OR “Dementia Praecox” OR hebephrenia OR paraphrenia OR “Delusional Disorder” OR “Delusional Disorders” OR “schizoaffective psychosis” OR “schizo affective disorder” OR “schizo affective psychosis” OR “schizoaffective disorder” OR “schizophreniform disorder” OR “schizophreniform psychosis” OR “Shared Paranoid Disorder” OR “Shared Psychotic Disorder” OR

“Shared Psychotic Disorders” OR “Shared Paranoid Disorders” OR “Folie a Deux” OR “Folie a Trois” OR “Brain Ischemia”[Mesh] OR “Chronic stroke” OR “brain ischemia” OR “brain ischaemia” OR “cerebral blood circulation disorder” OR “cerebral circulation disorder” OR “cerebral circulatory disorder” OR “cerebral ischaemia” OR “cerebral ischemia” OR “cerebrovascular ischaemia” OR “cerebrovascular ischemia” OR “ischaemic brain disease” OR “ischaemic encephalopathy” OR “ischaemic stroke” OR “ischemic brain disease” OR “ischemic encephalopathy” OR “ischemic stroke” OR “neural ischaemia” OR “neural ischemia” OR “cerebral vasospasm” OR “intracranial vasospasm” OR “Call-Fleming syndrome” OR “brain hypoxia ischaemia” OR “brain hypoxia ischemia” OR “brain hypoxic ischemic injury” OR “cerebral hypoxia ischaemia” OR “cerebral hypoxia ischemia” OR “cerebral hypoxic ischaemic injury” OR “cerebral hypoxic ischemic damage” OR “cerebral hypoxic ischemic injuries” OR “cerebral hypoxic ischemic injury” OR “cerebral ischaemia hypoxia” OR “cerebral ischemia hypoxia” OR “hypoxic ischaemic brain damage” OR “hypoxic ischaemic brain injury” OR “hypoxic ischaemic cerebral damage” OR “hypoxic ischaemic cerebral injury” OR “hypoxic ischemic brain damage” OR “hypoxic ischemic brain injuries” OR “hypoxic ischemic brain injury” OR “hypoxic ischemic cerebral damage” OR “hypoxic ischemic cerebral injury” OR “ischaemic attack” OR “ischemic attack” OR “ischemic seizure” OR “Brain Infarction” OR “Brain Stem Infarctions” OR “Brain Stem Infarction” OR “Brainstem Infarctions” OR “Brainstem Infarction” OR “Brainstem Stroke” OR “Claude Syndrome” OR “Weber Syndrome” OR “Millard Gublar Syndrome” OR “Top of the Basilar Syndrome” OR “Foville Syndrome” OR “Lateral Medullary Syndrome” OR “Lateral Medullary Syndromes” OR “Posterior Inferior Cerebellar Artery Syndrome” OR “Wallenberg’s Syndrome” OR “Wallenberg Syndrome” OR “Dorsolateral Medullary Syndrome” OR “Lateral Bulbar Syndrome” OR “Cerebral Infarction” OR “Cerebral Infarctions” OR “Subcortical Infarction” OR “Subcortical Infarctions” OR “Choroidal Artery Infarction” OR “Cerebral Artery Infarction” OR “Cerebral Artery Infarctions” OR “ACA Infarction” OR “ACA Infarctions” OR “Cerebral Artery Stroke” OR “Cerebral Artery Syndrome” OR “MCA Infarction” OR “Cerebral Artery Thrombosis” OR “PCA Infarction” OR “Substance-Related Disorders”[Mesh] OR alcoholism OR “drug dependence” OR “drug addiction” OR “Drug Habituation” OR “Drug Abuse” OR “Substance Abuse” OR “Substance Abuses” OR “Substance Dependence” OR “Substance Addiction” OR “Substance Use Disorders” OR “Substance Use Disorder” OR “Drug Dependence” OR “Drug Addiction” OR “substance abuser” OR “substance dependence” OR “amphetamine related disorders” OR “drug abuser” OR “drug problem” OR “needle sharing” OR “phencyclidine abuse” OR “alcohol addiction” OR “alcohol dependence” OR “alcohol dependents” OR “alcohol polyneuropathy” OR “alcohol dependent individual” OR “alcohol induced disorders” OR “alcohol related disorders” OR dipsomania* OR “ethanol dependence” OR “problem drinker” OR “problematic drinker” OR “analgesic abuse” OR doping OR “drug misuse” OR “inhalant abuse” OR “intravenous drug abuse” OR “intravenous drug user” OR “prescription drug diversion” OR “drug use disorder” OR “drug use disorders” OR “Alcohol Related Disorders” OR “Alcohol Related Disorder” OR “Alcohol Induced Disorders” OR “Alcohol Induced Disorder” OR “Alcohol Amnestic Syndrome” OR “Alcohol Induced Amnestic Syndrome” OR “Alcohol Induced Korsakoff Syndrome” OR “Alcohol Induced Persisting Amnestic Disorder” OR “Korsakoff Syndrome” OR “Korsakoff Psychosis” OR “Korsakoff Psychoses” OR “Alcoholic Neuropathy” OR “Alcoholic Neuropathies” OR “Alcoholic Polyneuropathies” OR “Alcoholic Polyneuropathy” OR “Alcoholic Polyneuritis” OR “Alcohol Induced Polyneuropathy” OR “Alcohol Related Polyneuropathy” OR “Alcohol Induced Peripheral Neuropathy” OR “Alcoholic Cardiomyopathy” OR “Fetal Alcohol Spectrum Disorders” OR “FASD”[tiab] OR “FASDs”[tiab] OR “Alcohol Related Birth Defects” OR “Alcohol Related Neurodevelopmental Disorder” OR “Fetal Alcohol Effects” OR “Fetal Alcohol Syndrome” OR “Alcoholic Liver Diseases” OR “Alcoholic Liver Disease” OR “Alcoholic Fatty Liver” OR “Alcoholic Steatohepatitis” OR “Chronic Alcoholic Hepatitis” OR “Alcoholic Liver Cirrhosis” OR “Alcoholic Cirrhosis” OR “Alcoholic Hepatic Cirrhosis” OR “Alcoholic Pancreatitis” OR “Alcoholic Psychoses” OR “Chronic Alcoholic

Intoxication” OR “Alcohol Abuse” OR “Amphetamine Related Disorders” OR “Amphetamine Abuse” OR “Amphetamine Addiction” OR “Amphetamine Dependence” OR “Cocaine Related Disorders” OR “Cocaine Related Disorder” OR “Cocaine Abuse” OR “Cocaine Dependence” OR “Cocaine Addiction” OR “Glue Sniffing” OR “Glue Sniffings” OR “Glue Abuse” OR “Marijuana Abuse” OR “Marihuana Abuse” OR “Hashish Abuse” OR “Cannabis Related Disorder” OR “Cannabis Abuse” OR “Cannabis Dependence” OR “Marijuana Dependence” OR “Opioid Related Disorders” OR “Opiate Dependence” OR “Opiate Addiction” OR “Narcotic Abuse” OR “Narcotic Dependence” OR “Narcotic Addiction” OR “Heroin Dependence” OR “Heroin Addiction” OR “Heroin Abuse” OR “Morphine Dependence” OR “Morphine Addiction” OR “Morphine Abuse” OR “PCP Abuse” OR “Angel Dust Abuse” OR “Substance Induced Psychoses” OR “Toxic Psychoses” OR “Drug Psychoses” OR “Intravenous Substance Abuse” OR “Parenteral Drug Abuse” OR “Tobacco Use Disorder” OR “Tobacco Use Disorders” OR “Nicotine Use Disorder” OR “Nicotine Use Disorders” OR “Tobacco Dependence” OR “Tobacco Dependences” OR “Nicotine Dependence” OR “alcoholic individual” OR “alcoholics” OR “alcoholic polyneuropathy” OR “ethanol dependence” OR “narcotic depression” OR “narcotism” OR “heroin addict” OR “heroinism” OR “morphine addict” OR “opiate addict” OR “opioid dependence” OR “opium addict” OR “opium addiction” OR “opium addiction” OR “benzodiazepine dependence” OR “benzodiazepine addiction” OR “cannabis addiction” OR “drug abuse pattern” OR “methamphetamine dependence” OR “toxicomania” OR “drug addict” OR “drug dependence” OR “drug dependency”)

Embase

‘controlled clinical trial’/it OR ‘randomized controlled trial’/it OR ‘controlled clinical trial’/exp OR ‘randomized controlled trial’/exp AND (‘young adult’/exp OR ‘adult’/exp OR ‘middle aged’/exp OR ‘aged’/exp OR ‘aged hospital patient’/exp OR ‘frail elderly’/exp OR ‘very elderly’/exp OR ‘geriatrics’/exp OR adult OR adults OR ‘Middle age’ OR ‘middle aged’ OR ‘middle ages’ OR geriatric* OR Aged OR Elder* OR ‘Oldest Old’ OR Nonagenarian* OR Octogenarian* OR Centenarian* OR ‘senior citizen’ OR ‘senior citizens’ OR senium OR ‘very old’ OR ‘older patients’ OR ‘older patient’ OR ‘older people’) AND (‘chronic disease’/exp OR ‘chronic disease’ OR ‘chronic illness’ OR ‘chronic Diseases’ OR ‘Chronic Illnesses’ OR ‘Chronically Ill’ OR ‘asthma’/exp OR asthma* OR ‘arthritis’/exp OR ‘Arthritis’ OR ‘Arthritides’ OR ‘arthrotuberculosis’ OR ‘articular tuberculosis’ OR ‘bone joint tuberculosis’ OR ‘white joint swelling’ OR ‘joint tuberculosis’ OR ‘osteo-articular tuberculosis’ OR ‘osteoarticular tuberculosis’ OR ‘tuberculosis joint’ OR ‘tuberculosis sacroileitis’ OR ‘osteoarticular tuberculosis’ OR ‘white swelling’ OR ‘Psoriasis Arthropathica’ OR ‘Juvenile-Onset Still Disease’ OR ‘Juvenile Onset Still Disease’ OR ‘Juvenile-Onset Stills Disease’ OR ‘Juvenile-Onset Stills Disease’ OR ‘Juvenile Onset Stills Disease’ OR ‘Caplan Syndromes’ OR ‘Caplans Syndrome’ OR ‘Caplans Syndrome’ OR ‘Felty Syndrome’ OR ‘Feltys Syndrome’ OR ‘Rheumatoid Nodule’ OR ‘Rheumatoid Nodules’ OR ‘Rheumatoid Nodulosis’ OR ‘Rheumatoid Noduloses’ OR ‘Rheumatoid Vasculitis’ OR ‘Rheumatoid Vasculitides’ OR ‘Sjogren Syndrome’ OR ‘Sjogrens Syndrome’ OR ‘Sjogrens Syndrome’ OR ‘Sicca Syndrome’ OR ‘Adult-Onset Stills Disease’ OR ‘Adult Onset Stills Disease’ OR ‘Adult-Onset Stills Disease’ OR ‘Adult-Onset Still Disease’ OR ‘Adult Onset Still Disease’ OR ‘Chondrocalcinosis’ OR ‘Calcium Pyrophosphate Dihydrate Deposition’ OR ‘Pseudogout’ OR ‘Chondrocalcinosis’ OR ‘Gout’ OR ‘Gouts’ OR ‘gouty’ OR ‘Osteoarthritis’ OR ‘Osteoarthritis’ OR ‘Osteoarthrosis’ OR ‘Osteoarthroses’ OR ‘Periarthritis’ OR ‘Periarthritides’ OR ‘Rheumatic Fevers’ OR ‘Inflammatory Rheumatism’ OR ‘Rheumatic Fever’ OR ‘Rheumatic Nodule’ OR ‘Rheumatic Nodules’ OR ‘Aschoff Bodies’ OR ‘Wisslers Syndrome’ OR ‘Wissler Syndrome’ OR ‘Wisslers Syndrome’ OR ‘Wissler-Fanconi Syndrome’ OR ‘Wissler Fanconi Syndrome’ OR ‘Subsepsis Allergica’ OR ‘Subsepsis Hyperergica’ OR ‘Sacroiliitis’ OR ‘Sacroiliitides’ OR ‘Spondylarthropathies’ OR ‘Spondylarthropathy’ OR ‘Bechterew Disease’ OR ‘Bechterews Disease’ OR ‘Bechterews Disease’ OR ‘Ankylosing Spondyloarthritis’ OR ‘Ankylosing Spondyloarthritides’ OR ‘Rheumatoid Spondylitis’ OR ‘Spondylarthritis Ankylopoietica’ OR

'Ankylosing Spondylarthritis' OR 'Ankylosing Spondylarthritides' OR 'Ankylosing Spondylitis' OR 'Marie-Struempell Disease' OR 'Marie Struempell Disease' OR 'Coxarthrosis' OR 'Coxarthroses' OR 'hip arthrosis' OR 'hip joint arthrosis' OR 'cox arthrosis' OR 'coxarthrosis' OR 'hip osteo-arthritis' OR 'hip osteo-arthrosis' OR 'malum coxae senilis' OR 'arthrochondritis' OR 'arthrosynovitis' OR 'joint inflammation' OR 'oligoarthritis' OR 'antisynthetase syndrome' OR 'Behcet disease' OR 'Behcets syndrome' OR 'Behcet syndrome' OR 'behcet ulcer' OR 'Behcets disease' OR 'Behcets syndrome' OR 'Blau syndrome' OR 'arthrocutaneous granulomatosis' OR 'Blaus syndrome' OR 'Blau type familial granulomatosis' OR 'Blaus syndrome' OR 'systemic granulomatosis' OR 'Jabs disease' OR 'Jabs syndrome' OR 'inflammatory joint disease' OR 'polyarthritis' OR 'urate inflammation' OR 'arthragra' OR 'autism'/exp OR 'Pervasive Child Development Disorders' OR 'Pervasive Development Disorders' OR 'Pervasive Development Disorder' OR 'PDD' OR 'PDDNOS' OR Autis* OR Asperger* OR 'Kanner syndrome' OR 'kanners syndrome' OR 'childhood disintegrative disorder' OR 'Rett syndrome' OR 'morbus rett' OR 'rett disease' OR 'Retts syndrome' OR 'neoplasm'/exp OR neoplas* OR tumor OR tumors OR tumour OR tumours OR cancer OR cancers OR cancerous OR leukemia* OR mycosis OR leukaemia* OR Leucocythaemia* OR Leucocythemia* OR Chloroma* OR incidentaloma* OR 'Myeloid Sarcoma' OR 'Myeloid Sarcomas' OR 'Granulocytic Sarcoma' OR 'Granulocytic Sarcomas' OR 'blast cell crisis' OR 'blast crisis' OR 'blastic crisis' OR carcinoma OR adenocarcinoma OR carcinomatous OR carcinosis OR choriocarcinoma OR 'chorio epithelioma' OR chorioepithelioma OR 'chorion epithelioma' OR 'chorioncarcinoma' OR 'chorionepithelioma' OR trophocarcinoma OR cystadenocarcinoma OR cystosarcoma OR 'cysto sarcoma' OR 'giant fibroadenoma' OR teratocarcinoma OR lymphoma* OR 'Hodgkin disease' OR 'hodgkins disease' OR 'hodgkins disease' OR 'lymphogranuloma malignum' OR lymphogranulomatosis OR 'malignant lymphogranuloma' OR 'morbus hodgkin' OR 'adenolymphoma' OR 'cystadenoma lymphomatousum' OR 'lymphoid malignancies' OR 'lymphoid malignancy' OR immunocytoma OR lymphosarcoma OR 'granuloma fungoides' OR 'Sezary syndrome' OR 'Sezary disease' OR 'syndrome sezary' OR astrocytoma OR astroglioma OR oligoastrocytoma OR 'pleomorphic xanthoastrocytoma' OR cholangiocarcinoma OR 'malignant cholangioma' OR carcinogenesis OR neoplasmodgenesis OR oncogenesis OR tumorigenesis OR 'tumorigenic effect' OR 'tumourigenesis' OR 'tumourigenic effect' OR osteosarcoma OR glioma OR ependymoblastoma OR ependymoma OR glioblastoma OR gliosarcoma OR medulloblastoma OR oligodendroglioma OR subependymoma OR blastoma OR blastomere OR blastomeres OR oligodendrocytosis OR carcinoid* OR microcarcinoma OR 'childhood malignancy' OR 'paediatric malignancy' OR 'pediatric malignancy' OR melanoma* OR 'malignant lentigo' OR 'dubreuilh melanosis' OR 'hutchinson melanotic freckle' OR 'hutchinsons melanotic freckle' OR 'lentigo maligna' OR 'melanosis circumscripta praecancerosa' OR 'melanosis circumscripta precancerosa' OR 'melanotic freckle' OR nevocarcinoma OR 'melano ameloblastoma' OR 'melanotic adamantinoma' OR 'melanotic ameloblastoma' OR 'melanotic progonoma' OR progonoma OR retinoblastoma OR neuroblastoma OR ganglioneuroblastoma OR sympathicoblastoma OR sympathicogonioma OR sympathoblastoma OR neuroepithelioma OR neurocytoma OR retinocytoma OR hepatoma OR hepatoblastoma OR hepatocarcinogenesis OR hepatocarcinoma OR 'schneeberg disease' OR 'Pancoast syndrome' OR 'Pancoasts syndrome' OR macroglobulinemia OR mesothelioma OR celothelioma OR mesotheliomatosis OR myeloma OR myeloplaxoma OR esthesioneuroblastoma OR 'nasal glial heterotopia' OR dysgerminoma OR 'call exner body' OR gynandroblastoma OR 'demons meigs syndrome' OR rhinopharyngioma OR pheochromocytoma OR 'medullary paraganglioma' OR phaeochromocytoma OR pinealoblastoma OR pinealocytoma OR pinealoma OR pineocytoma OR 'hypophyseal adenoma' OR 'pituitary adenoma' OR 'pituitary gland adenoma' OR 'pituitary microadenoma' OR rhabdomyosarcoma OR thymoma OR leiomyosarcoma OR neuroblastoma OR 'heart arrhythmia'/exp OR Arrhythmia* OR Arrhythmia* OR 'cardiac dysrhythmia' OR proarrhythmia OR proarrhythmias OR 'ectopic heart rhythm' OR

'ectopic rhythm' OR 'heart aberrant conduction' OR 'heart dysrhythmia' OR 'heart ectopic beat' OR 'heart ectopic ventricle contraction' OR 'heart rhythm disorder' OR tachycardia OR bradycardia OR 'nodal rhythm' OR 'nodal rhythms' OR brachycardia OR bradyarrhythmia OR bradycardy OR bradycardia OR 'low heart rate' OR hypoarrhythmia OR 'carotid sinus syndrome' OR 'carotid cavernous syndrome' OR 'sinus caroticus syndrome' OR 'sinus reflex' OR 'weiss baker syndrome' OR 'cardiac channelopathy' OR 'cardiac channelopathies' OR 'Brugada syndrome' OR 'Brugadas syndrome' OR 'Brugadas syndrome' OR 'long QT syndrome' OR 'Andersen syndrome' OR 'Andersen Tawil syndrome' OR 'Andersen triad' OR 'Andersens syndrome' OR 'Andersens syndrome' OR 'Jervell and Lange-Nielsen syndrome' OR 'Jervell Lange Nielsen syndrome' OR 'Jervell Lange Nielson syndrome' OR 'Jervell Nielsen syndrome' OR 'Jervell-Lange Nielsen syndrome' OR 'Lange Nielson Jervell syndrome' OR 'Romano-Ward syndrome' OR 'Romano Ward ECG' OR 'progressive cardiac conduction defect' OR 'Lenegre disease' OR 'Lenegre syndrome' OR 'Lenegres disease' OR 'Lenegres syndrome' OR 'Lev Lenegre disease' OR 'short QT syndrome' OR 'short QT interval syndrome' OR 'cardiopulmonary arrest' OR 'sinus node disease' OR 'sinus node dysfunction' OR 'sick sinus syndrome' OR 'sinus arrest' OR 'atrial arrest' OR 'atrial asystole' OR 'atrial standstill' OR 'atrium standstill' OR 'cardiac sinus arrest' OR 'heart atrium arrest' OR 'sinoatrial arrest' OR 'sinus node arrest' OR 'sinus node syndrome' OR 'heart fibrillation' OR 'cardiac fibrillation' OR 'atrium fibrillation' OR 'atrial fibrillation' OR 'auricular fibrillation' OR 'auricular fibrillation' OR 'conduction defect' OR 'conduction defects' OR 'conduction disease' OR 'conduction diseases' OR 'conduction disorder' OR 'conduction disorders' OR 'conduction disturbance' OR 'conduction disturbances' OR cardiopalmus OR palpitation OR proarrhythmia OR parasystole OR 'hyperkinetic heart syndrome' OR 'chronic kidney disease'/exp OR 'chronic kidney disorder' OR 'chronic nephropathy' OR 'chronic renal disease' OR 'chronic kidney failure' OR 'End Stage Kidney Disease' OR 'End Stage Renal Disease' OR 'End Stage Renal Failure' OR 'Chronic Renal Failure' OR 'ESRD' OR 'Frasier Syndrome' OR 'Chronic Renal Insufficiencis' OR 'Chronic Renal Insufficiency' OR 'Chronic Kidney Insufficiency' OR 'Chronic Kidney Insufficiencis' OR 'Chronic Kidney Diseases' OR 'Chronic Kidney Disease' OR 'Chronic Renal Diseases' OR 'chronic obstructive lung disease'/exp OR 'COPD' OR 'Chronic Obstructive Pulmonary Disease' OR 'COAD' OR 'Chronic Obstructive Airway Disease' OR 'Chronic Obstructive Lung Disease' OR 'Chronic Airflow Obstructions' OR 'Chronic Airflow Obstruction' OR 'chronic obstructive bronchitis' OR 'chronic obstructive bronchopulmonary disease' OR 'chronic obstructive lung disorder' OR 'chronic obstructive pulmonary disorder' OR 'chronic obstructive respiratory disease' OR 'Chronic Bronchitis' OR 'Pulmonary Emphysema' OR 'pulmonary Emphysemas' OR 'Focal Emphysema' OR 'Focal Emphysemas' OR 'Panacinar Emphysema' OR 'Panacinar Emphysemas' OR 'Panlobular Emphysema' OR 'Panlobular Emphysemas' OR 'Centriacinar Emphysema' OR 'Centriacinar Emphysemas' OR 'Centrilobular Emphysema' OR 'Centrilobular Emphysemas' OR 'congestive heart failure'/exp OR 'cardiac congestive failure' OR 'congestive cardiac failure' OR 'congestive heart insufficiency' OR 'congestive heart failure' OR 'cor pulmonale' OR corpulmonale OR 'pulmonary cardiac disease' OR 'pulmonary heart disease' OR 'diastolic heart failure' OR 'heart failure with preserved ejection fraction' OR 'heart edema' OR 'cardiac edema' OR 'cardiac oedema' OR 'heart oedema' OR 'systolic heart failure' OR 'coronary artery disease'/exp OR 'Coronary Artery Diseases' OR 'Coronary Artery Disease' OR 'Coronary Arteriosclerosis' OR 'Coronary Arterioscleroses' OR 'Coronary Atheroscleroses' OR 'Coronary Atherosclerosis' OR 'coronary disease' OR dementia/exp OR Dementia* OR Amentia* OR Alzheimer* OR CADASIL OR 'Lewy body' OR 'DNTC' OR 'diffuse neurofibrillary tangles with calcification' OR 'frontotemporal lobar degeneration' OR 'FTD' OR 'FTLD' OR 'Picks complex' OR 'Pick complex' OR fvFTD OR bvFTD OR 'primary progressive aphasia' OR 'Mesulam syndrome' OR 'PPA' OR tvFTD OR 'progressive nonfluent aphasia' OR 'non-fluent progressive aphasia' OR 'nonfluent progressive aphasia' OR 'PNFA' OR 'progressive non-fluent aphasia' OR 'AIDS encephalopathy' OR 'HIV 1 associated cognitive motor complex' OR 'HIV associated

cognitive motor complex' OR 'HIV associated neurocognitive disorder' OR 'HIV encephalopathy' OR 'HIV Encephalopathies' OR 'Huntington Disease' OR 'Huntington chorea' OR 'chorea Huntington' OR 'chronic progressive chorea' OR 'hereditary chorea' OR 'Huntingtons chorea' OR 'Huntingtons disease' OR 'Kluver Bucy' OR 'Kluever Bucy' OR 'Kluver-Bucy' OR 'mental deterioration' OR 'cognitive deterioration' OR 'mental regression' OR 'neuronal ceroid lipofuscinosis' OR 'amaurotic familial idiocy' OR 'amaurotic idiocy' OR 'Batten disease' OR 'batten mayou disease' OR 'familial amaurotic idiocy' OR 'neuronal ceroid-lipofuscinoses' OR 'neuronal ceroid-lipofuscinosis' OR 'neuronal ceroidosis' OR 'Pick disease' OR 'pick syndrome' OR 'prion disease' OR 'bovine spongiform encephalopathy' OR 'chronic wasting disease' OR 'Creutzfeldt Jakob disease' OR 'fatal familial insomnia' OR 'Gerstmann Straussler Scheinker syndrome' OR 'kuru' OR 'scrapie' OR 'transmissible mink encephalopathy' OR 'transmissible neurodegenerative disease' OR 'subacute spongiform' OR 'transmissible spongiform encephalopathy' OR 'pseudodementia' OR 'Rett syndrome' OR 'rett disease' OR 'Retts syndrome' OR senility OR 'senile confusion' OR 'senile psychosis' OR tauopathy OR tauopathies OR 'Kohlschutter-Tonz Syndrome' OR 'depression'/exp OR depression* OR 'depressive disease' OR 'depressive disorder' OR 'depressive episode' OR 'depressive illness' OR 'depressive personality disorder' OR 'depressive state' OR 'depressive symptom' OR 'depressive symptoms' OR 'depressive syndrome' OR Melancholia OR Melancholias OR 'depressive Disorders' OR 'Depressive Neuroses' OR 'Depressive Neurosis' OR 'Depressive Syndrome' OR 'Depressive Syndromes' OR 'Involutional Psychoses' OR 'Involutional Psychosis' OR 'Involutional paraphrenia' OR 'Therapy Resistant Depressive' OR 'Therapy-Resistant Depressives' OR 'Treatment Resistant Depressive' OR 'treatment Resistant Depressives' OR 'Dysthymic Disorders' OR 'Dysthymic Disorder' OR 'Premenstrual Dysphoric Disorder' OR 'Premenstrual Dysphoric Syndrome' OR 'Seasonal Affective Disorder' OR 'Seasonal Mood Disorder' OR 'Seasonal Mood Disorders' OR 'Seasonal Affective Disorders' OR 'bipolar disorder' OR 'bipolar affective disorder' OR 'bipolar illness' OR 'bipolar psychosis' OR 'manic depressive' OR 'maniodepressive psychosis' OR 'mano depressive syndrome' OR 'bipolar mania' OR cyclothymia OR cyclophrenia OR 'cyclothymic depressive' OR 'cyclothymic disorder' OR 'cyclothymic personality' OR 'rapid cycling mood disorder' OR 'depressive psychosis' OR dysphoria OR dysforia OR dysthymia OR 'depressive reaction' OR 'dysthymic disorder' OR 'mental anorexia' OR 'mental fatigue' OR melancholy OR 'unipolar disorder' OR 'mourning syndrome' OR 'Perry syndrome' OR 'Perrys syndrome' OR 'diabetes mellitus'/exp OR 'insulin dependent diabetes mellitus'/exp OR 'non insulin dependent diabetes mellitus'/exp OR 'lipoatrophic diabetes mellitus'/exp OR 'insulin-Dependent Diabetes Mellitus' OR 'Juvenile Onset Diabetes' OR 'Type 1 Diabetes' OR 'Sudden-Onset Diabetes Mellitus' OR 'Diabetes Mellitus Type I' OR 'IDDM' OR 'Insulin Dependent Diabetes' OR 'Brittle Diabetes' OR 'Ketosis-Prone Diabetes Mellitus' OR 'Autoimmune Diabetes' OR 'DIDMOAD' OR 'DIDMOADUD' OR 'Wolfram Syndrome' OR 'NIDDM' OR 'Maturity Onset Diabetes' OR 'Adult Onset Diabetes' OR 'Ketosis Resistant Diabetes Mellitus' OR 'Non Insulin Dependent Diabetes Mellitus' OR 'Slow Onset Diabetes Mellitus' OR 'Stable Diabetes Mellitus' OR 'MODY' OR 'Type 2 Diabetes' OR 'Noninsulin Dependent Diabetes' OR 'Lipoatrophic Diabetes' OR 'Lipoatrophic Diabete' OR diabetic* OR 'diabetes mellitus type I' OR 'early onset diabetes' OR 'iddm' OR 'juvenile diabetes' OR 'ketoacidotic diabetes' OR 'labile diabetes mellitus' OR 'mckusick 22210' OR 'type I diabetes' OR 'diabetes mellitus type 2' OR 'diabetes mellitus type ii' OR 'diabetes type 2' OR 'diabetes type II' OR 'insulin independent diabetes' OR 'ketosis resistant diabetes' OR 'type II diabetes' OR 'diabetes lipoatrophic' OR 'chronic hepatitis'/exp OR 'Chronic Hepatitis' OR 'Chronic Active Hepatitis' OR 'Chronic Persistent Hepatitides' OR 'Chronic Persistent Hepatitis' OR 'Chronic Delta Hepatitis' OR 'Chronic Delta Hepatitides' OR 'Autoimmune Hepatitides' OR 'Chronic Hepatitides' OR 'Autoimmune Hepatitis' OR 'chronic hepatopathy' OR 'Human immunodeficiency virus'/exp OR 'HIV' OR 'AIDS Virus' OR 'AIDS Viruses' OR HTLV-III OR 'Human Immunodeficiency Virus' OR 'Human Immunodeficiency Viruses' OR 'Human T Cell Lymphotropic Virus Type III' OR 'Human T Lymphotropic

Virus Type III' OR 'Human T-Cell Leukemia Virus Type III' OR 'Human T Cell Leukemia Virus Type III' OR 'Human T-Cell Lymphotropic Virus Type III' OR 'Human T-Lymphotropic Virus Type III' OR 'LAV-HTLV-III' OR 'Lymphadenopathy-Associated Virus' OR 'Lymphadenopathy Associated Virus' OR 'Lymphadenopathy-Associated Viruses' OR 'Acquired Immune Deficiency Syndrome Virus' OR 'Acquired Immunodeficiency Syndrome Virus' OR 'HIV-1' OR 'HIV-2' OR 'aids associated lentivirus' OR 'aids associated retrovirus' OR 'aids associated virus' OR 'aids related virus' OR 'immunodeficiency associated virus' OR 'immunodeficiency viruses' OR 'lymphadenopathy associated retrovirus' OR 'hyperlipidemia'/exp OR Hyperlipemia OR Hyperlipemias OR Hyperlipidemia OR Lipidemia OR Lipidemias OR Lipemia OR Lipemias OR Hypercholesterolemia OR Hypercholesterolemias OR 'Elevated Cholesterol' OR 'Hypercholesteremia' OR Hypercholesteremias OR hyperlipaemia OR hyperlipidaemia OR hyperlipidemias OR hyperlipidemic OR lipaemia OR lipidaemia OR cholesteremia OR cholesterinemia OR cholesterolemia OR hypercholesterinaemia OR hypercholesterinemia OR hypercholesterolaemia OR 'Buerger Gruetz syndrome' OR 'Burger Grutz syndrome' OR hyperbetalipoproteinaemia OR hyperbetalipoproteinemia OR hypercholesterolemic OR 'familial hyperlipoproteinaemia type ii' OR 'familial hyperlipoproteinemia type ii' OR 'harbitz mueller syndrome' OR 'hyper low density lipoproteinaemia' OR 'hyper low density lipoproteinemia' OR 'hypercholesterolaemic xanthomatosis' OR 'hyperlipoproteinaemia type 2' OR 'hyperlipoproteinaemia type ii' OR 'hyperlipoproteinemia type 2' OR 'hyperlipoproteinemia type ii' OR 'ldl receptor disorder' OR 'tendinous xanthogranulomatosis' OR 'tendinous xanthomatosis' OR 'tendon xanthogranulomatosis' OR 'xanthogranulomatosis tendinosum' OR 'xanthogranulomatosis tendinous' OR 'xanthoma tendinosum' OR 'xanthoma tuberosum' OR hypertriglyceridemia OR hypertriglyceridaemia OR 'triglyceride storage disease' OR triglyceridemia OR 'hypertriglyceridemic waist' OR Hyperlipoproteinemias OR 'hypertension'/exp OR Hypertension* OR Hypertensive OR 'High Blood Pressure' OR 'High Blood Pressures' OR 'Goldblatt Syndrome' OR 'apparent mineralocorticoid excess syndrome' OR 'Gordon syndrome' OR 'Gordons syndrome' OR 'Liddle syndrome' OR 'Liddles syndrome' OR 'metabolic syndrome' OR 'insulin resistance syndrome' OR 'ocular ischaemic syndrome' OR 'ocular ischemic syndrome' OR 'orthostatic hypertension' OR 'posterior encephalopathy' OR 'posterior leucoencephalopathy' OR 'posterior leucoencephalopathy' OR 'posterior leucoencephalopathy' OR 'posterior reversible encephalopathy' OR 'posterior reversible leucoencephalopathy' OR 'posterior reversible leucoencephalopathy' OR 'PRES' OR 'RPLS' OR prehypertension OR 'pre-hypertension' OR 'goldblatt kidney' OR nephrosclerosis OR 'renal arteriosclerosis' OR 'renal atherosclerosis' OR renosclerosis OR 'osteoporosis'/exp OR Osteoporosis OR Osteoporoses OR 'Age-Related Bone Loss' OR 'Age-Related Bone Losses' OR 'pathological decalcification' OR 'osteoporotic decalcification' OR 'female athlete triad' OR 'Perimenopausal Bone Loss' OR 'Postmenopausal Bone Loss' OR 'Perimenopausal Bone Losses' OR 'posttraumatic osteopenia' OR 'Sudeck atrophy' OR 'Sudeck disease' OR 'Sudeck dystrophy' OR 'Sudeck Leriche syndrome' OR 'Sudeck syndrome' OR 'Sudecks atrophy' OR 'Suedeck dystrophy' OR 'Suedeck reflex dystrophy' OR 'schizophrenia'/exp OR Schizophrenia* OR Schizophrenic* OR 'Dementia Praecox' OR hebephrenia OR paraphrenia OR 'Delusional Disorder' OR 'Delusional Disorders' OR 'schizo affective psychosis' OR 'schizo affective disorder' OR 'schizo affective psychosis' OR 'schizo affective disorder' OR 'schizophreniform disorder' OR 'schizophreniform psychosis' OR 'Shared Paranoid Disorder' OR 'Shared Psychotic Disorder' OR 'Shared Psychotic Disorders' OR 'Shared Paranoid Disorders' OR 'Folie a Deux' OR 'Folie a Trois' OR 'brain ischemia'/exp OR 'Chronic stroke' OR 'brain ischemia' OR 'brain arterial insufficiency' OR 'brain circulation disorder' OR 'brain ischaemia' OR 'cerebral blood circulation disorder' OR 'cerebral blood flow disorder' OR 'cerebral circulation disorder' OR 'cerebral circulatory disorder' OR 'cerebral ischaemia' OR 'cerebral ischemia' OR 'cerebrovascular circulation disorder' OR 'cerebrovascular ischaemia' OR 'cerebrovascular ischemia' OR 'ischaemia cerebri' OR 'ischaemic brain disease' OR 'ischaemic encephalopathy' OR 'ischaemic stroke' OR 'ischemia cerebri'

OR 'ischemic brain disease' OR 'ischemic encephalopathy' OR 'ischemic stroke' OR 'neural ischaemia' OR 'neural ischemia' OR 'brain vasospasm' OR 'cerebral vasospasm' OR 'intracranial vasospasm' OR 'Call-Fleming syndrome' OR 'brain hypoxia ischaemia' OR 'brain hypoxia ischemia' OR 'brain hypoxic ischaemic injuries' OR 'brain hypoxic ischaemic injury' OR 'brain hypoxic ischemic damage' OR 'brain hypoxic ischemic injuries' OR 'brain hypoxic ischemic injury' OR 'cerebral hypoxia ischaemia' OR 'cerebral hypoxia ischemia' OR 'cerebral hypoxic ischaemic damage' OR 'cerebral hypoxic ischaemic injuries' OR 'cerebral hypoxic ischaemic injury' OR 'cerebral hypoxic ischemic damage' OR 'cerebral hypoxic ischemic injuries' OR 'cerebral hypoxic ischemic injury' OR 'cerebral ischaemia hypoxia' OR 'cerebral ischemia hypoxia' OR 'hypoxic ischaemic brain damage' OR 'hypoxic ischaemic brain injuries' OR 'hypoxic ischaemic brain injury' OR 'hypoxic ischaemic cerebral damage' OR 'hypoxic ischaemic cerebral injuries' OR 'hypoxic ischaemic cerebral injury' OR 'hypoxic ischemic brain damage' OR 'hypoxic ischemic brain injuries' OR 'hypoxic ischemic brain injury' OR 'hypoxic ischemic cerebral damage' OR 'hypoxic ischemic cerebral injuries' OR 'hypoxic ischemic cerebral injury' OR 'circulatory epilepsy' OR 'epilepsy circulatory' OR 'ischaemic attack' OR 'ischemic attack' OR 'ischaemic seizure' OR 'ischemic seizure' OR 'Brain Infarction' OR 'Brain Stem Infarctions' OR 'Brain Stem Infarction' OR 'Brainstem Infarctions' OR 'Brainstem Infarction' OR 'Brainstem Stroke' OR 'Claude Syndrome' OR 'Weber Syndrome' OR 'Millard Gublar Syndrome' OR 'Top of the Basilar Syndrome' OR 'Benedict Syndrome' OR 'Foville Syndrome' OR 'Lateral Medullary Syndrome' OR 'Lateral Medullary Syndromes' OR 'Posterior Inferior Cerebellar Artery Syndrome' OR 'Wallenbergs Syndrome' OR 'Wallenbergs Syndrome' OR 'Wallenberg Syndrome' OR 'Dorsolateral Medullary Syndrome' OR 'Lateral Bulbar Syndrome' OR 'Cerebral Infarction' OR 'Cerebral Infarctions' OR 'Subcortical Infarction' OR 'Subcortical Infarctions' OR 'Choroidal Artery Infarction' OR 'Cerebral Artery Infarction' OR 'Cerebral Artery Infarctions' OR 'ACA Infarction' OR 'ACA Infarctions' OR 'Cerebral Artery Stroke' OR 'Heubner Artery Infarction' OR 'Heubners Artery Infarction' OR 'Heubners Artery Infarction' OR 'Cerebral Artery Syndrome' OR 'MCA Infarction' OR 'Cerebral Artery Thrombosis' OR 'Cerebral Artery Thrombotic Infarction' OR 'PCA Infarction' OR 'Cerebral Artery Embolic Infarction' OR 'substance abuse'/exp OR 'alcoholism'/exp 'drug abuse'/exp OR 'drug dependence'/exp OR alcoholism OR 'drug dependence' OR 'drug addiction' OR 'Drug Habituation' OR 'Drug Abuse' OR 'Substance Abuse' OR 'Substance Abuses' OR 'Substance Dependence' OR 'Substance Addiction' OR 'Substance Use Disorders' OR 'Substance Use Disorder' OR 'Drug Dependence' OR 'Drug Addiction' OR 'substance abuser' OR 'substance dependence' OR 'amphetamine-related disorders' OR 'chronic drug overuser' OR 'drug abuser' OR 'drug problem' OR 'needle sharing' OR 'phencyclidine abuse' OR 'alcohol addiction' OR 'alcohol dependence' OR 'alcohol dependents' OR 'alcohol polyneuropathy' OR 'alcohol dependent individual' OR 'alcohol induced disorders' OR 'alcohol related disorders' OR dipsomania* OR 'ethanol dependence' OR 'problem drinker' OR 'problematic drinker' OR 'analgesic agent abuse' OR 'analgesic abuse' OR doping OR 'drug misuse' OR 'inhalant abuse' OR 'intravenous drug abuse' OR 'intravenous drug user' OR 'prescription drug diversion' OR 'drug use disorder' OR 'drug use disorders' OR 'Alcohol Related Disorders' OR 'Alcohol Related Disorder' OR 'Alcohol Induced Disorders' OR 'Alcohol Induced Disorder' OR 'Ethanol Induced Nervous System Disorders' OR 'Alcohol Amnestic Disorders' OR 'Alcohol Amnestic Syndrome' OR 'Alcohol Amnestic Syndromes' OR 'Alcohol Induced Amnestic Psychosis' OR 'Alcohol Induced Amnestic Syndrome' OR 'Alcohol Induced Dismnesic Syndrome' OR 'Alcohol Induced Dismnesic Syndromes' OR 'Alcohol Induced Korsakoff Syndrome' OR 'Alcohol Induced Korsakoff Syndromes' OR 'Alcohol Induced Persisting Amnestic Disorder' OR 'Alcoholic Korsakoff Syndrome' OR 'Alcoholic Korsakoff Syndromes' OR 'Alcohol Induced Amnestic Psychoses' OR 'Alcohol Induced Dismnesic Psychosis' OR 'Alcohol Induced Dismnesic Psychoses' OR 'Korsakoff Syndrome' OR 'Korsakoff Psychosis' OR 'Korsakoff Psychoses' OR 'Alcoholic Neuropathy' OR 'Alcoholic Neuropathies' OR 'Alcohol Induced Peripheral Neuropathies' OR

'Alcoholic Polyneuropathies' OR 'Alcoholic Polyneuropathy' OR 'Alcoholic Polyneuritides' OR 'Alcoholic Polyneuritis' OR 'Alcohol Induced Polyneuropathy' OR 'Alcohol Induced Polyneuropathies' OR 'Alcohol Related Autonomic Polyneuropathy' OR 'Alcohol Related Autonomic Polyneuropathies' OR 'Alcohol Related Polyneuropathy' OR 'Alcohol-Related Polyneuropathies' OR 'Alcohol Induced Peripheral Neuropathy' OR 'Alcoholic Axonal Neuropathy' OR 'Alcoholic Axonal Neuropathies' OR 'Alcoholic Cardiomyopathy' OR 'Fetal Alcohol Spectrum Disorders' OR 'FASD' OR 'FASDs' OR 'Alcohol Related Birth Defects' OR 'Alcohol Related Neurodevelopmental Disorder' OR 'Fetal Alcohol Effects' OR 'Fetal Alcohol Syndrome' OR 'Alcoholic Liver Diseases' OR 'Alcoholic Liver Disease' OR 'Alcoholic Fatty Liver' OR 'Alcoholic Steatohepatitis' OR 'Chronic Alcoholic Hepatitis' OR 'Chronic Alcoholic Hepatitides' OR 'Alcoholic Liver Cirrhosis' OR 'Alcoholic Cirrhosis' OR 'Alcoholic Hepatic Cirrhosis' OR 'Alcoholic Pancreatitis' OR 'Alcoholic Psychoses' OR 'Chronic Alcoholic Intoxication' OR 'Alcohol Abuse' OR 'Amphetamine Related Disorders' OR 'Amphetamine Abuse' OR 'Amphetamine Addiction' OR 'Amphetamine Dependence' OR 'Cocaine Related Disorders' OR 'Cocaine Related Disorder' OR 'Cocaine Abuse' OR 'Cocaine Dependence' OR 'Cocaine Addiction' OR 'Inhalant Abuses' OR 'Glue Sniffing' OR 'Glue Sniffings' OR 'Glue Abuse' OR 'Glue Abuses' OR 'Marijuana Abuse' OR 'Marihuana Abuse' OR 'Hashish Abuse' OR 'Cannabis Related Disorder' OR 'Cannabis Abuse' OR 'Cannabis Dependence' OR 'Marijuana Dependence' OR 'Opioid Related Disorders' OR 'Opiate Dependence' OR 'Opiate Addiction' OR 'Narcotic Abuse' OR 'Narcotic Abuses' OR 'Narcotic Dependence' OR 'Narcotic Addiction' OR 'Heroin Dependence' OR 'Heroin Addiction' OR 'Heroin Abuse' OR 'Morphine Dependence' OR 'Morphine Addiction' OR 'Morphine Abuse' OR 'Phencyclidine Abuses' OR 'PCP Abuse' OR 'Angel Dust Abuse' OR 'Phencyclidine Related Disorders' OR 'Phencyclidine Related Disorder' OR 'Substance Induced Psychoses' OR 'Toxic Psychoses' OR 'Drug Psychoses' OR 'Intravenous Substance Abuse' OR 'Parenteral Drug Abuse' OR 'Tobacco Use Disorder' OR 'Tobacco Use Disorders' OR 'Nicotine Use Disorder' OR 'Nicotine Use Disorders' OR 'Tobacco Dependence' OR 'Tobacco Dependences' OR 'Nicotine Dependence' OR 'alcoholic individual' OR 'alcoholics' OR 'alcoholic polyneuropathy' OR 'ethanol dependence' OR 'narcotic depression' OR 'narcotism' OR 'heroin addict' OR heroinism OR 'morphine addict' OR 'opiate addict' OR 'opioid dependence' OR 'opium addict' OR 'opium addiction' OR 'opium alkaloid addiction' OR 'opium addiction' OR 'benzodiazepine dependence' OR 'benzodiazepine addiction' OR 'cannabis addiction' OR 'drug abuse pattern' OR 'methamphetamine dependence' OR toxicomania OR 'drug addict' OR 'drug dependence' OR 'drug dependency')

4. Reader training materials

Along with a comprehensive review of the extraction process, the extraction form and items, and a thorough extraction testing process with sample articles, all readers carefully reviewed the following resources to gain an understanding of background material and relevant concepts.

I. Systematic Review and Meta-Analysis

- a. Egger M, Smith GD, Altman D. "Chapter 1: Rationale, potentials & promise of systematic reviews." Systematic reviews in health care: meta-analysis in context. John Wiley & Sons; 2008.

II. Relevant published reviews

- a. Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA: the journal of the American Medical Association. 2011;306(24):2670-2672.
- b. Boyd CM, Vollenweider D, Puhan MA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. PLoS One. 2012;7(8):e41601.
- c. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA : the journal of the American Medical Association. Mar 21 2007;297(11):1233-1240.
- d. Kenning C, Coventry PA, Bower P. Self-management interventions in patients with long-term conditions: a structured review of approaches to reporting inclusion, assessment, and outcomes in multimorbidity. 2014. 2014-08-28 2014;4(1):9.

III. Randomized Controlled Trials (RCT)

a. Overview

- i. Stolberg HO, Norman G, Trop I. Randomized controlled trials. American Journal of Roentgenology. 2004;183(6):1539-1544.
- ii. Stanley K. Design of randomized controlled trials. Circulation. 2007;115(9):1164-1169.

b. Reporting in RCT

- i. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC medicine. 2010;8(1):18.
- ii. Sample Study
 1. <http://www.consort-statement.org/examples/sample>
- iii. Jun M, Zoungas S, Perkovic V, Webster AC. How to read a report of a randomized controlled trial. Nephrology. 2010;15(2):153-157.

c. Quality of RCTs and risk of bias

- i. Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2008. Chapter 5- Assessing the quality of randomized controlled trials

- ii. Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2008. Chapter 8- Assessing risk of bias in included studies

5. Extraction codebook

Data Dictionary Codebook

| # | Variable / Field Name | Field Label <i>Field Note</i> | Field Attributes (Field Type, Validation, Choices, Calculations, etc.) | | | | | | | | | | | | |
|---------------------------------|-----------------------|---|--|---|-----------------|----------|------------|----------------|-------------------------|---|----------------|---------------------|---------------|---|--------|
| Instrument: Basic | | | | | | | | | | | | | | | |
| 1 | record_id | Record Number | text | | | | | | | | | | | | |
| 2 | journal_type | Journal Type | dropdown <table border="1"> <tr> <td>0</td> <td>General Medical</td> </tr> <tr> <td>1</td> <td>Specialty</td> </tr> </table> | 0 | General Medical | 1 | Specialty | | | | | | | | |
| 0 | General Medical | | | | | | | | | | | | | | |
| 1 | Specialty | | | | | | | | | | | | | | |
| 3 | pub_year_category | Publication Year Category | dropdown <table border="1"> <tr> <td>0</td> <td>2000-2004</td> </tr> <tr> <td>1</td> <td>2005-2009</td> </tr> <tr> <td>2</td> <td>2010-2014</td> </tr> </table> | 0 | 2000-2004 | 1 | 2005-2009 | 2 | 2010-2014 | | | | | | |
| 0 | 2000-2004 | | | | | | | | | | | | | | |
| 1 | 2005-2009 | | | | | | | | | | | | | | |
| 2 | 2010-2014 | | | | | | | | | | | | | | |
| 4 | fund_source | Funding Source | checkbox <table border="1"> <tr> <td>0</td> <td>fund_source__0</td> <td>Industry</td> </tr> <tr> <td>1</td> <td>fund_source__1</td> <td>Non-Industry</td> </tr> <tr> <td>2</td> <td>fund_source__2</td> <td>Not Reported</td> </tr> </table> | 0 | fund_source__0 | Industry | 1 | fund_source__1 | Non-Industry | 2 | fund_source__2 | Not Reported | | | |
| 0 | fund_source__0 | Industry | | | | | | | | | | | | | |
| 1 | fund_source__1 | Non-Industry | | | | | | | | | | | | | |
| 2 | fund_source__2 | Not Reported | | | | | | | | | | | | | |
| 5 | region | Region | dropdown <table border="1"> <tr> <td>0</td> <td>North America</td> </tr> <tr> <td>1</td> <td>Europe</td> </tr> <tr> <td>2</td> <td>Middle East</td> </tr> <tr> <td>3</td> <td>Asia/Pacific</td> </tr> <tr> <td>4</td> <td>Latin America</td> </tr> <tr> <td>5</td> <td>Africa</td> </tr> </table> | 0 | North America | 1 | Europe | 2 | Middle East | 3 | Asia/Pacific | 4 | Latin America | 5 | Africa |
| 0 | North America | | | | | | | | | | | | | | |
| 1 | Europe | | | | | | | | | | | | | | |
| 2 | Middle East | | | | | | | | | | | | | | |
| 3 | Asia/Pacific | | | | | | | | | | | | | | |
| 4 | Latin America | | | | | | | | | | | | | | |
| 5 | Africa | | | | | | | | | | | | | | |
| 6 | registered | Is this study reported to be a registered clinical trial? | checkbox <table border="1"> <tr> <td>0</td> <td>registered__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>registered__1</td> <td>Yes- clinicaltrials.gov</td> </tr> <tr> <td>2</td> <td>registered__2</td> <td>Yes- other registry</td> </tr> </table> | 0 | registered__0 | No | 1 | registered__1 | Yes- clinicaltrials.gov | 2 | registered__2 | Yes- other registry | | | |
| 0 | registered__0 | No | | | | | | | | | | | | | |
| 1 | registered__1 | Yes- clinicaltrials.gov | | | | | | | | | | | | | |
| 2 | registered__2 | Yes- other registry | | | | | | | | | | | | | |
| 7 | basic_complete | Complete? | dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table> | 0 | Incomplete | 1 | Unverified | 2 | Complete | | | | | | |
| 0 | Incomplete | | | | | | | | | | | | | | |
| 1 | Unverified | | | | | | | | | | | | | | |
| 2 | Complete | | | | | | | | | | | | | | |
| Instrument: Intervention | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----|---|--|---|---|--------------|-----------|--|--------------|---|---|---|--------------------------|---|--------------|--------|---|--------------|---------------------|---|--------------|------------------------|---|--------------|---------------------------------------|---|--------------|--------------------------|---|--------------|-------------------------|----|---------------|----------|----|---------------|------------|----|---------------|----------|----|---------------|-----------|----|---------------|------------------------------------|----|---------------|----------------|----|---------------|--------------|----|---------------|--------------|----|---------------|---------------|----|---------------|--------|----|---------------|---------------------------|----|---------------|-----------------------------|
| 8 | sample_cc_targeted | Is the trial selection targeting individuals with multiple chronic conditions? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes, individuals with a specific set of chronic conditions</td> </tr> <tr> <td>2</td> <td>Yes, individuals with multiple chronic conditions, regardless of conditions</td> </tr> <tr> <td>3</td> <td>Yes, individuals with any combination of chronic conditions within a specific set of conditions</td> </tr> </table> | 0 | No | 1 | Yes, individuals with a specific set of chronic conditions | 2 | Yes, individuals with multiple chronic conditions, regardless of conditions | 3 | Yes, individuals with any combination of chronic conditions within a specific set of conditions | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes, individuals with a specific set of chronic conditions | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Yes, individuals with multiple chronic conditions, regardless of conditions | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | Yes, individuals with any combination of chronic conditions within a specific set of conditions | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | cc_list Show the field ON LY if: [sample_cc_targeted]="0" | Is the trial selection targeting individuals with one condition from a specific set of chronic conditions? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | sample_cc Show the field ON LY if: [sample_cc_targeted]="0" or [sample_cc_targeted]="1" or [sample_cc_targeted]="3" | The study sample consists of individuals with which chronic condition(s) ? | <p>checkbox</p> <table border="1"> <tr><td>1</td><td>sample_cc__1</td><td>Arthritis</td></tr> <tr><td>2</td><td>sample_cc__2</td><td>Asthma</td></tr> <tr><td>3</td><td>sample_cc__3</td><td>Autism spectrum disorder</td></tr> <tr><td>4</td><td>sample_cc__4</td><td>Cancer</td></tr> <tr><td>5</td><td>sample_cc__5</td><td>Cardiac arrhythmias</td></tr> <tr><td>6</td><td>sample_cc__6</td><td>Chronic kidney disease</td></tr> <tr><td>7</td><td>sample_cc__7</td><td>Chronic obstructive pulmonary disease</td></tr> <tr><td>8</td><td>sample_cc__8</td><td>Congestive heart failure</td></tr> <tr><td>9</td><td>sample_cc__9</td><td>Coronary artery disease</td></tr> <tr><td>10</td><td>sample_cc__10</td><td>Dementia</td></tr> <tr><td>11</td><td>sample_cc__11</td><td>Depression</td></tr> <tr><td>12</td><td>sample_cc__12</td><td>Diabetes</td></tr> <tr><td>13</td><td>sample_cc__13</td><td>Hepatitis</td></tr> <tr><td>14</td><td>sample_cc__14</td><td>Human immunodeficiency virus (HIV)</td></tr> <tr><td>15</td><td>sample_cc__15</td><td>Hyperlipidemia</td></tr> <tr><td>16</td><td>sample_cc__16</td><td>Hypertension</td></tr> <tr><td>17</td><td>sample_cc__17</td><td>Osteoporosis</td></tr> <tr><td>18</td><td>sample_cc__18</td><td>Schizophrenia</td></tr> <tr><td>19</td><td>sample_cc__19</td><td>Stroke</td></tr> <tr><td>20</td><td>sample_cc__20</td><td>Substance abuse disorders</td></tr> <tr><td>21</td><td>sample_cc__21</td><td>Chronic condition (General)</td></tr> </table> | 1 | sample_cc__1 | Arthritis | 2 | sample_cc__2 | Asthma | 3 | sample_cc__3 | Autism spectrum disorder | 4 | sample_cc__4 | Cancer | 5 | sample_cc__5 | Cardiac arrhythmias | 6 | sample_cc__6 | Chronic kidney disease | 7 | sample_cc__7 | Chronic obstructive pulmonary disease | 8 | sample_cc__8 | Congestive heart failure | 9 | sample_cc__9 | Coronary artery disease | 10 | sample_cc__10 | Dementia | 11 | sample_cc__11 | Depression | 12 | sample_cc__12 | Diabetes | 13 | sample_cc__13 | Hepatitis | 14 | sample_cc__14 | Human immunodeficiency virus (HIV) | 15 | sample_cc__15 | Hyperlipidemia | 16 | sample_cc__16 | Hypertension | 17 | sample_cc__17 | Osteoporosis | 18 | sample_cc__18 | Schizophrenia | 19 | sample_cc__19 | Stroke | 20 | sample_cc__20 | Substance abuse disorders | 21 | sample_cc__21 | Chronic condition (General) |
| 1 | sample_cc__1 | Arthritis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | sample_cc__2 | Asthma | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | sample_cc__3 | Autism spectrum disorder | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | sample_cc__4 | Cancer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | sample_cc__5 | Cardiac arrhythmias | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | sample_cc__6 | Chronic kidney disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | sample_cc__7 | Chronic obstructive pulmonary disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | sample_cc__8 | Congestive heart failure | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | sample_cc__9 | Coronary artery disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | sample_cc__10 | Dementia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11 | sample_cc__11 | Depression | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | sample_cc__12 | Diabetes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 13 | sample_cc__13 | Hepatitis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 14 | sample_cc__14 | Human immunodeficiency virus (HIV) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 15 | sample_cc__15 | Hyperlipidemia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 16 | sample_cc__16 | Hypertension | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17 | sample_cc__17 | Osteoporosis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 18 | sample_cc__18 | Schizophrenia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 19 | sample_cc__19 | Stroke | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 | sample_cc__20 | Substance abuse disorders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 21 | sample_cc__21 | Chronic condition (General) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | |
|----|---|--|--|---|----|---|-----|
| 11 | number_arms | Number of experimental study arms | text (integer, Min: 1, Max: 4) | | | | |
| 12 | randomized_1 | Is the number of participants randomized to this group reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 13 | sample_size_1 Show the field ON LY if: [randomized_1]= "1" | Sample Size | text (integer) | | | | |
| 14 | randomized_2 | Is the number of participants randomized to this group reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 15 | sample_size_2 Show the field ON LY if: [randomized_2]= "1" | Sample Size | text (integer) | | | | |
| 16 | randomized_3 Show the field ON LY if: [number_arms]>1 | Is the number of participants randomized to this group reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 17 | sample_size_3 Show the field ON LY if: [number_arms]>1 and [randomized_3]= "1" | Sample Size | text (integer) | | | | |
| 18 | randomized_4 Show the field ON LY if: [number_arms]>2 | Is the number of participants randomized to this group reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 19 | sample_size_4 Show the field ON LY if: | Sample Size | text (integer) | | | | |

| | | | | | | | | | | | | | | | | | | |
|--------------------------------|---|--|--|---|-----------------------|--|------------|-----------------------|----------------|---|-----------------------|---------------------------------|---|-----------------------|--------------------------|---|-----------------------|-------|
| | [number_arms]>2 and [randomized_4] = "1" | | | | | | | | | | | | | | | | | |
| 20 | randomized_5 Show the field ON LY if: [number_arms]>3 | Is the number of participants randomized to this group reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 21 | sample_size_5 Show the field ON LY if: [number_arms]>3 and [randomized_5] = "1" | Sample Size | text (integer) | | | | | | | | | | | | | | | |
| 22 | randomized_total | Is the total number of participants randomized reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 23 | sample_size_total Show the field ON LY if: [randomized_total] = "1" | Studywide Sample Size | text (integer) | | | | | | | | | | | | | | | |
| 24 | sample_size_total_calc | Calculated Studywide Sample Size | calc Calculation: sum([sample_size_1],[sample_size_2],[sample_size_3],[sample_size_4],[sample_size_5]) | | | | | | | | | | | | | | | |
| 25 | intervention_behav | What is the behavioral component of the intervention ? | checkbox <table border="1"> <tr> <td>0</td> <td>intervention_behav__0</td> <td>Weight management/diet/physical activity</td> </tr> <tr> <td>1</td> <td>intervention_behav__1</td> <td>Tobacco habits</td> </tr> <tr> <td>2</td> <td>intervention_behav__2</td> <td>Adherence to disease management</td> </tr> <tr> <td>3</td> <td>intervention_behav__3</td> <td>Psychological well-being</td> </tr> <tr> <td>4</td> <td>intervention_behav__4</td> <td>Other</td> </tr> </table> | 0 | intervention_behav__0 | Weight management/diet/physical activity | 1 | intervention_behav__1 | Tobacco habits | 2 | intervention_behav__2 | Adherence to disease management | 3 | intervention_behav__3 | Psychological well-being | 4 | intervention_behav__4 | Other |
| 0 | intervention_behav__0 | Weight management/diet/physical activity | | | | | | | | | | | | | | | | |
| 1 | intervention_behav__1 | Tobacco habits | | | | | | | | | | | | | | | | |
| 2 | intervention_behav__2 | Adherence to disease management | | | | | | | | | | | | | | | | |
| 3 | intervention_behav__3 | Psychological well-being | | | | | | | | | | | | | | | | |
| 4 | intervention_behav__4 | Other | | | | | | | | | | | | | | | | |
| 26 | intervention_complete | Complete? | dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table> | 0 | Incomplete | 1 | Unverified | 2 | Complete | | | | | | | | | |
| 0 | Incomplete | | | | | | | | | | | | | | | | | |
| 1 | Unverified | | | | | | | | | | | | | | | | | |
| 2 | Complete | | | | | | | | | | | | | | | | | |
| Instrument: Eligibility | | | | | | | | | | | | | | | | | | |
| 27 | elig_reported | Is eligibility criteria reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> </table> | 0 | No | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | | |
|----|--|--|--|---|---------------|-------------|-----|---------------|------------------------|---|---------------|---------------------|---|---------------|-------------------|---|---------------|------|---|---------------|--------|
| | | | <table border="1"> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 1 | Yes | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | |
| 28 | elig_criteria_behav | Were any behavioral factors/conditions are used as inclusion or exclusion criteria? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | |
| 29 | elig_behav Show the field ONLY if: [elig_criteria_behav]="1" | Which of the following behavioral factors/conditions were reported as eligibility criteria? | <p>checkbox</p> <table border="1"> <tr> <td>0</td> <td>elig_behav__0</td> <td>Alcohol use</td> </tr> <tr> <td>1</td> <td>elig_behav__1</td> <td>Smoking or tobacco use</td> </tr> <tr> <td>2</td> <td>elig_behav__2</td> <td>Other substance use</td> </tr> <tr> <td>3</td> <td>elig_behav__3</td> <td>Physical activity</td> </tr> <tr> <td>4</td> <td>elig_behav__4</td> <td>Diet</td> </tr> <tr> <td>5</td> <td>elig_behav__5</td> <td>Weight</td> </tr> </table> | 0 | elig_behav__0 | Alcohol use | 1 | elig_behav__1 | Smoking or tobacco use | 2 | elig_behav__2 | Other substance use | 3 | elig_behav__3 | Physical activity | 4 | elig_behav__4 | Diet | 5 | elig_behav__5 | Weight |
| 0 | elig_behav__0 | Alcohol use | | | | | | | | | | | | | | | | | | | |
| 1 | elig_behav__1 | Smoking or tobacco use | | | | | | | | | | | | | | | | | | | |
| 2 | elig_behav__2 | Other substance use | | | | | | | | | | | | | | | | | | | |
| 3 | elig_behav__3 | Physical activity | | | | | | | | | | | | | | | | | | | |
| 4 | elig_behav__4 | Diet | | | | | | | | | | | | | | | | | | | |
| 5 | elig_behav__5 | Weight | | | | | | | | | | | | | | | | | | | |
| 30 | mcc_exclusion | Did trial explicitly exclude individuals with multiple chronic conditions, regardless of conditions? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | |
| 31 | mcc_exclusion_report Show the field ONLY if: [mcc_exclusion]="1" | Is the number of individuals excluded for having comorbid chronic conditions reported? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | |
| 32 | mcc_exclusion_just Show the field ONLY if: [mcc_exclusion]="1" | Is a justification for MCC exclusion provided? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | |
| 33 | mcc_ability Show the field ONLY if: | Is this justification based on ability to | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|----|---|---|---|---|-------------------------|-----------|-----|-------------------------|--------|---|-------------------------|--------------------------|---|-------------------------|--------|---|-------------------------|---------------------|---|-------------------------|------------------------|---|-------------------------|---------------------------------------|
| | [mcc_exclusion_jus t]="1" | participate in the study? | | | | | | | | | | | | | | | | | | | | | | |
| 34 | elig_charlson | Was the Charlson comorbidity index used in eligibility criteria? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | |
| 35 | elig_vague | Are there any vague exclusions for medical or psychologic al conditions (not reported above)? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | |
| 36 | vague_ability Show the field ON LY if: [elig_vague]="1" | Is this exclusion based on ability to participate in the study? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | |
| 37 | condition_exclusio n | Did trial exclude individuals with specific chronic conditions? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | |
| 38 | condition_ability Show the field ON LY if: [condition_exclusio n]="1" | Is this exclusion based on ability to participate in the study? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | |
| 39 | conditions_exclude d Show the field ON LY if: [condition_exclusio n]="1" | Which chronic conditions were subject to exclusions? <i>Check all that apply</i> | checkbox <table border="1"> <tr> <td>1</td> <td>conditions_excluded___1</td> <td>Arthritis</td> </tr> <tr> <td>2</td> <td>conditions_excluded___2</td> <td>Asthma</td> </tr> <tr> <td>3</td> <td>conditions_excluded___3</td> <td>Autism Spectrum Disorder</td> </tr> <tr> <td>4</td> <td>conditions_excluded___4</td> <td>Cancer</td> </tr> <tr> <td>5</td> <td>conditions_excluded___5</td> <td>Cardiac Arrhythmias</td> </tr> <tr> <td>6</td> <td>conditions_excluded___6</td> <td>Chronic Kidney Disease</td> </tr> <tr> <td>7</td> <td>conditions_excluded___7</td> <td>Chronic Obstructive Pulmonary Disease</td> </tr> </table> | 1 | conditions_excluded___1 | Arthritis | 2 | conditions_excluded___2 | Asthma | 3 | conditions_excluded___3 | Autism Spectrum Disorder | 4 | conditions_excluded___4 | Cancer | 5 | conditions_excluded___5 | Cardiac Arrhythmias | 6 | conditions_excluded___6 | Chronic Kidney Disease | 7 | conditions_excluded___7 | Chronic Obstructive Pulmonary Disease |
| 1 | conditions_excluded___1 | Arthritis | | | | | | | | | | | | | | | | | | | | | | |
| 2 | conditions_excluded___2 | Asthma | | | | | | | | | | | | | | | | | | | | | | |
| 3 | conditions_excluded___3 | Autism Spectrum Disorder | | | | | | | | | | | | | | | | | | | | | | |
| 4 | conditions_excluded___4 | Cancer | | | | | | | | | | | | | | | | | | | | | | |
| 5 | conditions_excluded___5 | Cardiac Arrhythmias | | | | | | | | | | | | | | | | | | | | | | |
| 6 | conditions_excluded___6 | Chronic Kidney Disease | | | | | | | | | | | | | | | | | | | | | | |
| 7 | conditions_excluded___7 | Chronic Obstructive Pulmonary Disease | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----|---|---|---|---|------------------------|--------------------------|-----|------------------------|-------------------------|----|-------------------------|---------------------------|----|-------------------------|------------------------|----|-------------------------|--------------------------------------|----|-------------------------|-----------|----|-------------------------|------------------------------------|----|-------------------------|----------------|----|-------------------------|--------------|----|-------------------------|--------------|----|-------------------------|---------------|----|-------------------------|--------|----|-------------------------|---------------------------|
| | | | <table border="1"> <tr><td>8</td><td>conditions_excluded__8</td><td>Congestive Heart Failure</td></tr> <tr><td>9</td><td>conditions_excluded__9</td><td>Coronary Artery Disease</td></tr> <tr><td>10</td><td>conditions_excluded__10</td><td>Dementia</td></tr> <tr><td>11</td><td>conditions_excluded__11</td><td>Depression</td></tr> <tr><td>12</td><td>conditions_excluded__12</td><td>Diabetes</td></tr> <tr><td>13</td><td>conditions_excluded__13</td><td>Hepatitis</td></tr> <tr><td>14</td><td>conditions_excluded__14</td><td>Human Immunodeficiency Virus (HIV)</td></tr> <tr><td>15</td><td>conditions_excluded__15</td><td>Hyperlipidemia</td></tr> <tr><td>16</td><td>conditions_excluded__16</td><td>Hypertension</td></tr> <tr><td>17</td><td>conditions_excluded__17</td><td>Osteoporosis</td></tr> <tr><td>18</td><td>conditions_excluded__18</td><td>Schizophrenia</td></tr> <tr><td>19</td><td>conditions_excluded__19</td><td>Stroke</td></tr> <tr><td>20</td><td>conditions_excluded__20</td><td>Substance Abuse Disorders</td></tr> </table> | 8 | conditions_excluded__8 | Congestive Heart Failure | 9 | conditions_excluded__9 | Coronary Artery Disease | 10 | conditions_excluded__10 | Dementia | 11 | conditions_excluded__11 | Depression | 12 | conditions_excluded__12 | Diabetes | 13 | conditions_excluded__13 | Hepatitis | 14 | conditions_excluded__14 | Human Immunodeficiency Virus (HIV) | 15 | conditions_excluded__15 | Hyperlipidemia | 16 | conditions_excluded__16 | Hypertension | 17 | conditions_excluded__17 | Osteoporosis | 18 | conditions_excluded__18 | Schizophrenia | 19 | conditions_excluded__19 | Stroke | 20 | conditions_excluded__20 | Substance Abuse Disorders |
| 8 | conditions_excluded__8 | Congestive Heart Failure | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | conditions_excluded__9 | Coronary Artery Disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | conditions_excluded__10 | Dementia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11 | conditions_excluded__11 | Depression | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | conditions_excluded__12 | Diabetes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 13 | conditions_excluded__13 | Hepatitis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 14 | conditions_excluded__14 | Human Immunodeficiency Virus (HIV) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 15 | conditions_excluded__15 | Hyperlipidemia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 16 | conditions_excluded__16 | Hypertension | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17 | conditions_excluded__17 | Osteoporosis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 18 | conditions_excluded__18 | Schizophrenia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 19 | conditions_excluded__19 | Stroke | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 | conditions_excluded__20 | Substance Abuse Disorders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 40 | <p>exclusion_n_report_1</p> <p>Show the field ON LY if: [conditions_excluded(1)]= "1"</p> | <p>Is the number of individuals excluded for having Arthritis reported?</p> | <p>dropdown</p> <table border="1"> <tr><td>0</td><td>No</td></tr> <tr><td>1</td><td>Yes</td></tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 41 | <p>exclusion_1</p> <p>Show the field ON LY if: [conditions_excluded(1)]= "1"</p> | <p>Is exclusion of individuals with Arthritis narrowed?</p> | <p>checkbox</p> <table border="1"> <tr><td>0</td><td>exclusion_1__0</td><td>No</td></tr> <tr><td>1</td><td>exclusion_1__1</td><td>Yes- narrowed by type</td></tr> <tr><td>2</td><td>exclusion_1__2</td><td>Yes- narrowed by severity</td></tr> <tr><td>3</td><td>exclusion_1__3</td><td>Yes- narrowed by onset</td></tr> <tr><td>4</td><td>exclusion_1__4</td><td>Yes- narrowed by other specification</td></tr> </table> | 0 | exclusion_1__0 | No | 1 | exclusion_1__1 | Yes- narrowed by type | 2 | exclusion_1__2 | Yes- narrowed by severity | 3 | exclusion_1__3 | Yes- narrowed by onset | 4 | exclusion_1__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | exclusion_1__0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | exclusion_1__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | exclusion_1__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | exclusion_1__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | exclusion_1__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 42 | <p>exclusion_n_report_2</p> <p>Show the field ON LY if: [conditions_excluded(2)]= "1"</p> | <p>Is the number of individuals excluded for having Asthma reported?</p> | <p>dropdown</p> <table border="1"> <tr><td>0</td><td>No</td></tr> <tr><td>1</td><td>Yes</td></tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 43 | <p>exclusion_2</p> <p>Show the field ON LY if: [conditions_excluded(2)]= "1"</p> | <p>Is exclusion of individuals with Asthma narrowed?</p> | <p>checkbox</p> <table border="1"> <tr><td>0</td><td>exclusion_2__0</td><td>No</td></tr> <tr><td>1</td><td>exclusion_2__1</td><td>Yes- narrowed by type</td></tr> <tr><td>2</td><td>exclusion_2__2</td><td>Yes- narrowed by severity</td></tr> <tr><td>3</td><td>exclusion_2__3</td><td>Yes- narrowed by onset</td></tr> </table> | 0 | exclusion_2__0 | No | 1 | exclusion_2__1 | Yes- narrowed by type | 2 | exclusion_2__2 | Yes- narrowed by severity | 3 | exclusion_2__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | exclusion_2__0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | exclusion_2__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | exclusion_2__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | exclusion_2__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | |
|----|---|---|---|
| | | | 4 exclusion_2__4 Yes- narrowed by other specification |
| 44 | exclusion_n_report_3 Show the field ON LY if: [conditions_excluded(3)]= "1" | Is the number of individuals excluded for having Autism Spectrum Disorder reported? | dropdown 0 No 1 Yes |
| 45 | exclusion_3 Show the field ON LY if: [conditions_excluded(3)]= "1" | Is exclusion of individuals with Autism Spectrum Disorder narrowed? | checkbox 0 exclusion_3__0 No 1 exclusion_3__1 Yes- narrowed by type 2 exclusion_3__2 Yes- narrowed by severity 3 exclusion_3__3 Yes- narrowed by onset 4 exclusion_3__4 Yes- narrowed by other specification |
| 46 | exclusion_n_report_4 Show the field ON LY if: [conditions_excluded(4)]= "1" | Is the number of individuals excluded for having Cancer reported? | dropdown 0 No 1 Yes |
| 47 | exclusion_4 Show the field ON LY if: [conditions_excluded(4)]= "1" | Is exclusion of individuals with Cancer narrowed? | checkbox 0 exclusion_4__0 No 1 exclusion_4__1 Yes- narrowed by type 2 exclusion_4__2 Yes- narrowed by severity 3 exclusion_4__3 Yes- narrowed by onset 4 exclusion_4__4 Yes- narrowed by other specification |
| 48 | exclusion_n_report_5 Show the field ON LY if: [conditions_excluded(5)]= "1" | Is the number of individuals excluded for having Cardiac Arrhythmias reported? | dropdown 0 No 1 Yes |
| 49 | exclusion_5 Show the field ON LY if: [conditions_excluded(5)]= "1" | Is exclusion of individuals with Cardiac | checkbox 0 exclusion_5__0 No 1 exclusion_5__1 Yes- narrowed by type 2 exclusion_5__2 Yes- narrowed by severity |

| | | | | | | | | | | | | | | | | | | |
|----|---|--|---|---|----------------|------------------------|-----|----------------|--------------------------------------|---|----------------|---------------------------|---|----------------|------------------------|---|----------------|--------------------------------------|
| | | Arrhythmias narrowed? | <table border="1"> <tr> <td>3</td> <td>exclusion_5__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_5__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 3 | exclusion_5__3 | Yes- narrowed by onset | 4 | exclusion_5__4 | Yes- narrowed by other specification | | | | | | | | | |
| 3 | exclusion_5__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_5__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 50 | <p>exclusion_n_report_6</p> <p>Show the field ON LY if: [conditions_excluded(6)]= "1"</p> | Is the number of individuals excluded for having Chronic Kidney Disease reported? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 51 | <p>exclusion_6</p> <p>Show the field ON LY if: [conditions_excluded(6)]= "1"</p> | Is exclusion of individuals with Chronic Kidney Disease narrowed? | <p>checkbox</p> <table border="1"> <tr> <td>0</td> <td>exclusion_6__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_6__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_6__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_6__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_6__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_6__0 | No | 1 | exclusion_6__1 | Yes- narrowed by type | 2 | exclusion_6__2 | Yes- narrowed by severity | 3 | exclusion_6__3 | Yes- narrowed by onset | 4 | exclusion_6__4 | Yes- narrowed by other specification |
| 0 | exclusion_6__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_6__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_6__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_6__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_6__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 52 | <p>exclusion_n_report_7</p> <p>Show the field ON LY if: [conditions_excluded(7)]= "1"</p> | Is the number of individuals excluded for having Chronic Obstructive Pulmonary Disease reported? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 53 | <p>exclusion_7</p> <p>Show the field ON LY if: [conditions_excluded(7)]= "1"</p> | Is exclusion of individuals with Chronic Obstructive Pulmonary Disease narrowed? | <p>checkbox</p> <table border="1"> <tr> <td>0</td> <td>exclusion_7__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_7__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_7__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_7__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_7__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_7__0 | No | 1 | exclusion_7__1 | Yes- narrowed by type | 2 | exclusion_7__2 | Yes- narrowed by severity | 3 | exclusion_7__3 | Yes- narrowed by onset | 4 | exclusion_7__4 | Yes- narrowed by other specification |
| 0 | exclusion_7__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_7__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_7__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_7__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_7__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 54 | <p>exclusion_n_report_8</p> <p>Show the field ON LY if: [conditions_excluded(8)]= "1"</p> | Is the number of individuals excluded for having Congestive Heart Failure reported? | <p>dropdown</p> <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|----|---|--|--|---|-----------------|----|-----|-----------------|-----------------------|---|-----------------|---------------------------|---|-----------------|------------------------|---|-----------------|--------------------------------------|
| 55 | exclusion_8 Show the field ON LY if: [conditions_excluded(8)]= "1" | Is exclusion of individuals with Congestive Heart Failure narrowed? | checkbox <table border="1"> <tr> <td>0</td> <td>exclusion_8__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_8__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_8__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_8__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_8__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_8__0 | No | 1 | exclusion_8__1 | Yes- narrowed by type | 2 | exclusion_8__2 | Yes- narrowed by severity | 3 | exclusion_8__3 | Yes- narrowed by onset | 4 | exclusion_8__4 | Yes- narrowed by other specification |
| 0 | exclusion_8__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_8__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_8__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_8__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_8__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 56 | exclusion_n_report_9 Show the field ON LY if: [conditions_excluded(9)]= "1" | Is the number of individuals excluded for having Coronary Artery Disease reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 57 | exclusion_9 Show the field ON LY if: [conditions_excluded(9)]= "1" | Is exclusion of individuals with Coronary Artery Disease narrowed? | checkbox <table border="1"> <tr> <td>0</td> <td>exclusion_9__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_9__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_9__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_9__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_9__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_9__0 | No | 1 | exclusion_9__1 | Yes- narrowed by type | 2 | exclusion_9__2 | Yes- narrowed by severity | 3 | exclusion_9__3 | Yes- narrowed by onset | 4 | exclusion_9__4 | Yes- narrowed by other specification |
| 0 | exclusion_9__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_9__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_9__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_9__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_9__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 58 | exclusion_n_report_10 Show the field ON LY if: [conditions_excluded(10)]= "1" | Is the number of individuals excluded for having Dementia reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 59 | exclusion_10 Show the field ON LY if: [conditions_excluded(10)]= "1" | Is exclusion of individuals with Dementia narrowed? | checkbox <table border="1"> <tr> <td>0</td> <td>exclusion_10__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_10__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_10__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_10__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_10__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_10__0 | No | 1 | exclusion_10__1 | Yes- narrowed by type | 2 | exclusion_10__2 | Yes- narrowed by severity | 3 | exclusion_10__3 | Yes- narrowed by onset | 4 | exclusion_10__4 | Yes- narrowed by other specification |
| 0 | exclusion_10__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_10__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_10__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_10__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_10__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 60 | exclusion_n_report_11 Show the field ON LY if: [conditions_excluded(11)]= "1" | Is the number of individuals excluded for having Depression reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|----|--|--|--|---|-----------------|----|-----|-----------------|-----------------------|---|-----------------|---------------------------|---|-----------------|------------------------|---|-----------------|--------------------------------------|
| 61 | exclusion_11 Show the field ON LY if: [conditions_excluded(11)]= "1" | Is exclusion of individuals with Depression narrowed? | checkbox <table border="1"> <tr> <td>0</td> <td>exclusion_11__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_11__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_11__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_11__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_11__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_11__0 | No | 1 | exclusion_11__1 | Yes- narrowed by type | 2 | exclusion_11__2 | Yes- narrowed by severity | 3 | exclusion_11__3 | Yes- narrowed by onset | 4 | exclusion_11__4 | Yes- narrowed by other specification |
| 0 | exclusion_11__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_11__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_11__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_11__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_11__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 62 | exclusion_justified_11 Show the field ON LY if: [conditions_excluded(11)]= "1" | Is a justification for Depression exclusion provided? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 63 | exclusion_n_report_12 Show the field ON LY if: [conditions_excluded(12)]= "1" | Is the number of individuals excluded for having Diabetes reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 64 | exclusion_12 Show the field ON LY if: [conditions_excluded(12)]= "1" | Is exclusion of individuals with Diabetes narrowed? | checkbox <table border="1"> <tr> <td>0</td> <td>exclusion_12__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_12__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_12__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_12__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_12__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_12__0 | No | 1 | exclusion_12__1 | Yes- narrowed by type | 2 | exclusion_12__2 | Yes- narrowed by severity | 3 | exclusion_12__3 | Yes- narrowed by onset | 4 | exclusion_12__4 | Yes- narrowed by other specification |
| 0 | exclusion_12__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_12__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_12__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_12__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_12__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 65 | exclusion_n_report_13 Show the field ON LY if: [conditions_excluded(13)]= "1" | Is the number of individuals excluded for having Hepatitis reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 66 | exclusion_13 Show the field ON LY if: [conditions_excluded(13)]= "1" | Is exclusion of individuals with Hepatitis narrowed? | checkbox <table border="1"> <tr> <td>0</td> <td>exclusion_13__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_13__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_13__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_13__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_13__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_13__0 | No | 1 | exclusion_13__1 | Yes- narrowed by type | 2 | exclusion_13__2 | Yes- narrowed by severity | 3 | exclusion_13__3 | Yes- narrowed by onset | 4 | exclusion_13__4 | Yes- narrowed by other specification |
| 0 | exclusion_13__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_13__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_13__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_13__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_13__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 67 | exclusion_n_report_14 | Is the number of | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> </table> | 0 | No | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|----|---|---|--|---|-----------------|----|-----|-----------------|-----------------------|---|-----------------|---------------------------|---|-----------------|------------------------|---|-----------------|--------------------------------------|
| | Show the field ON LY if: [conditions_excluded(14)]= "1" | individuals excluded for having HIV reported? | <table border="1"><tr><td>1</td><td>Yes</td></tr></table> | 1 | Yes | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 68 | exclusion_14 Show the field ON LY if: [conditions_excluded(14)]= "1" | Is exclusion of individuals with HIV narrowed? | checkbox <table border="1"><tr><td>0</td><td>exclusion_14__0</td><td>No</td></tr><tr><td>1</td><td>exclusion_14__1</td><td>Yes- narrowed by type</td></tr><tr><td>2</td><td>exclusion_14__2</td><td>Yes- narrowed by severity</td></tr><tr><td>3</td><td>exclusion_14__3</td><td>Yes- narrowed by onset</td></tr><tr><td>4</td><td>exclusion_14__4</td><td>Yes- narrowed by other specification</td></tr></table> | 0 | exclusion_14__0 | No | 1 | exclusion_14__1 | Yes- narrowed by type | 2 | exclusion_14__2 | Yes- narrowed by severity | 3 | exclusion_14__3 | Yes- narrowed by onset | 4 | exclusion_14__4 | Yes- narrowed by other specification |
| 0 | exclusion_14__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_14__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_14__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_14__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_14__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 69 | exclusion_n_report_15 Show the field ON LY if: [conditions_excluded(15)]= "1" | Is the number of individuals excluded for having Hyperlipidemia reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 70 | exclusion_15 Show the field ON LY if: [conditions_excluded(15)]= "1" | Is exclusion of individuals with Hyperlipidemia narrowed? | checkbox <table border="1"><tr><td>0</td><td>exclusion_15__0</td><td>No</td></tr><tr><td>1</td><td>exclusion_15__1</td><td>Yes- narrowed by type</td></tr><tr><td>2</td><td>exclusion_15__2</td><td>Yes- narrowed by severity</td></tr><tr><td>3</td><td>exclusion_15__3</td><td>Yes- narrowed by onset</td></tr><tr><td>4</td><td>exclusion_15__4</td><td>Yes- narrowed by other specification</td></tr></table> | 0 | exclusion_15__0 | No | 1 | exclusion_15__1 | Yes- narrowed by type | 2 | exclusion_15__2 | Yes- narrowed by severity | 3 | exclusion_15__3 | Yes- narrowed by onset | 4 | exclusion_15__4 | Yes- narrowed by other specification |
| 0 | exclusion_15__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_15__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_15__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_15__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_15__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 71 | exclusion_n_report_16 Show the field ON LY if: [conditions_excluded(16)]= "1" | Is the number of individuals excluded for having Hypertension reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 72 | exclusion_16 Show the field ON LY if: [conditions_excluded(16)]= "1" | Is exclusion of individuals with Hypertension narrowed? | checkbox <table border="1"><tr><td>0</td><td>exclusion_16__0</td><td>No</td></tr><tr><td>1</td><td>exclusion_16__1</td><td>Yes- narrowed by type</td></tr><tr><td>2</td><td>exclusion_16__2</td><td>Yes- narrowed by severity</td></tr><tr><td>3</td><td>exclusion_16__3</td><td>Yes- narrowed by onset</td></tr><tr><td>4</td><td>exclusion_16__4</td><td>Yes- narrowed by other specification</td></tr></table> | 0 | exclusion_16__0 | No | 1 | exclusion_16__1 | Yes- narrowed by type | 2 | exclusion_16__2 | Yes- narrowed by severity | 3 | exclusion_16__3 | Yes- narrowed by onset | 4 | exclusion_16__4 | Yes- narrowed by other specification |
| 0 | exclusion_16__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_16__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_16__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_16__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_16__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 73 | exclusion_n_report_17 | Is the number of individuals | dropdown <table border="1"><tr><td>0</td><td>No</td></tr></table> | 0 | No | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|----|---|--|--|---|-----------------|----|-----|-----------------|-----------------------|---|-----------------|---------------------------|---|-----------------|------------------------|---|-----------------|--------------------------------------|
| | Show the field ON LY if: [conditions_excluded(17)]= "1" | excluded for having Osteoporosis reported? | <table border="1"><tr><td>1</td><td>Yes</td></tr></table> | 1 | Yes | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 74 | exclusion_17 Show the field ON LY if: [conditions_excluded(17)]= "1" | Is exclusion of individuals with Osteoporosis narrowed? | checkbox <table border="1"><tr><td>0</td><td>exclusion_17__0</td><td>No</td></tr><tr><td>1</td><td>exclusion_17__1</td><td>Yes- narrowed by type</td></tr><tr><td>2</td><td>exclusion_17__2</td><td>Yes- narrowed by severity</td></tr><tr><td>3</td><td>exclusion_17__3</td><td>Yes- narrowed by onset</td></tr><tr><td>4</td><td>exclusion_17__4</td><td>Yes- narrowed by other specification</td></tr></table> | 0 | exclusion_17__0 | No | 1 | exclusion_17__1 | Yes- narrowed by type | 2 | exclusion_17__2 | Yes- narrowed by severity | 3 | exclusion_17__3 | Yes- narrowed by onset | 4 | exclusion_17__4 | Yes- narrowed by other specification |
| 0 | exclusion_17__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_17__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_17__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_17__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_17__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 75 | exclusion_n_report_18 Show the field ON LY if: [conditions_excluded(18)]= "1" | Is the number of individuals excluded for having Schizophrenia reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 76 | exclusion_18 Show the field ON LY if: [conditions_excluded(18)]= "1" | Is exclusion of individuals with Schizophrenia narrowed? | checkbox <table border="1"><tr><td>0</td><td>exclusion_18__0</td><td>No</td></tr><tr><td>1</td><td>exclusion_18__1</td><td>Yes- narrowed by type</td></tr><tr><td>2</td><td>exclusion_18__2</td><td>Yes- narrowed by severity</td></tr><tr><td>3</td><td>exclusion_18__3</td><td>Yes- narrowed by onset</td></tr><tr><td>4</td><td>exclusion_18__4</td><td>Yes- narrowed by other specification</td></tr></table> | 0 | exclusion_18__0 | No | 1 | exclusion_18__1 | Yes- narrowed by type | 2 | exclusion_18__2 | Yes- narrowed by severity | 3 | exclusion_18__3 | Yes- narrowed by onset | 4 | exclusion_18__4 | Yes- narrowed by other specification |
| 0 | exclusion_18__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_18__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_18__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_18__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_18__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 77 | exclusion_n_report_19 Show the field ON LY if: [conditions_excluded(19)]= "1" | Is the number of individuals excluded for having Stroke reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 78 | exclusion_19 Show the field ON LY if: [conditions_excluded(19)]= "1" | Is exclusion of individuals with Stroke narrowed? | checkbox <table border="1"><tr><td>0</td><td>exclusion_19__0</td><td>No</td></tr><tr><td>1</td><td>exclusion_19__1</td><td>Yes- narrowed by type</td></tr><tr><td>2</td><td>exclusion_19__2</td><td>Yes- narrowed by severity</td></tr><tr><td>3</td><td>exclusion_19__3</td><td>Yes- narrowed by onset</td></tr><tr><td>4</td><td>exclusion_19__4</td><td>Yes- narrowed by other specification</td></tr></table> | 0 | exclusion_19__0 | No | 1 | exclusion_19__1 | Yes- narrowed by type | 2 | exclusion_19__2 | Yes- narrowed by severity | 3 | exclusion_19__3 | Yes- narrowed by onset | 4 | exclusion_19__4 | Yes- narrowed by other specification |
| 0 | exclusion_19__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_19__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_19__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_19__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_19__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 79 | exclusion_n_report_20 Show the field ON LY if: | Is the number of individuals excluded for | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|--------------------------------------|--|---|--|---|---------------------|-------------|------------|---------------------|-----------------------|---|-----------------|---------------------------|---|-----------------|------------------------|---|-----------------|--------------------------------------|
| | [conditions_exclud ed(20)]="1" | having Substance Abuse Disorders reported? | | | | | | | | | | | | | | | | |
| 80 | exclusion_20 Show the field ON LY if: [conditions_exclud ed(20)]="1" | Is exclusion of individuals with Substance Abuse Disorders narrowed? | checkbox <table border="1"> <tr> <td>0</td> <td>exclusion_20__0</td> <td>No</td> </tr> <tr> <td>1</td> <td>exclusion_20__1</td> <td>Yes- narrowed by type</td> </tr> <tr> <td>2</td> <td>exclusion_20__2</td> <td>Yes- narrowed by severity</td> </tr> <tr> <td>3</td> <td>exclusion_20__3</td> <td>Yes- narrowed by onset</td> </tr> <tr> <td>4</td> <td>exclusion_20__4</td> <td>Yes- narrowed by other specification</td> </tr> </table> | 0 | exclusion_20__0 | No | 1 | exclusion_20__1 | Yes- narrowed by type | 2 | exclusion_20__2 | Yes- narrowed by severity | 3 | exclusion_20__3 | Yes- narrowed by onset | 4 | exclusion_20__4 | Yes- narrowed by other specification |
| 0 | exclusion_20__0 | No | | | | | | | | | | | | | | | | |
| 1 | exclusion_20__1 | Yes- narrowed by type | | | | | | | | | | | | | | | | |
| 2 | exclusion_20__2 | Yes- narrowed by severity | | | | | | | | | | | | | | | | |
| 3 | exclusion_20__3 | Yes- narrowed by onset | | | | | | | | | | | | | | | | |
| 4 | exclusion_20__4 | Yes- narrowed by other specification | | | | | | | | | | | | | | | | |
| 81 | age_restrict | Were there any age restrictions for trial participants (aside from 18 years or older)? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 82 | age_restric_type Show the field ON LY if: [age_restrict]="1" | What type of age exclusion? | checkbox <table border="1"> <tr> <td>0</td> <td>age_restric_type__0</td> <td>Minimum Age</td> </tr> <tr> <td>1</td> <td>age_restric_type__1</td> <td>Maximum Age</td> </tr> </table> | 0 | age_restric_type__0 | Minimum Age | 1 | age_restric_type__1 | Maximum Age | | | | | | | | | |
| 0 | age_restric_type__0 | Minimum Age | | | | | | | | | | | | | | | | |
| 1 | age_restric_type__1 | Maximum Age | | | | | | | | | | | | | | | | |
| 83 | max_age Show the field ON LY if: [age_restric_type(1)]="1" | Excluded those above age: | text (integer) | | | | | | | | | | | | | | | |
| 84 | eligibility_complete | Complete? | dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table> | 0 | Incomplete | 1 | Unverified | 2 | Complete | | | | | | | | | |
| 0 | Incomplete | | | | | | | | | | | | | | | | | |
| 1 | Unverified | | | | | | | | | | | | | | | | | |
| 2 | Complete | | | | | | | | | | | | | | | | | |
| Instrument: Patient Selection | | | | | | | | | | | | | | | | | | |
| 85 | mcc_reported | Are multiple chronic conditions included in the participant characteristi cs? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | |
| 86 | mcc_infer | Could the inclusion of | dropdown | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----|---|--|---|---|----------------------|-----------|-----|----------------------|--|---|----------------------|--------------------------|---|----------------------|--------|---|----------------------|---------------------|---|----------------------|------------------------|---|----------------------|---------------------------------------|---|----------------------|--------------------------|---|----------------------|-------------------------|----|-----------------------|----------|----|-----------------------|------------|----|-----------------------|----------|----|-----------------------|-----------|----|-----------------------|------------------------------------|----|-----------------------|----------------|----|-----------------------|--------------|----|-----------------------|--------------|----|-----------------------|---------------|----|-----------------------|--------|----|-----------------------|---------------------------|
| | | individuals with multiple chronic conditions be inferred? | <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> <tr> <td>2</td> <td>Extracted before 8/7/15 (DON'T SELECT)</td> </tr> </table> | 0 | No | 1 | Yes | 2 | Extracted before 8/7/15 (DON'T SELECT) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Extracted before 8/7/15 (DON'T SELECT) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 87 | mcc_reported_spec Show the field ONLY if: [mcc_reported]="1" | Is this description general or condition specific? | checkbox <table border="1"> <tr> <td>0</td> <td>mcc_reported_spec__0</td> <td>General</td> </tr> <tr> <td>1</td> <td>mcc_reported_spec__1</td> <td>Condition Specific</td> </tr> </table> | 0 | mcc_reported_spec__0 | General | 1 | mcc_reported_spec__1 | Condition Specific | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | mcc_reported_spec__0 | General | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | mcc_reported_spec__1 | Condition Specific | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 88 | mcc_reported_cond Show the field ONLY if: [mcc_reported_spec(1)]= "1" or [mcc_infer]= "1" | Which specific conditions are reported or inferred in the participant characteristics? | checkbox <table border="1"> <tr> <td>1</td> <td>mcc_reported_cond__1</td> <td>Arthritis</td> </tr> <tr> <td>2</td> <td>mcc_reported_cond__2</td> <td>Asthma</td> </tr> <tr> <td>3</td> <td>mcc_reported_cond__3</td> <td>Autism Spectrum Disorder</td> </tr> <tr> <td>4</td> <td>mcc_reported_cond__4</td> <td>Cancer</td> </tr> <tr> <td>5</td> <td>mcc_reported_cond__5</td> <td>Cardiac Arrhythmias</td> </tr> <tr> <td>6</td> <td>mcc_reported_cond__6</td> <td>Chronic Kidney Disease</td> </tr> <tr> <td>7</td> <td>mcc_reported_cond__7</td> <td>Chronic Obstructive Pulmonary Disease</td> </tr> <tr> <td>8</td> <td>mcc_reported_cond__8</td> <td>Congestive Heart Failure</td> </tr> <tr> <td>9</td> <td>mcc_reported_cond__9</td> <td>Coronary Artery Disease</td> </tr> <tr> <td>10</td> <td>mcc_reported_cond__10</td> <td>Dementia</td> </tr> <tr> <td>11</td> <td>mcc_reported_cond__11</td> <td>Depression</td> </tr> <tr> <td>12</td> <td>mcc_reported_cond__12</td> <td>Diabetes</td> </tr> <tr> <td>13</td> <td>mcc_reported_cond__13</td> <td>Hepatitis</td> </tr> <tr> <td>14</td> <td>mcc_reported_cond__14</td> <td>Human Immunodeficiency Virus (HIV)</td> </tr> <tr> <td>15</td> <td>mcc_reported_cond__15</td> <td>Hyperlipidemia</td> </tr> <tr> <td>16</td> <td>mcc_reported_cond__16</td> <td>Hypertension</td> </tr> <tr> <td>17</td> <td>mcc_reported_cond__17</td> <td>Osteoporosis</td> </tr> <tr> <td>18</td> <td>mcc_reported_cond__18</td> <td>Schizophrenia</td> </tr> <tr> <td>19</td> <td>mcc_reported_cond__19</td> <td>Stroke</td> </tr> <tr> <td>20</td> <td>mcc_reported_cond__20</td> <td>Substance Abuse Disorders</td> </tr> </table> | 1 | mcc_reported_cond__1 | Arthritis | 2 | mcc_reported_cond__2 | Asthma | 3 | mcc_reported_cond__3 | Autism Spectrum Disorder | 4 | mcc_reported_cond__4 | Cancer | 5 | mcc_reported_cond__5 | Cardiac Arrhythmias | 6 | mcc_reported_cond__6 | Chronic Kidney Disease | 7 | mcc_reported_cond__7 | Chronic Obstructive Pulmonary Disease | 8 | mcc_reported_cond__8 | Congestive Heart Failure | 9 | mcc_reported_cond__9 | Coronary Artery Disease | 10 | mcc_reported_cond__10 | Dementia | 11 | mcc_reported_cond__11 | Depression | 12 | mcc_reported_cond__12 | Diabetes | 13 | mcc_reported_cond__13 | Hepatitis | 14 | mcc_reported_cond__14 | Human Immunodeficiency Virus (HIV) | 15 | mcc_reported_cond__15 | Hyperlipidemia | 16 | mcc_reported_cond__16 | Hypertension | 17 | mcc_reported_cond__17 | Osteoporosis | 18 | mcc_reported_cond__18 | Schizophrenia | 19 | mcc_reported_cond__19 | Stroke | 20 | mcc_reported_cond__20 | Substance Abuse Disorders |
| 1 | mcc_reported_cond__1 | Arthritis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | mcc_reported_cond__2 | Asthma | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | mcc_reported_cond__3 | Autism Spectrum Disorder | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | mcc_reported_cond__4 | Cancer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | mcc_reported_cond__5 | Cardiac Arrhythmias | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | mcc_reported_cond__6 | Chronic Kidney Disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | mcc_reported_cond__7 | Chronic Obstructive Pulmonary Disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | mcc_reported_cond__8 | Congestive Heart Failure | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | mcc_reported_cond__9 | Coronary Artery Disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | mcc_reported_cond__10 | Dementia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11 | mcc_reported_cond__11 | Depression | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | mcc_reported_cond__12 | Diabetes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 13 | mcc_reported_cond__13 | Hepatitis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 14 | mcc_reported_cond__14 | Human Immunodeficiency Virus (HIV) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 15 | mcc_reported_cond__15 | Hyperlipidemia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 16 | mcc_reported_cond__16 | Hypertension | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17 | mcc_reported_cond__17 | Osteoporosis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 18 | mcc_reported_cond__18 | Schizophrenia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 19 | mcc_reported_cond__19 | Stroke | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 | mcc_reported_cond__20 | Substance Abuse Disorders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 89 | mcc_infer_1 Show the field ONLY if: [mcc_reported_cond(1)]= "1" | Is the total number of participants with Arthritis reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | |
|----|--|--|--|---|----|---|-----|
| 90 | mcc_infer_2 Show the field ON LY if: [mcc_reported_cond(2)]= "1" | Is the total number of participants with Asthma reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 91 | mcc_infer_3 Show the field ON LY if: [mcc_reported_cond(3)]= "1" | Is the total number of participants with Autism Spectrum Disorder reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 92 | mcc_infer_4 Show the field ON LY if: [mcc_reported_cond(4)]= "1" | Is the total number of participants with Cancer reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 93 | mcc_infer_5 Show the field ON LY if: [mcc_reported_cond(5)]= "1" | Is the total number of participants with Cardiac Arrhythmias reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 94 | mcc_infer_6 Show the field ON LY if: [mcc_reported_cond(6)]= "1" | Is the total number of participants with Chronic Kidney Disease reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 95 | mcc_infer_7 Show the field ON LY if: [mcc_reported_cond(7)]= "1" | Is the total number of participants with Chronic Obstructive Pulmonary Disease reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 96 | mcc_infer_8 Show the field ON LY if: [mcc_reported_cond(8)]= "1" | Is the total number of participants with Congestive Heart Failure reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |

| | | | | | | | |
|-----|--|--|--|---|----|---|-----|
| 97 | mcc_infer_9 Show the field ON LY if: [mcc_reported_con d(9)]= "1" | Is the total number of participants with Coronary Artery Disease reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 98 | mcc_infer_10 Show the field ON LY if: [mcc_reported_con d(10)]= "1" | Is the total number of participants with Dementia reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 99 | mcc_infer_11 Show the field ON LY if: [mcc_reported_con d(11)]= "1" | Is the total number of participants with Depression reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 100 | mcc_infer_12 Show the field ON LY if: [mcc_reported_con d(12)]= "1" | Is the total number of participants with Diabetes reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 101 | mcc_infer_13 Show the field ON LY if: [mcc_reported_con d(13)]= "1" | Is the total number of participants with Hepatitis reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 102 | mcc_infer_14 Show the field ON LY if: [mcc_reported_con d(14)]= "1" | Is the total number of participants with HIV reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 103 | mcc_infer_15 Show the field ON LY if: [mcc_reported_con d(15)]= "1" | Is the total number of participants with Hyperlipidemia reported? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes |
| 0 | No | | | | | | |
| 1 | Yes | | | | | | |
| 104 | mcc_infer_16 | Is the total number of | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> </table> | 0 | No | | |
| 0 | No | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|---|---|--|---|------------------------|--------|-----|------------------------|------------|---|------------------------|------|---|------------------------|----------------------------|
| | Show the field ON LY if: [mcc_reported_cond(16)]= "1" | participants with Hypertension reported? | <table border="1"><tr><td>1</td><td>Yes</td></tr></table> | 1 | Yes | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | |
| 105 | mcc_infer_17 Show the field ON LY if: [mcc_reported_cond(17)]= "1" | Is the total number of participants with Osteoporosis reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | |
| 106 | mcc_infer_18 Show the field ON LY if: [mcc_reported_cond(18)]= "1" | Is the total number of participants with Schizophrenia reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | |
| 107 | mcc_infer_19 Show the field ON LY if: [mcc_reported_cond(19)]= "1" | Is the total number of participants with Stroke reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | |
| 108 | mcc_infer_20 Show the field ON LY if: [mcc_reported_cond(20)]= "1" | Is the total number of participants with Substance Abuse Disorders reported? | dropdown <table border="1"><tr><td>0</td><td>No</td></tr><tr><td>1</td><td>Yes</td></tr></table> | 0 | No | 1 | Yes | | | | | | | | |
| 0 | No | | | | | | | | | | | | | | |
| 1 | Yes | | | | | | | | | | | | | | |
| 109 | mcc_report_cond_total | What is the total number of chronic conditions (aside from index condition) reported in the trial (explicit or inferred)? | text (integer, Min: 0, Max: 20) | | | | | | | | | | | | |
| 110 | mcc_reported_number Show the field ON LY if: [mcc_reported_spec(0)] = 1 | Are any of the following statistics regarding participants | checkbox <table border="1"><tr><td>0</td><td>mcc_reported_number__0</td><td>Number</td></tr><tr><td>1</td><td>mcc_reported_number__1</td><td>Percentage</td></tr><tr><td>2</td><td>mcc_reported_number__2</td><td>Mean</td></tr><tr><td>3</td><td>mcc_reported_number__3</td><td>Charlson comorbidity index</td></tr></table> | 0 | mcc_reported_number__0 | Number | 1 | mcc_reported_number__1 | Percentage | 2 | mcc_reported_number__2 | Mean | 3 | mcc_reported_number__3 | Charlson comorbidity index |
| 0 | mcc_reported_number__0 | Number | | | | | | | | | | | | | |
| 1 | mcc_reported_number__1 | Percentage | | | | | | | | | | | | | |
| 2 | mcc_reported_number__2 | Mean | | | | | | | | | | | | | |
| 3 | mcc_reported_number__3 | Charlson comorbidity index | | | | | | | | | | | | | |

| | | | |
|---------------------------------------|----------------------------|---|--|
| | | with MCC reported? | 4 mcc_reported_number__4 Not reported |
| 111 | patient_selection_complete | Complete? | dropdown 0 Incomplete 1 Unverified 2 Complete |
| Instrument: Quality Assessment | | | |
| 112 | bias_rand_seq | Random sequence generation (selection bias) | dropdown 0 Low Risk 1 High Risk 2 Unclear Risk |
| 113 | bias_alloc | Allocation concealment (selection bias) | dropdown 0 Low Risk 1 High Risk 2 Unclear Risk |
| 114 | bias_performance | Blinding of participants and personnel (performance bias) | dropdown 0 Low Risk 1 High Risk 2 Unclear Risk |
| 115 | bias_detection | Blinding of outcome assessment (detection bias) | dropdown 0 Low Risk 1 High Risk 2 Unclear Risk |
| 116 | bias_attrition | Incomplete outcome data (attrition bias) | dropdown 0 Low Risk 1 High Risk 2 Unclear Risk |
| 117 | bias_report | Selective outcome reporting (reporting bias) | dropdown 0 Low Risk 1 High Risk 2 Unclear Risk |
| 118 | quality_score | Quality Score | calc Calculation: sum((if([bias_rand_seq]>1,0,if([bias_rand_seq]<1,-1,[bias_rand_seq]))),(if([bias_alloc]>1,0,if([bias_alloc]<1,-1,[bias_alloc]))),(if([bias_performance]>1,0,if([bias_performance]<1,-1,[bias_performance]))),(if([bias_detection]>1,0,if([bias_detection]<1,-1,[bias_detection]))),(|

| | | | | | | | | | |
|-----------------------------|-----------------------------|---|---|---|------------|---|------------|---|----------|
| | | | if([bias_attrition]>1,0,if([bias_attrition]<1,-1,[bias_attrition]))),(if([bias_report]>1,0,if([bias_report]<1,-1,[bias_report]))) | | | | | | |
| 119 | quality_assessment_complete | Complete? | dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table> | 0 | Incomplete | 1 | Unverified | 2 | Complete |
| 0 | Incomplete | | | | | | | | |
| 1 | Unverified | | | | | | | | |
| 2 | Complete | | | | | | | | |
| Instrument: Outcomes | | | | | | | | | |
| 120 | sub_analysis_comorbidity | Were comorbidities used in a subgroup analysis? | dropdown <table border="1"> <tr> <td>0</td> <td>No</td> </tr> <tr> <td>1</td> <td>Yes</td> </tr> </table> | 0 | No | 1 | Yes | | |
| 0 | No | | | | | | | | |
| 1 | Yes | | | | | | | | |
| 121 | outcomes_complete | Complete? | dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table> | 0 | Incomplete | 1 | Unverified | 2 | Complete |
| 0 | Incomplete | | | | | | | | |
| 1 | Unverified | | | | | | | | |
| 2 | Complete | | | | | | | | |

6. Included studies

1. Aas AMB, I.: Thorsby, P. M.: Johannesen, O.: Solberg, M.: Birkeland, K. I. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study. *Diabetic medicine : a journal of the British Diabetic Association*. Mar 2005;22(3):316-322.
2. Adamsen LQ, M.: Andersen, C.: Moller, T.: Herrstedt, J.: Kronborg, D.: Baadsgaard, M. T.: Vistisen, K.: Midtgaard, J.: Christiansen, B.: Stage, M.: Kronborg, M. T.: Rorth, M. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. *BMJ (Clinical research ed.)*. 2009;339:b3410. Pmc2762035:
3. Adeyemo AT, B. O.: Luke, A.: Ogedegbe, O.: Durazo-Arvizu, R.: Cooper, R. S. The Nigerian antihypertensive adherence trial: a community-based randomized trial. *Journal of hypertension*. Jan 2013;31(1):201-207. Pmc3530610:
4. Adler DAB, K. M.: Wilson, I. B.: Pei, Y.: Supran, S.: Peckham, E.: Cynn, D. J.: Rogers, W. H. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. *General Hospital Psychiatry*. 2004;26(3):199-209.
5. Aiken LSB, J.: Lockhart, C. A.: Volk-Craft, B. E.: Hamilton, G.: Williams, F. G. Outcome evaluation of a randomized trial of the PhoenixCare intervention: program of case management and coordinated care for the seriously chronically ill. *Journal of palliative medicine*. Feb 2006;9(1):111-126.
6. Alessi SMH, T.: Wieners, M.: Petry, N. M. Low-cost contingency management in community clinics: delivering incentives partially in group therapy. *Experimental and clinical psychopharmacology*. Jun 2007;15(3):293-300.
7. Alessi SMP, N. M. Smoking reductions and increased self-efficacy in a randomized controlled trial of smoking abstinence- contingent incentives in residential substance abuse treatment patients. *Nicotine and Tobacco Research*. 2014;16(11):1436-1445.
8. Alexopoulos GSR, P.: Arean, P. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. *American Journal of Geriatric Psychiatry*. 2003;11(1):46-52.
9. Allen SMS, A. C.: Nezu, A. M.: Nezu, C. M.: Ciambone, D.: Hogan, J.: Mor, V. A problem-solving approach to stress reduction among younger women with breast carcinoma: A randomized controlled trial. *Cancer*. 2002;94(12):3089-3100.
10. Almeida LBS, A. C.: Duran, A. C.: Jaime, P. C. Impact of a nutritional counseling program on prevention of HAART-related metabolic and morphologic abnormalities. *AIDS care*. Jun 2011;23(6):755-763.
11. Alterman AIK, J. M.: Mulholland, E.: Ladden, L. J.: Baime, M. J. Pilot trial of effectiveness of mindfulness meditation for substance abuse patients. *Journal of Substance Use*. 2004;9(6):259-268.
12. Andersen LJR, M. B.: Westh, K.: Martone, D.: Hansen, P. R.: Junge, A.: Dvorak, J.: Bangsbo, J.: Krstrup, P. Football as a treatment for hypertension in untrained 30-55-year-old men: a prospective randomized study. *Scandinavian journal of medicine & science in sports*. Apr 2010;20 Suppl 1:98-102.
13. Anderson KHF, S.: Robson, D.: Cassis, J.: Rodrigues, C.: Gray, R. An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia. *International journal of mental health nursing*. Oct 2010;19(5):340-349.
14. Anderson KOM, T. R.: Payne, R.: Valero, V.: Palos, G. R.: Nazario, A.: Richman, S. P.: Hurley, J.: Gning, I.: Lynch, G. R.: Kalish, D.: Cleeland, C. S. Pain education for underserved minority cancer patients: a randomized controlled trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Dec 15 2004;22(24):4918-4925.

15. Andersson GB, J.: Hollandare, F.: Carlbring, P.: Kaldø, V.: Ekselius, L. Internet-based self-help for depression: randomised controlled trial. *The British journal of psychiatry : the journal of mental science*. Nov 2005;187:456-461.
16. Andrade ASAM, H. F.: Wu, A. W.: Celano, S. A.: Skolasky Jr, R. L.: Selnes, O. A.: Huang, I. C.: McArthur, J. C. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. *Clinical Infectious Diseases*. 2005;41(6):875-882.
17. Angell KLK, M. A.: McCoy, R.: Donnelly, P.: Turner-Cobb, J. M.: Graddy, K.: Kraemer, H. C.: Koopman, C. Psychosocial intervention for rural women with breast cancer: The Sierra Stanford partnership. *Journal of general internal medicine*. 2003;18(7):499-507.
18. Antoni MHC, D. G.: Cruess, S.: Lutgendorf, S.: Kumar, M.: Ironson, G.: Klimas, N.: Fletcher, M. A.: Schneiderman, N. Cognitive-behavioral stress management intervention effects on anxiety, 24-hr urinary norepinephrine output, and T-cytotoxic/suppressor cells over time among symptomatic HIV-infected gay men. *Journal of consulting and clinical psychology*. 2000;68(1):31-45.
19. Antoni MHW, S. R.: Lechner, S. C.: Kazi, A.: Sifre, T.: Urcuyo, K. R.: Phillips, K.: Smith, R. G.: Petronis, V. M.: Guellati, S.: Wells, K. A.: Blomberg, B.: Carver, C. S. Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. *The American journal of psychiatry*. Oct 2006;163(10):1791-1797.
20. Aranda SS, P.: Weih, L.: Milne, D.: Yates, P.: Faulkner, R. Meeting the support and information needs of women with advanced breast cancer: a randomised controlled trial. *British journal of cancer*. Sep 18 2006;95(6):667-673. Pmc2360523:
21. Araya RR, G.: Fritsch, R.: Gaete, J.: Rojas, M.: Simon, G.: Peters, T. J. Treating depression in primary care in low-income women in Santiago, Chile: A randomised controlled trial. *Lancet*. 2003;361(9362):995-1000.
22. Artinian NTH, J. K.: Kronenberg, M. W.: Vander Wal, J. S.: Daher, E.: Stephens, Q.: Bazzi, R. I. Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. *Heart and Lung: Journal of Acute and Critical Care*. 2003;32(4):226-233.
23. Ashing KR, M. A telephonic-based trial to reduce depressive symptoms among Latina breast cancer survivors. *Psycho-oncology*. May 2014;23(5):507-515.
24. Ashing-Giwa KT. Enhancing physical well-being and overall quality of life among underserved Latina-American cervical cancer survivors: feasibility study. *Journal of cancer survivorship : research and practice*. Sep 2008;2(3):215-223.
25. Ay SKD, S.: Evcik, D. Is there an effective way to prescribe a home-based exercise program in patients with knee osteoarthritis? a randomized controlled study. *Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi*. 2013;59(1):1-6.
26. Backx KM, A.: Wasley, D.: Dunseath, G.: Luzio, S.: Owens, D. The effect of a supported exercise programme in patients with newly diagnosed Type 2 diabetes: a pilot study. *Journal of sports sciences*. Mar 2011;29(6):579-586.
27. Bailey DEM, M. H.: Belyea, M.: Stewart, J. L.: Mohler, J. Uncertainty intervention for watchful waiting in prostate cancer. *Cancer nursing*. Sep-Oct 2004;27(5):339-346.
28. Baird CLS, L. P. Effect of guided imagery with relaxation on health-related quality of life in older women with osteoarthritis. *Research in nursing & health*. Oct 2006;29(5):442-451.
29. Baker AL, N. K.: Claire, M.: Lewin, T. J.: Grant, T.: Pohlman, S.: Saunders, J. B.: Kay-Lambkin, F.: Constable, P.: Jenner, L.: Carr, V. J. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. *Addiction (Abingdon, England)*. Mar 2005;100(3):367-378.

30. Balldin JB, M.: Borg, S.: Mansson, M.: Bendtsen, P.: Franck, J.: Gustafsson, L.: Halldin, J.: Nilsson, L. H.: Stolt, G.: Willander, A. A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. *Alcoholism: Clinical and Experimental Research*. 2003;27(7):1142-1149.
31. Banerjee KH, M.: Mansheim, K.: Beattie, M. Comparison of Health Realization and 12-Step treatment in women's residential substance abuse treatment programs. *The American journal of drug and alcohol abuse*. 2007;33(2):207-215.
32. Baradaran HRK-J, R. P.: Wallia, S.: Rodgers, A. A controlled trial of the effectiveness of a diabetes education programme in a multi-ethnic community in Glasgow [ISRCT28317455]. *BMC Public Health*. 2006;6.
33. Barbanel DE, S.: Griffiths, C. Can a self-management programme delivered by a community pharmacist improve asthma control? A randomised trial. *Thorax*. 2003;58(10):851-854.
34. Barker AB, P.: Berlowitz, D.: Page, K.: Jackson, B.: Lim, W. K. Pharmacist directed home medication reviews in patients with chronic heart failure: a randomised clinical trial. *International journal of cardiology*. Aug 23 2012;159(2):139-143.
35. Barlow JHT, A. P.: Wright, C. C. A randomized controlled study of the arthritis self-management programme in the UK. *Health Education Research*. 2000;15(6):665-680.
36. Barnason SZ, L.: Nieveen, J.: Hertzog, M. Impact of a telehealth intervention to augment home health care on functional and recovery outcomes of elderly patients undergoing coronary artery bypass grafting. *Heart & lung : the journal of critical care*. Jul-Aug 2006;35(4):225-233.
37. Barrera Jr MG, R. E.: McKay, H. G.: Boles, S. M.: Feil, E. G. Do Internet-based support interventions change perceptions of social support?: An experimental trial of approaches for supporting diabetes self-management. *American journal of community psychology*. 2002;30(5):637-654.
38. Basak Cinar AS, L. Health promotion for patients with diabetes: Health coaching or formal health education? *Vol 642014:20-28*.
39. Battaglia GA, M.: Inguglia, M.: Roccella, M.: Caramazza, G.: Bellafiore, M.: Palma, A. Soccer practice as an add-on treatment in the management of individuals with a diagnosis of schizophrenia. *Neuropsychiatric Disease and Treatment*. 2013;9:595-603.
40. Battersby MWB, J.: Pols, R. G.: Smith, D. P.: Condon, J.: Blunden, S. A randomised controlled trial of the Flinders Program(trademark) of chronic condition management in Vietnam veterans with co-morbid alcohol misuse, and psychiatric and medical conditions. *Australian and New Zealand Journal of Psychiatry*. 2013;47(5):451-462.
41. Bechdolf AK, B.: Kuntermann, C.: Schiller, S.: Klosterkotter, J.: Hambrecht, M.: Pukrop, R. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. *Acta psychiatrica Scandinavica*. Jul 2004;110(1):21-28.
42. Bechi MS, M.: Bosia, M.: Zanoletti, A.: Fresi, F.: Buonocore, M.: Cocchi, F.: Guglielmino, C.: Smeraldi, E.: Cavallaro, R. Theory of Mind intervention for outpatients with schizophrenia. *Neuropsychological rehabilitation*. 2013;23(3):383-400.
43. Beck CKV, T. S.: Rasin, J. H.: Uriri, J. T.: O'Sullivan, P.: Walls, R.: Phillips, R.: Baldwin, B. Effects of behavioral interventions on disruptive behavior and affect in demented nursing home residents. *Nursing research*. 2002;51(4):219-228.
44. Bell MB, G.: Wexler, B. E. Cognitive remediation of working memory deficits: Durability of training effects in severely impaired and less severely impaired schizophrenia. *Acta psychiatrica Scandinavica*. 2003;108(2):101-109.

45. Bellary SOH, J. P.: Raymond, N. T.: Gumber, A.: Mughal, S.: Szczepura, A.: Kumar, S.: Barnett, A. H. Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial. *Lancet*. May 24 2008;371(9626):1769-1776.
46. Belleau FPH, L.: Masse, B. Effects of an educational intervention on the anxiety of women awaiting mastectomies. *Canadian oncology nursing journal = Revue canadienne de nursing oncologique*. 2001;11(4):172-180.
47. Beney JD, E. B.: Chow, V.: Ignoffo, R. J.: Mitsunaga, L.: Shahkarami, M.: McMillan, A.: Bero, L. A. Effect of telephone follow-up on the physical well-being dimension of quality of life in patients with cancer. *Pharmacotherapy*. 2002;22(10):1301-1311.
48. Bennell KLH, R. S.: Metcalf, B. R.: Buchbinder, R.: McConnell, J.: McColl, G.: Green, S.: Crossley, K. M. Efficacy of physiotherapy management of knee joint osteoarthritis: a randomised, double blind, placebo controlled trial. *Annals of the rheumatic diseases*. Jun 2005;64(6):906-912. Pmc1755542:
49. Beune EJMvC, E. P.: Beem, L.: Mohrs, J.: Agyemang, C. O.: Ogedegbe, G.: Haafkens, J. A. Culturally adapted hypertension education (CAHE) to improve blood pressure control and treatment adherence in patients of African origin with uncontrolled hypertension: cluster-randomized trial. *PloS one*. 2014;9(3):e90103. Pmc3943841:
50. Blank MBH, N. P.: Fishbein, M.: Wu, E. S.: Tennille, J. A.: Ten Have, T. R.: Kutney-Lee, A. M.: Gross, R.: Hines, J. M.: Coyne, J. C.: Aiken, L. H. A randomized trial of a nursing intervention for HIV disease management among persons with serious mental illness. *Psychiatric services (Washington, D.C.)*. Nov 2011;62(11):1318-1324.
51. Blixen CEB, K. A.: Hammel, J. P.: Tilley, B. C. A pilot study of health education via a nurse-run telephone self-management programme for elderly people with osteoarthritis. *Journal of telemedicine and telecare*. 2004;10(1):44-49.
52. Bloom JRS, S. L.: D'Onofrio, C. N.: Luce, J.: Banks, P. J. Addressing the needs of young breast cancer survivors at the 5 year milestone: can a short-term, low intensity intervention produce change? *Journal of cancer survivorship : research and practice*. Sep 2008;2(3):190-204.
53. Bockting CLHS, P.: Wouters, L. F.: Koeter, M. W. J.: Schene, A. H. Long-term effects of preventive cognitive therapy in recurrent depression: A 5.5-year follow-up study. *Journal of Clinical Psychiatry*. 2009;70(12):1621-1628.
54. Bogenschutz MPR, S. L.: Tonigan, J. S.: Vogel, H. S.: Nowinski, J.: Hume, D.: Arenella, P. B. 12-step facilitation for the dually diagnosed: a randomized clinical trial. *Journal of substance abuse treatment*. Apr 2014;46(4):403-411. Pmc3976999:
55. Bogner HRdV, H. F. Integration of depression and hypertension treatment: a pilot, randomized controlled trial. *Annals of family medicine*. Jul-Aug 2008;6(4):295-301. Pmc2478504:
56. Book KD, A.: Henrich, G.: Stuhr, C.: Peuker, M.: Hartl, K.: Brahler, E.: Herschbach, P. The effect of including a 'psychooncological statement' in the discharge summary on patient-physician communication: a randomized controlled trial. *Psycho-oncology*. Dec 2013;22(12):2789-2796.
57. Boss HMVS, S. M.: Deijle, I. A.: de Melker, E. C.: van den Berg, B. T.: Scherder, E. J.: Bosboom, W. M.: Weinstein, H. C.: Van den Berg-Vos, R. M. Safety and feasibility of post-stroke care and exercise after minor ischemic stroke or transient ischemic attack: MotiveS & MoveIT. *NeuroRehabilitation*. 2014;34(3):401-407.
58. Bowie CRG, M.: Holshausen, K.: Jokic, R.: Best, M.: Milev, R. Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. *The Journal of nervous and mental disease*. Aug 2013;201(8):680-685.

59. Bowles KHH, D. E.: Horowitz, D. A. A comparison of in-person home care, home care with telephone contact and home care with telemonitoring for disease management. *Journal of telemedicine and telecare*. 2009;15(7):344-350. Pmc2882290:
60. Boyd AY, C. T.: Estell, K.: Ms, C. T.: Gerald, L. B.: Dransfield, M.: Bamman, M.: Bonner, J.: Atkinson, T. P.: Schwiebert, L. M. Feasibility of exercising adults with asthma: a randomized pilot study. *Allergy, Asthma and Clinical Immunology*. 2012;8(1).
61. Braun SMB, A. J.: Kleylen, M.: Oudelaar, B.: Schols, J. M.: Wade, D. T. A multicenter randomized controlled trial to compare subacute 'treatment as usual' with and without mental practice among persons with stroke in dutch nursing homes. *Journal of the American Medical Directors Association*. 2012;13(1):85.e81-85.e87.
62. Breedland IvS, C.: Leijmsma, M.: Verheij-Jansen, N. P.: van Weert, E. Effects of a group-based exercise and educational program on physical performance and disease self-management in rheumatoid arthritis: a randomized controlled study. *Physical therapy*. Jun 2011;91(6):879-893.
63. Brems CD, S. L.: Johnson, M. E.: Eldridge, G. D. Brief motivational interventions for HIV/STI risk reduction among individuals receiving alcohol detoxification. *AIDS education and prevention : official publication of the International Society for AIDS Education*. Oct 2009;21(5):397-414.
64. Brismee JMP, R. L.: Chyu, M. C.: Boatright, J. D.: Hagar, J. M.: McCaleb, J. A.: Quintela, M. M.: Feng, D.: Xu, K. T.: Shen, C. L. Group and home-based tai chi in elderly subjects with knee osteoarthritis: a randomized controlled trial. *Clinical rehabilitation*. Feb 2007;21(2):99-111.
65. Britton WBH, P. L.: Fridel, K. W.: Bootzin, R. R. Polysomnographic and subjective profiles of sleep continuity before and after mindfulness-based cognitive therapy in partially remitted depression. *Psychosomatic medicine*. Jul 2010;72(6):539-548.
66. Brodaty HD, B. M.: Millar, J.: Low, L. F.: Lie, D.: Sharah, S.: Paton, H. Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. *Journal of Clinical Psychiatry*. 2003;64(1):63-72.
67. Brook OHVH, H. P. J.: Nieuwenhuysa, H.: De Haan, M. Effects of coaching by community pharmacists on psychological symptoms of antidepressant users; a randomised controlled trial. *European Neuropsychopharmacology*. 2003;13(5):347-354.
68. Brooks ACR, D.: Carise, D.: Kirby, K. C. Feasibility and effectiveness of computer-based therapy in community treatment. *Journal of substance abuse treatment*. Oct 2010;39(3):227-235.
69. Brooner RKK, M. S.: King, V. L.: Stoller, K. B.: Peirce, J. M.: Bigelow, G. E.: Kolodner, K. Behavioral contingencies improve counseling attendance in an adaptive treatment model. *Journal of substance abuse treatment*. Oct 2004;27(3):223-232.
70. Brown TGS, P.: Tremblay, J.: Annis, H. Matching substance abuse aftercare treatments to client characteristics. *Addictive behaviors*. Jul-Aug 2002;27(4):585-604.
71. Bryson GL, P.: Bell, M. Quality of life benefits of paid work activity in schizophrenia. *Schizophrenia bulletin*. 2002;28(2):249-257.
72. Bucci PP, G.: Mucci, A.: Merlotti, E.: Chieffi, M.: De Riso, F.: De Angelis, M.: Di Munzio, W.: Galderisi, S. Neurocognitive individualized training versus social skills individualized training: a randomized trial in patients with schizophrenia. *Schizophrenia research*. Oct 2013;150(1):69-75.
73. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. *Journal of consulting and clinical psychology*. 2000;68(6):1051-1061.
74. Burke V, Beilin LJ, Cutt HE, Mansour J, Williams A, Mori TA. A lifestyle program for treated hypertensives improved health-related behaviors and cardiovascular risk factors, a randomized controlled trial. *Journal of clinical epidemiology*. Feb 2007;60(2):133-141.

75. Burnand Y, Andreoli A, Kolatte E, Venturini A, Rosset N. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. *Psychiatric Services*. 2002;53(5):585-590.
76. Burns DS. The effect of the bonny method of guided imagery and music on the mood and life quality of cancer patients. *Journal of music therapy*. 2001;38(1):51-65.
77. Butler SFC, E.:Thum, C. C.:Budman, S. H. Working it out: development and testing of a multimedia, vocational education program. *Substance use & misuse*. 2004;39(13-14):2525-2558.
78. Campbell KL, Ash S, Davies PSW, Bauer JD. Randomized Controlled Trial of Nutritional Counseling on Body Composition and Dietary Intake in Severe CKD. *American Journal of Kidney Diseases*. 2008;51(5):748-758.
79. Capoccia KL, Boudreau DM, Blough DK, et al. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. *American Journal of Health-System Pharmacy*. 2004;61(4):364-372.
80. Carmody TP, Delucchi K, Duncan CL, et al. Intensive intervention for alcohol-dependent smokers in early recovery: a randomized trial. *Drug and alcohol dependence*. May 1 2012;122(3):186-194. Pmc3288470:
81. Carpenter KM, Smith JL, Aharonovich E, Nunes EV. Developing therapies for depression in drug dependence: results of a stage 1 therapy study. *The American journal of drug and alcohol abuse*. 2008;34(5):642-652.
82. Carrico AW, Antoni MH, Pereira DB, et al. Cognitive behavioral stress management effects on mood, social support, and a marker of antiviral immunity are maintained up to 1 year in HIV-infected gay men. *International journal of behavioral medicine*. 2005;12(4):218-226.
83. Carroll KM, Easton CJ, Nich C, et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. *Journal of consulting and clinical psychology*. Oct 2006;74(5):955-966. Pmc2148500:
84. Cartmel B, Bowen D, Ross D, Johnson E, Mayne ST. A randomized trial of an intervention to increase fruit and vegetable intake in curatively treated patients with early-stage head and neck cancer. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Dec 2005;14(12):2848-2854.
85. Casas A, Troosters T, Garcia-Aymerich J, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. *European Respiratory Journal*. 2006;28(1):123-130.
86. Chabannes JP, Bazin N, Leguay D, et al. Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug. *European psychiatry : the journal of the Association of European Psychiatrists*. Jan 2008;23(1):8-13.
87. Chan AW, Lee A, Suen LK, Tam WW. Tai chi Qigong improves lung functions and activity tolerance in COPD clients: a single blind, randomized controlled trial. *Complementary therapies in medicine*. Feb 2011;19(1):3-11.
88. Chan SH, Lee SW, Chan IW. TRIP: a psycho-educational programme in Hong Kong for people with schizophrenia. *Occupational therapy international*. 2007;14(2):86-98.
89. Chan YM, Lee PW, Fong DY, et al. Effect of individual psychological intervention in Chinese women with gynecologic malignancy: a randomized controlled trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Aug 1 2005;23(22):4913-4924.
90. Chandwani KD, Thornton B, Perkins GH, et al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. *Journal of the Society for Integrative Oncology*. 2010;8(2):43-55.
91. Chang BH, Sommers E, Herz L. Acupuncture and relaxation response for substance use disorder recovery. *Journal of Substance Use*. 2010;15(6):390-401.

92. Chen HS, Wu TE, Jap TS, Lin SH, Hsiao LC, Lin HD. Improvement of glycaemia control in subjects with type 2 diabetes by self-monitoring of blood glucose: comparison of two management programs adjusting bedtime insulin dosage. *Diabetes, obesity & metabolism*. Jan 2008;10(1):34-40.
93. Chen HY, Cheng IC, Pan YJ, et al. Cognitive-behavioral therapy for sleep disturbance decreases inflammatory cytokines and oxidative stress in hemodialysis patients. *Kidney international*. Aug 2011;80(4):415-422.
94. Chen SH, Tsai YF, Sun CY, Wu IW, Lee CC, Wu MS. The impact of self-management support on the progression of chronic kidney disease - A prospective randomized controlled trial. *Nephrology Dialysis Transplantation*. 2011;26(11):3560-3566.
95. Chen SM, Creedy D, Lin HS, Wollin J. Effects of motivational interviewing intervention on self-management, psychological and glycemic outcomes in type 2 diabetes: a randomized controlled trial. *International journal of nursing studies*. Jun 2012;49(6):637-644.
96. Chong J, Moreno F. Feasibility and acceptability of clinic-based telepsychiatry for low-income Hispanic primary care patients. *Telemedicine journal and e-health : the official journal of the American Telemedicine Association*. May 2012;18(4):297-304.
97. Christensen A, Christrup LL, Fabricius PE, et al. The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial. *Journal of hypertension*. Jan 2010;28(1):194-200.
98. Christensen HG, K. M.:Jorm, A. F. Delivering interventions for depression by using the internet: randomised controlled trial. *BMJ (Clinical research ed.)*. Jan 31 2004;328(7434):265. Pmc324455:
99. Chung JS, Lee KK, Tomlinson B, Lee VW. Clinical and economic impact of clinical pharmacy service on hyperlipidemic management in Hong Kong. *Journal of cardiovascular pharmacology and therapeutics*. Mar 2011;16(1):43-52.
100. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. *PLoS medicine*. Mar 2011;8(3):e1000422. Pmc3046986:
101. Clancy DE, Yeager DE, Huang P, Magruder KM. Further evaluating the acceptability of group visits in an uninsured or inadequately insured patient population with uncontrolled type 2 diabetes. *The Diabetes educator*. Mar-Apr 2007;33(2):309-314.
102. Clancy DEC, D. W.:Magruder, K. M.:Huang, P.:Wolfman, T. E. Evaluating concordance to American Diabetes Association standards of care for type 2 diabetes through group visits in an uninsured or inadequately insured patient population. *Diabetes care*. Jul 2003;26(7):2032-2036.
103. Clark NM, Gong ZM, Si JW, Lin X, Bria WF, Johnson TR. A randomized trial of a self-regulation intervention for women with asthma. *Chest*. 2007;132(1):88-97.
104. Clark NMJ, N. K.:Dodge, J. A.:Schork, M. A.:Fingerlin, T. E.:Wheeler, J. R.:Liang, J.:Keteyian, S. J.:Santinga, J. T. Changes in functional health status of older women with heart disease: evaluation of a program based on self-regulation. *The journals of gerontology. Series B, Psychological sciences and social sciences*. Mar 2000;55(2):S117-126.
105. Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-Reich A. Psychological Adjustment and Sleep Quality in a Randomized Trial of the Effects of a Tibetan Yoga Intervention in Patients with Lymphoma. *Cancer*. 2004;100(10):2253-2260.
106. Cohen LB, Taveira TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. *The Diabetes educator*. Nov-Dec 2011;37(6):801-812.
107. Coleman EA, Coon S, Hall-Barrow J, Richards K, Gaylor D, Stewart B. Feasibility of exercise during treatment for multiple myeloma. *Cancer nursing*. 2003;26(5):410-419.

108. Connors GJW, K. S.:Dermen, K. H. Preparing clients for alcoholism treatment: effects on treatment participation and outcomes. *Journal of consulting and clinical psychology*. Oct 2002;70(5):1161-1169.
109. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. *International journal of clinical practice*. Aug 2006;60(8):896-905. Pmc1619408:
110. Cooper H, Booth K, Gill G. A trial of empowerment-based education in type 2 diabetes-Global rather than glycaemic benefits. *Diabetes research and clinical practice*. 2008;82(2):165-171.
111. Coppel KJ, Kataoka M, Williams SM, Chisholm AW, Vorgers SM, Mann JI. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment - Lifestyle over and above drugs in diabetes (LOADD) study: Randomised controlled trial. *BMJ (Online)*. 2010;341(7766):237.
112. Cornbleet MAC, P.:Murray, S.:Stevenson, M.:Bond, S. Patient-held records in cancer and palliative care: a randomized, prospective trial. *Palliative medicine*. May 2002;16(3):205-212.
113. Cornman DH, Kiene SM, Christie S, et al. Clinic-based intervention reduces unprotected sexual behavior among HIV-infected patients in KwaZulu-Natal, South Africa: results of a pilot study. *Journal of acquired immune deficiency syndromes (1999)*. Aug 15 2008;48(5):553-560. Pmc2813056:
114. Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE, Handman M. The group psychotherapy and home-based physical exercise (GROUP-HOPE) trial in cancer survivors: Physical fitness and quality of life outcomes. *Psycho-oncology*. 2003;12(4):357-374.
115. Crane-Okada R, Freeman E, Kiger H, et al. Senior peer counseling by telephone for psychosocial support after breast cancer surgery: effects at six months. *Oncol Nurs Forum*. Jan 2012;39(1):78-89.
116. Danhauer SC, Mihalko SL, Russell GB, et al. Restorative yoga for women with breast cancer: Finding from a randomized pilot study. *Psycho-oncology*. 2009;18(4):360-368.
117. Dasgupta K, Grover SA, Da Costa D, Lowensteyn I, Yale JF, Rahme E. Impact of modified glucose target and exercise interventions on vascular risk factors. *Diabetes research and clinical practice*. Apr 2006;72(1):53-60.
118. Daskapan A, Arikan H, Caglar N, Tunali N, Ataman S. Comparison of supervised exercise training and home-based exercise training in chronic heart failure. *Saudi medical journal*. May 2005;26(5):842-847.
119. Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ (Clinical research ed.)*. Mar 1 2008;336(7642):491-495. Pmc2258400:
120. Davis MC. Life review therapy as an intervention to manage depression and enhance life satisfaction in individuals with right hemisphere cerebral vascular accidents. *Issues in mental health nursing*. Jul-Aug 2004;25(5):503-515.
121. Davis WTC, L.:Tax, J.:Lieber, C. S. A trial of "standard" outpatient alcoholism treatment vs. a minimal treatment control. *Journal of substance abuse treatment*. Jul 2002;23(1):9-19.
122. de Achaval S, Fraenkel L, Volk RJ, Cox V, Suarez-Almazor ME. Impact of educational and patient decision aids on decisional conflict associated with total knee arthroplasty. *Arthritis care & research*. Feb 2012;64(2):229-237. Pmc3634330:
123. de Castro MS, Fuchs FD, Costa Santos M, et al. Pharmaceutical Care Program for Patients With Uncontrolled Hypertension. Report of a Double-Blind Clinical Trial With Ambulatory Blood Pressure Monitoring. *American Journal of Hypertension*. 2006;19(5):528-533.
124. De Godoy DV, De Godoy RF. A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. *Archives of Physical Medicine and Rehabilitation*. 2003;84(8):1154-1157.

125. De Jonghe F, Kool S, Van Aalst G, Dekker J, Peen J. Combining psychotherapy and antidepressants in the treatment of depression. *Journal of Affective Disorders*. 2001;64(2-3):217-229.
126. de Mello MFM, L. M.:Menezes, P. R. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. *The Journal of psychotherapy practice and research*. Spring 2001;10(2):117-123. Pmc3330639:
127. De Wildt WAJM, Schippers GM, Van Den Brink W, Potgieter AS, Deckers F, Bets D. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? *Alcohol and Alcoholism*. 2002;37(4):375-382.
128. de Wit R, van Dam F. From hospital to home care: a randomized controlled trial of a Pain Education Programme for cancer patients with chronic pain. *Journal of advanced nursing*. 2001;36(6):742-754.
129. De Zeeuw ELEJ, Tak ECPM, Dusseldorp E, Hendriksen IJM. Workplace exercise intervention to prevent depression: A pilot randomized controlled trial. *Mental Health and Physical Activity*. 2010;3(2):72-77.
130. DeFulio A, Everly JJ, Leoutsakos JMS, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial. *Drug and alcohol dependence*. 2012;120(1-3):48-54.
131. DeVon HA, Rankin SH, Paul SM, Ochs AL. The Know & Go! program improves knowledge for patients with coronary heart disease in pilot testing. *Heart & lung : the journal of critical care*. Nov-Dec 2010;39(6 Suppl):S23-33.
132. Dhruva A, Miaskowski C, Abrams D, et al. Yoga breathing for cancer chemotherapy-associated symptoms and quality of life: results of a pilot randomized controlled trial. *Journal of alternative and complementary medicine (New York, N.Y.)*. May 2012;18(5):473-479. Pmc3353818:
133. Dilorio C, Resnicow K, McDonnell M, Soet J, McCarty F, Yeager K. Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. *The Journal of the Association of Nurses in AIDS Care : JANAC*. 2003;14(2):52-62.
134. Dimeo FC, Thomas F, Raabe-Menssen C, Propper F, Mathias M. Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery. A randomised controlled trial. *Supportive Care in Cancer*. 2004;12(11):774-779.
135. Doi T, Akai M, Fujino K, et al. Effect of home exercise of quadriceps on knee osteoarthritis compared with nonsteroidal antiinflammatory drugs: a randomized controlled trial. *American journal of physical medicine & rehabilitation / Association of Academic Physiatrists*. Apr 2008;87(4):258-269.
136. Donald KJ, McBurney H, Teichtahl H, Irving L. A pilot study of telephone based asthma management. *Australian family physician*. Mar 2008;37(3):170-173.
137. Donovan HS, Ward SE, Sereika SM, et al. Web-based symptom management for women with recurrent ovarian cancer: A pilot randomized controlled trial of the WRITE symptoms intervention. *Journal of pain and symptom management*. 2014;47(2):218-230.
138. Doorenbos A, Given B, Given C, Verbitsky N, Cimprich B, McCorkle R. Reducing symptom limitations: a cognitive behavioral intervention randomized trial. *Psycho-oncology*. Jul 2005;14(7):574-584. Pmc1904496:
139. Doucette WR, Witry MJ, Farris KB, McDonough RP. Community pharmacist-provided extended diabetes care. *Annals of Pharmacotherapy*. 2009;43(5):882-889.
140. Doughty RN, Wright SP, Pearl A, et al. Randomized, controlled trial of integrated heart failure management: The Auckland heart failure management study. *European Heart Journal*. 2002;23(2):139-146.
141. Dowrick C, Dunn G, Ayuso-Mateos JL, et al. Problem solving treatment and group psychoeducation for depression: Multicentre randomised controlled trial. *British Medical Journal*. 2000;321(7274):1450-1454.

142. Dracup K, McKinley S, Riegel B, et al. A randomized clinical trial to reduce patient prehospital delay to treatment in acute coronary syndrome. *Circulation: Cardiovascular Quality and Outcomes*. 2009;2(6):524-532.
143. Drummond C, Coulton S, James D, et al. Effectiveness and cost-effectiveness of a stepped care intervention for alcohol use disorders in primary care: pilot study. *The British journal of psychiatry : the journal of mental science*. Nov 2009;195(5):448-456.
144. Dunn NJ, Rehm LP, Schillaci J, et al. A randomized trial of self-management and psychoeducational group therapies for comorbid chronic posttraumatic stress disorder and depressive disorder. *Journal of traumatic stress*. Jun 2007;20(3):221-237.
145. Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P. Community center-based resistance training for the maintenance of glycemic control in adults with type 2 diabetes. *Diabetes care*. Dec 2006;29(12):2586-2591.
146. Duraiswamy G, Thirthalli J, Nagendra HR, Gangadhar BN. Yoga therapy as an add-on treatment in the management of patients with schizophrenia--a randomized controlled trial. *Acta psychiatrica Scandinavica*. Sep 2007;116(3):226-232.
147. Eakin EG, Bull SS, Riley KM, Reeves MM, McLaughlin P, Gutierrez S. Resources for Health: A Primary-Care-Based Diet and Physical Activity Intervention Targeting Urban Latinos With Multiple Chronic Conditions. *Health Psychology*. 2007;26(4):392-400.
148. Eberl C, Wiers RW, Pawelczack S, Rinck M, Becker ES, Lindenmeyer J. Approach bias modification in alcohol dependence: do clinical effects replicate and for whom does it work best? *Developmental cognitive neuroscience*. Apr 2013;4:38-51.
149. Echeverry D, Dike M, Jovanovic L, et al. Efforts to improve subsequent treatment of cardiovascular risk factors in older patients with diabetes hospitalized for a cardiac event. *The American journal of managed care*. Dec 2005;11(12):758-764.
150. Egan M, Kessler D, Laporte L, Metcalfe V, Carter M. A pilot randomized controlled trial of community-based occupational therapy in late stroke rehabilitation. *Topics in Stroke Rehabilitation*. 2007;14(5):37-45.
151. El Miedany Y, El Gaafary M, Palmer D. Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study. *Rheumatology international*. Oct 2012;32(10):3061-3068.
152. Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, Preston KL. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. *Drug and alcohol dependence*. Apr 1 2009;101(1-2):92-100. Pmc2943844:
153. Erbs S, Hollriegel R, Linke A, et al. Exercise training in patients with advanced chronic heart failure (NYHA IIIb) promotes restoration of peripheral vasomotor function, induction of endogenous regeneration, and improvement of left ventricular function. *Circulation. Heart failure*. Jul 2010;3(4):486-494.
154. Evans RA, Singh SJ, Collier R, Loke I, Steiner MC, Morgan MD. Generic, symptom based, exercise rehabilitation; integrating patients with COPD and heart failure. *Respiratory medicine*. Oct 2010;104(10):1473-1481.
155. Evans-Hudnall GL, Stanley MA, Clark AN, et al. Improving secondary stroke self-care among underserved ethnic minority individuals: a randomized clinical trial of a pilot intervention. *Journal of behavioral medicine*. Apr 2014;37(2):196-204.
156. Evcik DS, B. Effectiveness of a home-based exercise therapy and walking program on osteoarthritis of the knee. *Rheumatology international*. Jul 2002;22(3):103-106.
157. Evers AWK, F. W.:van Riel, P. L.:de Jong, A. J. Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. *Pain*. Nov 2002;100(1-2):141-153.

158. Faithfull S, Corner J, Meyer L, Huddart R, Dearnaley D. Evaluation of nurse-led follow up for patients undergoing pelvic radiotherapy. *British journal of cancer*. 2001;85(12):1853-1864.
159. Fals-Stewart W, O'Farrell TJ. Behavioral family counseling and naltrexone for male opioid-dependent patients. *Journal of consulting and clinical psychology*. 2003;71(3):432-442.
160. Faulkner MAW, E. C.:Lucas, B. D.:Hilleman, D. E. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. *Pharmacotherapy*. Apr 2000;20(4):410-416.
161. Feijo de Mello M, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. *Journal of Psychotherapy Practice and Research*. 2001;10(2):117-123.
162. Ferrer-Garcia JC, Sanchez Lopez P, Pablos-Abella C, et al. [Benefits of a home-based physical exercise program in elderly subjects with type 2 diabetes mellitus]. *Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion*. Oct 2011;58(8):387-394.
163. Ferrero-Arias J, Goni-Imizcoz M, Gonzalez-Bernal J, Lara-Ortega F, da Silva-Gonzalez A, Diez-Lopez M. The efficacy of nonpharmacological treatment for dementia-related apathy. *Alzheimer disease and associated disorders*. Jul-Sep 2011;25(3):213-219.
164. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. *The American journal of medicine*. Jan 2013;126(1):74.e11-77. Pmc3621718:
165. Figar S, Galarza C, Petrlik E, et al. Effect of Education on Blood Pressure Control in Elderly Persons. A Randomized Controlled Trial. *American Journal of Hypertension*. 2006;19(7):737-743.
166. Fillion L, Gagnon P, Leblond F, et al. A brief intervention for fatigue management in breast cancer survivors. *Cancer nursing*. Mar-Apr 2008;31(2):145-159.
167. Foster RP. Treating depression in vulnerable urban women: a feasibility study of clinical outcomes in community service settings. *The American journal of orthopsychiatry*. Jul 2007;77(3):443-453.
168. Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass surgery a randomized controlled trial. *Archives of General Psychiatry*. 2009;66(4):387-396.
169. Frizelle DJL, R. J.:Kaye, G.:Hargreaves, C.:Hasney, K.:Beaumont, N.:Moniz-Cook, E. Cognitive-behavioural rehabilitation programme for patients with an implanted cardioverter defibrillator: a pilot study. *British journal of health psychology*. Sep 2004;9(Pt 3):381-392.
170. Frosch DL, Uy V, Ochoa S, Mangione CM. Evaluation of a behavior support intervention for patients with poorly controlled diabetes. *Arch Intern Med*. Dec 12 2011;171(22):2011-2017.
171. Fu DF, H.:McGowan, P.:Shen, Y. E.:Zhu, L.:Yang, H.:Mao, J.:Zhu, S.:Ding, Y.:Wei, Z. Implementation and quantitative evaluation of chronic disease self-management programme in Shanghai, China: randomized controlled trial. *Bulletin of the World Health Organization*. 2003;81(3):174-182. Pmc2572423:
172. Fukui SK, A.:Okamura, H.:Kamiya, M.:Koike, M.:Nakanishi, T.:Imoto, S.:Kanagawa, K.:Uchitomi, Y. A psychosocial group intervention for Japanese women with primary breast carcinoma. *Cancer*. Sep 1 2000;89(5):1026-1036.
173. Gallagher R, McKinley S, Dracup K. Effects of a telephone counseling intervention on psychosocial adjustment in women following a cardiac event. *Heart and Lung: Journal of Acute and Critical Care*. 2003;32(2):79-87.
174. Garcia-Pena C, Thorogood M, Armstrong B, Reyes-Frausto S, Munoz O. Pragmatic randomized trial of home visits by a nurse to elderly people with hypertension in Mexico. *International Journal of Epidemiology*. 2001;30(6):1485-1491.

175. Garcia-Rodriguez O, Secades-Villa R, Higgins ST, et al. Effects of Voucher-Based Intervention on Abstinence and Retention in an Outpatient Treatment for Cocaine Addiction: A Randomized Controlled Trial. *Experimental and clinical psychopharmacology*. 2009;17(3):131-138.
176. Garland EL, Gaylord SA, Boettiger CA, Howard MO. Mindfulness training modifies cognitive, affective, and physiological mechanisms implicated in alcohol dependence: results of a randomized controlled pilot trial. *Journal of psychoactive drugs*. Jun 2010;42(2):177-192. Pmc2921532:
177. Garnefski N, Kraaij V, Benoist M, Bout Z, Karels E, Smit A. Effect of a cognitive behavioral self-help intervention on depression, anxiety, and coping self-efficacy in people with rheumatic disease. *Arthritis care & research*. Jul 2013;65(7):1077-1084.
178. Gary R, Lee SY. Physical function and quality of life in older women with diastolic heart failure: effects of a progressive walking program on sleep patterns. *Progress in cardiovascular nursing*. Spring 2007;22(2):72-80.
179. Gay MCP, P.:Luminet, O. Differential effectiveness of psychological interventions for reducing osteoarthritis pain: a comparison of Erikson [correction of Erickson] hypnosis and Jacobson relaxation. *European journal of pain (London, England)*. 2002;6(1):1-16.
180. Ghanem M, E.A EL, Mehany M, Tolba K. Home-based pulmonary rehabilitation program: Effect on exercise tolerance and quality of life in chronic obstructive pulmonary disease patients. *Annals of Thoracic Medicine*. 2010;5(1):18-25.
181. Ghee AC, Bolling LC, Johnson CS. The efficacy of a condensed Seeking Safety intervention for women in residential chemical dependence treatment at 30 days posttreatment. *Journal of child sexual abuse*. Sep 2009;18(5):475-488.
182. Gielissen MFM, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: A randomized controlled trial. *Journal of Clinical Oncology*. 2006;24(30):4882-4887.
183. Giraudet-Le Quintrec JS, Mayoux-Benhamou A, Ravaud P, et al. Effect of a collective educational program for patients with rheumatoid arthritis: a prospective 12-month randomized controlled trial. *The Journal of rheumatology*. Aug 2007;34(8):1684-1691.
184. Glass TA, Berkman LF, Hiltunen EF, et al. The families in recovery from stroke trial (FIRST): Primary study results. *Psychosomatic medicine*. 2004;66(6):889-897.
185. Goel V, Sawka CA, Thiel EC, Gort EH, O'Connor AM. Randomized trial of a patient decision aid for choice of surgical treatment for breast cancer. *Medical Decision Making*. 2001;21(1):1-6.
186. Goldie CL, Brown CA, Hains SM, Parlow JL, Birtwhistle R. Synergistic effects of low-intensity exercise conditioning and beta-blockade on cardiovascular and autonomic adaptation in pre- and postmenopausal women with hypertension. *Biological research for nursing*. Oct 2013;15(4):433-442.
187. Goswami NJ, DeKoven M, Kuznik A, et al. Impact of an integrated intervention program on atorvastatin adherence: A randomized controlled trial. *International Journal of General Medicine*. 2013;6:647-655.
188. Gotay CC, Moinpour CM, Unger JM, et al. Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. May 20 2007;25(15):2093-2099.
189. Goudswaard AN, Stolk RP, Zuithoff NPA, De Valk HW, Rutten GEHM. Long-term effects of self-management education for patients with Type 2 diabetes taking maximal oral hypoglycaemic therapy: A randomized trial in primary care. *Diabetic Medicine*. 2004;21(5):491-496.
190. Green BB, Anderson ML, Cook AJ, et al. e-Care for heart wellness: a feasibility trial to decrease blood pressure and cardiovascular risk. *American journal of preventive medicine*. Apr 2014;46(4):368-377. Pmc3978093:

191. Greer JA, Traeger L, Bemis H, et al. A pilot randomized controlled trial of brief cognitive-behavioral therapy for anxiety in patients with terminal cancer. *The oncologist*. 2012;17(10):1337-1345. Pmc3481900:
192. Groessl EJ, Cronan TA. A cost analysis of self-management programs for people with chronic illness. *American journal of community psychology*. 2000;28(4):455-480.
193. Grover SA, Lowensteyn I, Joseph L, et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy - The CHECK-UP study: A randomized controlled trial. *Archives of Internal Medicine*. 2007;167(21):2296-2303.
194. Gucciardi E, Demelo M, Lee RN, Grace SL. Assessment of two culturally competent diabetes education methods: individual versus individual plus group education in Canadian Portuguese adults with type 2 diabetes. *Ethnicity & health*. Apr 2007;12(2):163-187.
195. Guidetti S, Andersson K, Andersson M, Tham K, Von Koch L. Client-centred self-care intervention after stroke: a feasibility study. *Scandinavian journal of occupational therapy*. 2010;17(4):276-285.
196. Gustafson DH, McTavish FM, Chih MY, et al. A smartphone application to support recovery from alcoholism a randomized clinical trial. *JAMA Psychiatry*. 2014;71(5):566-572.
197. Haddock G, Barrowclough C, TARRIER N, et al. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-Month outcomes of a randomised controlled trial. *British Journal of Psychiatry*. 2003;183(NOV.):418-426.
198. Halkett GK, O'Connor M, Aranda S, et al. Pilot randomised controlled trial of a radiation therapist-led educational intervention for breast cancer patients prior to commencing radiotherapy. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. Jun 2013;21(6):1725-1733.
199. Hall SM, Tsoh JY, Prochaska JJ, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. *American journal of public health*. Oct 2006;96(10):1808-1814. Pmc1586139:
200. Halperin S, Nathan P, Drummond P, Castle D. A cognitive-behavioural, group-based intervention for social anxiety in schizophrenia. *Australian and New Zealand Journal of Psychiatry*. 2000;34(5):809-813.
201. Hammond A, Bryan J, Hardy A. Effects of a modular behavioural arthritis education programme: a pragmatic parallel-group randomized controlled trial. *Rheumatology (Oxford, England)*. Nov 2008;47(11):1712-1718.
202. Hammond A, Young A, Kidao R. A randomised controlled trial of occupational therapy for people with early rheumatoid arthritis. *Annals of the rheumatic diseases*. 2004;63(1):23-30.
203. Harari D, Norton C, Lockwood L, Swift C. Treatment of constipation and fecal incontinence in stroke patients: Randomized controlled trial. *Stroke*. 2004;35(11):2549-2555.
204. Hare JL, Hordern MD, Leano R, Stanton T, Prins JB, Marwick TH. Application of an exercise intervention on the evolution of diastolic dysfunction in patients with diabetes mellitus: efficacy and effectiveness. *Circulation. Heart failure*. Jul 2011;4(4):441-449.
205. Harrison MB, Browne GB, Roberts J, Tugwell P, Gafni A, Graham ID. Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition. *Medical care*. 2002;40(4):271-282.
206. Hartman CA, Manos TM, Winter C, Hartman DM, Li B, Smith JC. Effects of T'ai Chi training on function and quality of life indicators in older adults with osteoarthritis. *Journal of the American Geriatrics Society*. 2000;48(12):1553-1559.
207. Hayashi N, Yamashina M, Igarashi Y, Kazamatsuri H. Improvement of patient attitude toward treatment among inpatients with schizophrenia and its related factors: Controlled study of a psychological approach. *Comprehensive Psychiatry*. 2001;42(3):240-246.

208. Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. *Journal of acquired immune deficiency syndromes* (1999). Feb 1 2007;44(2):213-221.
209. Hebert JR, Ebbeling CB, Olendzki BC, et al. Change in women's diet and body mass following intensive intervention for early-stage breast cancer. *Journal of the American Dietetic Association*. 2001;101(4):421-431.
210. Heckman TG, Carlson B. A randomized clinical trial of two telephone-delivered, mental health interventions for HIV-infected persons in rural areas of the United States. *AIDS and behavior*. Jan 2007;11(1):5-14.
211. Hee-Sung K. Impact of Web-based nurse's education on glycosylated haemoglobin in type 2 diabetic patients. *Journal of clinical nursing*. Jul 2007;16(7):1361-1366.
212. Heil SH, Sigmon SC, Mongeon JA, Higgins ST. Characterizing and improving HIV/AIDS knowledge among cocaine-dependent outpatients. *Experimental and clinical psychopharmacology*. 2005;13(3):238-243.
213. Heiney SP, McWayne J, Hurley TG, et al. Efficacy of Therapeutic Group by Telephone for Women with Breast Cancer. *Cancer nursing*. 2003;26(6):439-447.
214. Heiney SP, Underwood SM, Tavakoli A, Adams SA, Wells LM, Bryant LH. Randomized trial of therapeutic group by teleconference: African American women with breast cancer. *Cancer*. 2012;118(15):3822-3832.
215. Hellerstein DJ, Little SAS, Samstag LW, et al. Adding group psychotherapy to medication treatment in dysthymia: A randomized prospective pilot study. *Journal of Psychotherapy Practice and Research*. 2001;10(2):93-103.
216. Hendricks LE, Hendricks RT. The effect of diabetes self-management education with frequent follow-up on the health outcomes of African American men. *The Diabetes educator*. 2000;26(6):995-1002.
217. Hermiz O, Comino E, Marks G, Daffurn K, Wilson S, Harris M. Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. *British Medical Journal*. 2002;325(7370):938-940.
218. Herz MI, Lamberti JS, Mintz J, et al. A program for relapse prevention in schizophrenia: A controlled study. *Archives of General Psychiatry*. 2000;57(3):277-283.
219. Heuts PH, de Bie R, Drietelaar M, et al. Self-management in osteoarthritis of hip or knee: a randomized clinical trial in a primary healthcare setting. *The Journal of rheumatology*. Mar 2005;32(3):543-549.
220. Hien DA, Wells EA, Jiang H, et al. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. *Journal of consulting and clinical psychology*. Aug 2009;77(4):607-619. Pmc2795638:
221. Higgins ST, Sigmon SC, Wong CJ, et al. Community reinforcement therapy for cocaine-dependent outpatients. *Archives of General Psychiatry*. 2003;60(10):1043-1052.
222. Hilberink SR, Jacobs JE, Bottema BJAM, De Vries H, Grol RPTM. Smoking cessation in patients with COPD in daily general practice (SMOCC): Six months' results. *Preventive Medicine*. 2005;41(5-6):822-827.
223. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: A randomised controlled trial. *Annals of the rheumatic diseases*. 2001;60(9):869-875.
224. Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge : A randomized clinical trial. *JAMA Internal Medicine*. 2014;174(2):186-193.

225. Hochhalter AK, Song J, Rush J, Sklar L, Stevens A. Making the Most of Your Healthcare intervention for older adults with multiple chronic illnesses. Patient education and counseling. Nov 2010;81(2):207-213.
226. Hoifodt RS, Lillevoll KR, Griffiths KM, et al. The clinical effectiveness of web-based cognitive behavioral therapy with face-to-face therapist support for depressed primary care patients: randomized controlled trial. Journal of medical Internet research. 2013;15(8):e153. Pmc3742404:
227. Holbrook A, Thabane L, Keshavjee K, et al. Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. Jul 7 2009;181(1-2):37-44. Pmc2704409:
228. Hollandare F, Johnsson S, Randestad M, et al. Randomized trial of Internet-based relapse prevention for partially remitted depression. Acta psychiatrica Scandinavica. Oct 2011;124(4):285-294.
229. Holmgren E, Gosman-Hedstrom G, Lindstrom B, Wester P. What is the benefit of a high-intensive exercise program on health-related quality of life and depression after stroke? A randomized controlled trial. Advances in Physiotherapy. 2010;12(3):125-133.
230. Hoshii J, Yotsumoto K, Tatsumi E, Tanaka C, Mori T, Hashimoto T. Subject-chosen activities in occupational therapy for the improvement of psychiatric symptoms of inpatients with chronic schizophrenia: a controlled trial. Clinical rehabilitation. Jul 2013;27(7):638-645.
231. Howell CA, Turnbull DA, Beilby JJ, Marshall CA, Briggs N, Newbury WL. Preventing relapse of depression in primary care: a pilot study of the "Keeping the blues away" program. The Medical journal of Australia. Jun 16 2008;188(12 Suppl):S138-141.
232. Huang TT, Li YT, Wang CH. Individualized programme to promote self-care among older adults with asthma: randomized controlled trial. Journal of advanced nursing. Feb 2009;65(2):348-358.
233. Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Archives of Family Medicine. 2000;9(8):700-708.
234. Hyman DJ, Pavlik VN, Taylor WC, Goodrick GK, Moye L. Simultaneous vs sequential counseling for multiple behavior change. Arch Intern Med. Jun 11 2007;167(11):1152-1158.
235. Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus IH. A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respiratory medicine. Jul 2010;104(7):986-994.
236. Irwig MS, Sood P, Ni D, et al. A diabetes scorecard does not improve HbA(1c), blood pressure, lipids, aspirin usage, exercise and diabetes knowledge over 9 months: a randomized controlled trial. Diabetic medicine : a journal of the British Diabetic Association. Sep 2012;29(9):1206-1212.
237. James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ. A group intervention which assists patients with dual diagnosis reduce their drug use: A randomized controlled trial. Psychological Medicine. 2004;34(6):983-990.
238. Javanbakht M, Prosser P, Grimes T, Weinstein M, Farthing C. Efficacy of an individualized adherence support program with contingent reinforcement among nonadherent HIV-positive patients: results from a randomized trial. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002). Dec 2006;5(4):143-150.
239. Jean-Baptiste M, Tek C, Liskov E, et al. A pilot study of a weight management program with food provision in schizophrenia. Schizophrenia research. Nov 2007;96(1-3):198-205.
240. Jerant A, Moore-Hill M, Franks P. Home-based, peer-led chronic illness self-management training: findings from a 1-year randomized controlled trial. Annals of family medicine. Jul-Aug 2009;7(4):319-327. Pmc2713168:

241. Jerant AF, Azari R, Nesbitt TS. Reducing the cost of frequent hospital admissions for congestive heart failure: a randomized trial of a home telecare intervention. *Medical care*. 2001;39(11):1234-1245.
242. Jolly K, Taylor RS, Lip GYH, et al. A randomized trial of the addition of home-based exercise to specialist heart failure nurse care: The Birmingham Rehabilitation Uptake Maximisation study for patients with Congestive Heart Failure (BRUM-CHF) study. *European journal of heart failure*. 2009;11(2):205-213.
243. Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. *Drug and alcohol dependence*. 2001;61(3):297-306.
244. Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. *Journal of studies on alcohol*. 2004;65(6):681-691.
245. Jung JG, Kim JS, Kim GJ, Oh MK, Kim SS. Brief insight-enhancement intervention among patients with alcohol dependence. *Journal of Korean medical science*. Jan 2011;26(1):11-16. Pmc3012834:
246. Kalichman SCR, D.:Cage, M.:DiFonzo, K.:Simpson, D.:Austin, J.:Luke, W.:Buckles, J.:Kyomugisha, F.:Benotsch, E.:Pinkerton, S.:Graham, J. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. *American journal of preventive medicine*. Aug 2001;21(2):84-92.
247. Kaltsatou AC, Kouidi EI, Anifanti MA, Douka SI, Deligiannis AP. Functional and psychosocial effects of either a traditional dancing or a formal exercising training program in patients with chronic heart failure: a comparative randomized controlled study. *Clinical rehabilitation*. Feb 2014;28(2):128-138.
248. Kang CM, Chang SC, Chen PL, et al. Comparison of family partnership intervention care vs. conventional care in adult patients with poorly controlled type 2 diabetes in a community hospital: a randomized controlled trial. *International journal of nursing studies*. Nov 2010;47(11):1363-1373.
249. Kanji N, White AR, Ernst E. Autogenic training reduces anxiety after coronary angioplasty: a randomized clinical trial. *American heart journal*. 2004;147(3):E10.
250. Karapolat H, Atasever A, Atamaz F, Kirazli Y, Elmas F, Erdinc E. Do the benefits gained using a short-term pulmonary rehabilitation program remain in COPD patients after participation? *Lung*. Jul-Aug 2007;185(4):221-225.
251. Kashner TM, Rosenheck R, Campinell AB, et al. Impact of work therapy on health status among homeless, substance-dependent veterans: A randomized controlled trial. *Archives of General Psychiatry*. 2002;59(10):938-944.
252. Katon WJ, Von Korff M, Lin EHB, et al. The pathways study: A randomized trial of collaborative care in patients with diabetes and depression. *Archives of General Psychiatry*. 2004;61(10):1042-1049.
253. Kattelman KK, Conti K, Ren C. The medicine wheel nutrition intervention: a diabetes education study with the Cheyenne River Sioux Tribe. *Journal of the American Dietetic Association*. Sep 2009;109(9):1532-1539. Pmc2765410:
254. Kauric-Klein Z. Improving blood pressure control in end stage renal disease through a supportive educative nursing intervention. *Nephrology nursing journal : journal of the American Nephrology Nurses' Association*. May-Jun 2012;39(3):217-228.
255. Kearney N, McCann L, Norrie J, et al. Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. Apr 2009;17(4):437-444.
256. Keller MBM, J. P.:Klein, D. N.:Arnow, B.:Dunner, D. L.:Gelenberg, A. J.:Markowitz, J. C.:Nemeroff, C. B.:Russell, J. M.:Thase, M. E.:Trivedi, M. H.:Zajecka, J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *The New England journal of medicine*. May 18 2000;342(20):1462-1470.

257. Kempf K, Tankova T, Martin S. ROSSO-in-praxi-international: long-term effects of self-monitoring of blood glucose on glucometabolic control in patients with type 2 diabetes mellitus not treated with insulin. *Diabetes technology & therapeutics*. Jan 2013;15(1):89-96.
258. Kenardy J, Mensch M, Bowen K, Green B, Walton J. Group therapy for binge eating in Type 2 diabetes: A randomized trial. *Diabetic Medicine*. 2002;19(3):234-239.
259. Kendall E, Catalano T, Kuipers P, Posner N, Buys N, Charker J. Recovery following stroke: the role of self-management education. *Social science & medicine* (1982). Feb 2007;64(3):735-746.
260. Kernick D, Powell R, Reinhold D. A pragmatic randomised controlled trial of an asthma nurse in general practice. *Primary Care Respiratory Journal*. 2002;11(1):6-8.
261. Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *British journal of clinical pharmacology*. Oct 2009;68(4):588-598. Pmc2780284:
262. Kidorf M, King VL, Neufeld K, Peirce J, Kolodner K, Brooner RK. Improving substance abuse treatment enrollment in community syringe exchangers. *Addiction (Abingdon, England)*. May 2009;104(5):786-795.
263. Kilbreath SL, Refshauge KM, Beith JM, et al. Upper limb progressive resistance training and stretching exercises following surgery for early breast cancer: a randomized controlled trial. *Breast cancer research and treatment*. Jun 2012;133(2):667-676.
264. Kim SE, LeBlanc AJ, Michalopoulos C, et al. Does telephone care management help medicaid beneficiaries with depression? *American Journal of Managed Care*. 2011;17(10):e375-e382.
265. Kim SH, Shin MS, Lee HS, et al. Randomized pilot test of a simultaneous stage-matched exercise and diet intervention for breast cancer survivors. *Oncol Nurs Forum*. Mar 2011;38(2):E97-106.
266. Kim YR, J. A.:Morrow, G. R. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. Jul 2002;10(5):416-421.
267. Kinnane N, Stuart E, Thompson L, Evans K, Schneider-Kolsky M. Evaluation of the addition of video-based education for patients receiving standard pre-chemotherapy education. *European Journal of Cancer Care*. 2008;17(4):328-339.
268. Kinsella J, Acher P, Ashfield A, et al. Demonstration of erectile management techniques to men scheduled for radical prostatectomy reduces long-term regret: A comparative cohort study. *BJU International*. 2012;109(2):254-258.
269. Kirk A, Mutrie N, MacIntyre P, Fisher M. Increasing physical activity in people with type 2 diabetes. *Diabetes care*. 2003;26(4):1186-1192.
270. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. *Psycho-oncology*. Apr 2007;16(4):277-286.
271. Koff PB, Jones RH, Cashman JM, Voelkel NF, Vandivier RW. Proactive integrated care improves quality of life in patients with COPD. *The European respiratory journal*. May 2009;33(5):1031-1038.
272. Kolanowski AM, Litaker M, Buettner L. Efficacy of theory-based activities for behavioral symptoms of dementia. *Nursing research*. Jul-Aug 2005;54(4):219-228.
273. Koloverou E, Tentolouris N, Bakoula C, Darviri C, Chrousos G. Implementation of a stress management program in outpatients with type 2 diabetes mellitus: A randomized controlled trial. *Hormones*. 2014;13(4):509-518.
274. Kono Y, Yamada S, Yamaguchi J, et al. Secondary prevention of new vascular events with lifestyle intervention in patients with noncardioembolic mild ischemic stroke: a single-center randomized controlled trial. *Cerebrovascular diseases (Basel, Switzerland)*. 2013;36(2):88-97.

275. Korhonen M, Kastarinen M, Uusitupa M, Puska P, Nissinen A. The effect of intensified diet counseling on the diet of hypertensive subjects in primary health care: A 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. *Preventive Medicine*. 2003;36(1):8-16.
276. Korstjens I, May AM, van Weert E, et al. Quality of life after self-management cancer rehabilitation: a randomized controlled trial comparing physical and cognitive-behavioral training versus physical training. *Psychosomatic medicine*. May 2008;70(4):422-429.
277. Korte J, Bohlmeijer ET, Cappeliez P, Smit F, Westerhof GJ. Life review therapy for older adults with moderate depressive symptomatology: a pragmatic randomized controlled trial. *Psychol Med*. Jun 2012;42(6):1163-1173.
278. Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. *Jama*. May 27 2009;301(20):2099-2110. Pmc2884224:
279. Kulzer B, Hermanns N, Reinecker H, Haak T. Effects of self-management training in Type 2 diabetes: a randomized, prospective trial. *Diabetic medicine : a journal of the British Diabetic Association*. Apr 2007;24(4):415-423.
280. Kumar P, Tiwari SC, Goel A, et al. Novel occupational therapy interventions may improve quality of life in older adults with dementia. *International Archives of Medicine*. 2014;7(1).
281. Kunik ME, Braun U, Stanley MA, et al. One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. *Psychological Medicine*. 2001;31(4):717-723.
282. Kuo CC, Lin CC, Lin SY, Yang YH, Chang CS, Chen CH. Effects of self-regulation protocol on physiological and psychological measures in patients with chronic obstructive pulmonary disease. *Journal of clinical nursing*. Oct 2013;22(19-20):2800-2811.
283. Kwekkeboom KL, Abbott-Anderson K, Cherwin C, Roiland R, Serlin RC, Ward SE. Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer. *Journal of pain and symptom management*. Dec 2012;44(6):810-822. Pmc3484234:
284. Lalonde LG-D, K.:Lowensteyn, I.:Marchand, S.:Dorais, M.:Michaels, G.:Llewellyn-Thomas, H. A.:O'Connor, A.:Grover, S. A. Comparing the benefits of diet and exercise in the treatment of dyslipidemia. *Prev Med*. Jul 2002;35(1):16-24.
285. Lam LCW, Lui VWC, Luk DNY, et al. Effectiveness of an individualized functional training program on affective disturbances and functional skills in mild and moderate dementia - A randomized control trial. *International journal of geriatric psychiatry*. 2010;25(2):133-141.
286. Lam WW, Chan M, Or A, Kwong A, Suen D, Fielding R. Reducing treatment decision conflict difficulties in breast cancer surgery: a randomized controlled trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Aug 10 2013;31(23):2879-2885.
287. Landis SE, Gaynes BN, Morrissey JP, Vinson N, Ellis AR, Domino ME. Generalist care managers for the treatment of depressed medicaid patients in North Carolina: a pilot study. *BMC family practice*. 2007;8:7. Pmc1838423:
288. Larson JL, Covey MK, Kapella MC, Alex CG, McAuley E. Self-efficacy enhancing intervention increases light physical activity in people with chronic obstructive pulmonary disease. *International Journal of COPD*. 2014;9:1081-1090.
289. Larson MRD, P. R.:Talbot, N. L.:Caldwell, C.:Moynihan, J. A. A presurgical psychosocial intervention for breast cancer patients. psychological distress and the immune response. *J Psychosom Res*. Feb 2000;48(2):187-194.
290. Lechner SC, Antoni MH, Lydston D, et al. Cognitive-behavioral interventions improve quality of life in women with AIDS. *Journal of Psychosomatic Research*. 2003;54(3):253-261.

291. Leclerc C, Lesage AD, Ricard N, Lecomte T, Cyr M. Assessment of a new rehabilitative coping skills module for persons with schizophrenia. *The American journal of orthopsychiatry*. 2000;70(3):380-388.
292. Ledderer L, la Cour K, Mogensen O, et al. Feasibility of a psychosocial rehabilitation intervention to enhance the involvement of relatives in cancer rehabilitation: pilot study for a randomized controlled trial. *The patient*. 2013;6(3):201-212.
293. Ledgerwood DM, Alessi SM, Hanson T, Godley MD, Petry NM. Contingency management for attendance to group substance abuse treatment administered by clinicians in community clinics. *Journal of applied behavior analysis*. Winter 2008;41(4):517-526. Pmc2606605:
294. Lee HL, Tan HK, Ma HI, Tsai CY, Liu YK. Effectiveness of a work-related stress management program in patients with chronic schizophrenia. *The American journal of occupational therapy : official publication of the American Occupational Therapy Association*. Jul-Aug 2006;60(4):435-441.
295. Lee LL, Arthur A, Avis M. Evaluating a community-based walking intervention for hypertensive older people in Taiwan: a randomized controlled trial. *Prev Med*. Feb 2007;44(2):160-166.
296. Lee MM, Camp CJ, Malone ML. Effects of intergenerational Montessori-based activities programming on engagement of nursing home residents with dementia. *Clinical interventions in aging*. 2007;2(3):477-483. Pmc2685273:
297. Lee TY, Chang SC, Chu H, et al. The effects of assertiveness training in patients with schizophrenia: a randomized, single-blind, controlled study. *Journal of advanced nursing*. Nov 2013;69(11):2549-2559.
298. Lemmens GMD, Eisler I, Buysse A, Heene E, Demyttenaere K. The effects on mood of adjunctive single-family and multi-family group therapy in the treatment of hospitalized patients with major depression: A 15-month follow-up study. *Psychotherapy and Psychosomatics*. 2009;78(2):98-105.
299. Leon-Pizarro C, Gich I, Barthe E, et al. A randomized trial of the effect of training in relaxation and guided imagery techniques in improving psychological and quality-of-life indices for gynecologic and breast brachytherapy patients. *Psycho-oncology*. Nov 2007;16(11):971-979.
300. Lepore SJ, Eton DT, Helgeson VS, Schulz R. Improving quality of life in men with prostate cancer: A randomized controlled trial of group education interventions. *Health Psychology*. 2003;22(5):443-452.
301. Lerman R, Jarski R, Rea H, Gellish R, Vicini F. Improving symptoms and quality of life of female cancer survivors: a randomized controlled study. *Annals of surgical oncology*. Feb 2012;19(2):373-378.
302. Leung RWM, McKeough ZJ, Peters MJ, Alison JA. Short-form Sun-style t'ai chi as an exercise training modality in people with COPD. *European Respiratory Journal*. 2013;41(5):1051-1057.
303. Lev EL, Owen SV. Counseling women with breast cancer using principles developed by Albert Bandura. *Perspectives in psychiatric care*. 2000;36(4):131-138.
304. Levesque DA, Van Marter DF, Schneider RJ, et al. Randomized trial of a computer-tailored intervention for patients with depression. *American journal of health promotion : AJHP*. Nov-Dec 2011;26(2):77-89.
305. Levine DM, Bone LR, Hill MN, et al. The effectiveness of a community/academic health center partnership in decreasing the level of blood pressure in an urban African-American population. *Ethnicity and Disease*. 2003;13(3):354-361.
306. Lie I, Arnesen H, Sandvik L, Hamilton G, E HB. Effects of a home-based intervention program on anxiety and depression 6 months after coronary artery bypass grafting: A randomized controlled trial. *Journal of Psychosomatic Research*. 2007;62(4):411-418.
307. Liebreich T, Plotnikoff RC, Courneya KS, Boule N. Diabetes NetPLAY: A physical activity website and linked email counselling randomized intervention for individuals with type 2 diabetes. *International Journal of Behavioral Nutrition and Physical Activity*. 2009;6.

308. Liew SM, Tong SF, Lee VK, Ng CJ, Leong KC, Teng CL. Text messaging reminders to reduce non-attendance in chronic disease follow-up: a clinical trial. *The British journal of general practice : the journal of the Royal College of General Practitioners*. Dec 2009;59(569):916-920. Pmc2784529:
309. Lin WFM, D.:Enright, R. D.:Krahn, D.:Baskin, T. W. Effects of forgiveness therapy on anger, mood, and vulnerability to substance use among inpatient substance-dependent clients. *Journal of consulting and clinical psychology*. Dec 2004;72(6):1114-1121.
310. Linden A, Butterworth SW. A comprehensive hospital-based intervention to reduce readmissions for chronically ill patients: A randomized controlled trial. *American Journal of Managed Care*. 2014;20(10):783-792.
311. Lindsay S, Bellaby P, Smith S, Baker R. Enabling healthy choices: is ICT the highway to health improvement? *Health (London, England : 1997)*. Jul 2008;12(3):313-331.
312. Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus Comprehensive Validation Therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. *Drug and alcohol dependence*. 2002;67(1):13-26.
313. Litaker DM, L.:Planavsky, L.:Kippes, C.:Mehta, N.:Frolkis, J. Physician - nurse practitioner teams in chronic disease management: the impact on costs, clinical effectiveness, and patients' perception of care. *Journal of interprofessional care*. Aug 2003;17(3):223-237.
314. Litt MD, Kadden RM, Kabela-Cormier E. Individualized assessment and treatment program for alcohol dependence: results of an initial study to train coping skills. *Addiction (Abingdon, England)*. Nov 2009;104(11):1837-1838. Pmc2763044:
315. Lobello K, Reddy S, Musgnung J, Pedersen R, Ninan PT. Patient outcomes with education, drug therapy, and support: a study of venlafaxine ER-treated outpatients with major depressive disorder. *Psychopharmacology bulletin*. 2010;43(2):28-44.
316. Loprinzi CE, Prasad K, Schroeder DR, Sood A. Stress Management and Resilience Training (SMART) program to decrease stress and enhance resilience among breast cancer survivors: a pilot randomized clinical trial. *Clinical breast cancer*. Dec 2011;11(6):364-368.
317. Lorig KR, Ritter PL, Gonzalez VM. Hispanic chronic disease self-management: a randomized community-based outcome trial. *Nursing research*. 2003;52(6):361-369.
318. Lovejoy TI, Heckman TG, Suhr JA, Anderson T, Heckman BD, France CR. Telephone-administered motivational interviewing reduces risky sexual behavior in HIV-positive late middle-age and older adults: a pilot randomized controlled trial. *AIDS and behavior*. Nov 2011;15(8):1623-1634.
319. Lumley MA, Keefe FJ, Mosley-Williams A, et al. The effects of written emotional disclosure and coping skills training in rheumatoid arthritis: A randomized clinical trial. *Journal of consulting and clinical psychology*. 2014;82(4):644-658.
320. Lund A, Michelet M, Sandvik L, Wyller T, Sveen U. A lifestyle intervention as supplement to a physical activity programme in rehabilitation after stroke: a randomized controlled trial. *Clinical rehabilitation*. Jun 2012;26(6):502-512.
321. Luszczynska A, Gregajtys A, Abraham C. Effects of a self-efficacy intervention on initiation of recommended exercises in patients with spondylosis. *Journal of aging and physical activity*. Jan 2007;15(1):26-40.
322. Lynch D, Tamburrino M, Nagel R, Smith MK. Telephone-based treatment for family practice patients with mild depression. *Psychological reports*. 2004;94(3 Pt 1):785-792.
323. Lynch TR, Morse JQ, Mendelson T, Robins C. Dialectical behavior therapy for depressed older adults: A randomized pilot study. *American Journal of Geriatric Psychiatry*. 2003;11(1):33-45.

324. Ma SH, Teasdale JD. Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. *Journal of consulting and clinical psychology*. 2004;72(1):31-40.
325. Maddison R, Prapavessis H, Armstrong GP, Hill C. A modeling intervention in heart failure. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*. Aug 2008;36(1):64-69.
326. Mahdizadeh M, Peymam N, Taghipour A, Esmaily H, Mousa Mahdizadeh S. Effect of health education program on promoting physical activity among diabetic women in Mashhad, Iran: Applying social cognitive theory. *Journal of Research in Health Sciences*. 2013;13(1):90-97.
327. Malm U, Ivarsson B, Allebeck P, Falloon IRH. Integrated care in schizophrenia: A 2-year randomized controlled study of two community-based treatment programs. *Acta psychiatrica Scandinavica*. 2003;107(6):415-423.
328. Manchanda SC, Narang R, Reddy KS, et al. Retardation of coronary atherosclerosis with yoga lifestyle intervention. *The Journal of the Association of Physicians of India*. 2000;48(7):687-694.
329. Mancuso CA, Peterson MG, Gaeta TJ, et al. A randomized controlled trial of self-management education for asthma patients in the emergency department. *Annals of emergency medicine*. Jun 2011;57(6):603-612.
330. Martire LM, Schulz R, Keefe FJ, Rudy TE, Starz TW. Couple-oriented education and support intervention: Effects on individuals with osteoarthritis and their spouses. *Rehabilitation Psychology*. 2007;52(2):121-132.
331. Mastel-Smith BA, McFarlane J, Sierpina M, Malecha A, Haile B. Improving depressive symptoms in community-dwelling older adults: a psychosocial intervention using life review and writing. *Journal of gerontological nursing*. May 2007;33(5):13-19.
332. Mayer-Davis EJ, D'Antonio AM, Smith SM, et al. Pounds off with empowerment (POWER): A clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities. *American journal of public health*. 2004;94(10):1736-1742.
333. McBride C, Segal Z, Kennedy S, Gemar M. Changes in autobiographical memory specificity following cognitive behavior therapy and pharmacotherapy for major depression. *Psychopathology*. 2007;40(3):147-152.
334. McCain NL, Gray DP, Elswick RK, et al. A randomized clinical trial of alternative stress management interventions in persons with HIV infection. *Journal of consulting and clinical psychology*. Jun 2008;76(3):431-441.
335. McClure JB, Catz SL, Ludman EJ, Richards J, Riggs K, Grothaus L. Feasibility and acceptability of a multiple risk factor intervention: the Step Up randomized pilot trial. *BMC Public Health*. 2011;11:167. Pmc3072336:
336. McDonald DD, Gifford T, Walsh S. Effect of a virtual pain coach on older adults' pain communication: a pilot study. *Pain management nursing : official journal of the American Society of Pain Management Nurses*. Mar 2011;12(1):50-56.
337. McGilton KS, Rivera TM, Dawson P. Can we help persons with dementia find their way in a new environment? *Aging and Mental Health*. 2003;7(5):363-371.
338. McKay HG, King D, Eakin EG, Seeley JR, Glasgow RE. The diabetes network internet-based physical activity intervention: a randomized pilot study. *Diabetes care*. 2001;24(8):1328-1334.
339. McKay JR, Lynch KG, Coviello D, et al. Randomized trial of continuing care enhancements for cocaine-dependent patients following initial engagement. *Journal of consulting and clinical psychology*. Feb 2010;78(1):111-120. Pmc3076098:

340. McKay JRL, K. G.:Shepard, D. S.:Ratichek, S.:Morrison, R.:Koppenhaver, J.:Pettinati, H. M. The effectiveness of telephone-based continuing care in the clinical management of alcohol and cocaine use disorders: 12-month outcomes. *Journal of consulting and clinical psychology*. Dec 2004;72(6):967-979.
341. McKinstry B, Hanley J, Heaney D, McCloughan L, Elton R, Webb DJ. Impact on hypertension control of a patient-held guideline: a randomised controlled trial. *The British journal of general practice : the journal of the Royal College of General Practitioners*. Nov 2006;56(532):842-847. Pmc1927092:
342. Menard J, Payette H, Baillargeon JP, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. Dec 6 2005;173(12):1457-1466. Pmc1316161:
343. Messier SP, Loeser RF, Miller GD, et al. Exercise and Dietary Weight Loss in Overweight and Obese Older Adults with Knee Osteoarthritis: The Arthritis, Diet, and Activity Promotion Trial. *Arthritis and rheumatism*. 2004;50(5):1501-1510.
344. Meszaros A, Orosz M, Magyar P, Mesko A, Vincze Z. Evaluation of asthma knowledge and quality of life in Hungarian asthmatics. *Allergy: European Journal of Allergy and Clinical Immunology*. 2003;58(7):624-628.
345. Milby JB, Schumacher JE, McNamara C, et al. Initiating abstinence in cocaine abusing dually diagnosed homeless persons. *Drug and alcohol dependence*. 2000;60(1):55-67.
346. Miles MS, Holditch-Davis D, Eron J, Black BP, Pedersen C, Harris DA. An HIV self-care symptom management intervention for African American mothers. *Nursing research*. 2003;52(6):350-360.
347. Miller CK, Gutschall M. A randomized trial about glycemic index and glycemic load improves outcomes among adults with type 2 diabetes. *Health education & behavior : the official publication of the Society for Public Health Education*. Jun 2009;36(3):615-626.
348. Miller CK, Kristeller JL, Headings A, Nagaraja H, Miser WF. Comparative effectiveness of a mindful eating intervention to a diabetes self-management intervention among adults with type 2 diabetes: a pilot study. *Journal of the Academy of Nutrition and Dietetics*. Nov 2012;112(11):1835-1842. Pmc3485681:
349. Min Z, Xu L, Chen H, Ding X, Yi Z, Mingyuan Z. A pilot assessment of relapse prevention for heroin addicts in a Chinese rehabilitation center. *The American journal of drug and alcohol abuse*. May 2011;37(3):141-147. Pmc3113608:
350. Mishel MHB, M.:Germino, B. B.:Stewart, J. L.:Bailey, D. E., Jr.:Robertson, C.:Mohler, J. Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects: nurse-delivered psychoeducational intervention over the telephone. *Cancer*. Mar 15 2002;94(6):1854-1866.
351. Mittal D, Owen R, Lacro J, et al. Antipsychotic adherence intervention for veterans over forty with schizophrenia: Results of a pilot study. *Clinical Schizophrenia and Related Psychoses*. 2009;2(4):317-325.
352. Moller T, Borregaard N, Tvede M, Adamsen L. Patient education - A strategy for prevention of infections caused by permanent central venous catheters in patients with haematological malignancies: A randomized clinical trial. *Journal of Hospital Infection*. 2005;61(4):330-341.
353. Montes JM, Maurino J, Diez T, Saiz-Ruiz J. Telephone-based nursing strategy to improve adherence to antipsychotic treatment in schizophrenia: A controlled trial. *International Journal of Psychiatry in Clinical Practice*. 2010;14(4):274-281.
354. Montgomery AA, Fahey T, Peters TJ. A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients. *British Journal of General Practice*. 2003;53(491):446-453.
355. Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. *Journal of the National Cancer Institute*. Sep 5 2007;99(17):1304-1312.

356. Monti DA, Kash KM, Kunkel EJ, et al. Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer. *Psycho-oncology*. Nov 2013;22(11):2565-2575.
357. Morey MC, Snyder DC, Sloane R, et al. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. *Jama*. May 13 2009;301(18):1883-1891. Pmc2752421:
358. Morgan K, Gregory P, Tomeny M, David BM, Gascoigne C. Self-help treatment for insomnia symptoms associated with chronic conditions in older adults: a randomized controlled trial. *J Am Geriatr Soc*. Oct 2012;60(10):1803-1810.
359. Moritz S, Kerstan A, Veckenstedt R, et al. Further evidence for the efficacy of a metacognitive group training in schizophrenia. *Behaviour research and therapy*. Mar 2011;49(3):151-157.
360. Moriyama M, Nakano M, Kuroe Y, Nin K, Niitani M, Nakaya T. Efficacy of a self-management education program for people with type 2 diabetes: results of a 12 month trial. *Japan journal of nursing science : JJNS*. Jun 2009;6(1):51-63.
361. Morley KC, Sitharthan G, Haber PS, Tucker P, Sitharthan T. The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: A multisite randomized controlled trial. *Journal of consulting and clinical psychology*. 2014;82(1):130-140.
362. Mugusi F, Mugusi S, Bakari M, et al. Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience. *Tropical medicine & international health : TM & IH*. Oct 2009;14(10):1226-1232.
363. Murchie P, Nicolson MC, Hannaford PC, Raja EA, Lee AJ, Campbell NC. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. *British journal of cancer*. May 11 2010;102(10):1447-1455. Pmc2869159:
364. Murphy SL, Strasburg DM, Lyden AK, et al. Effects of activity strategy training on pain and physical activity in older adults with knee or hip osteoarthritis: a pilot study. *Arthritis and rheumatism*. Oct 15 2008;59(10):1480-1487. Pmc3046422:
365. Murray G, Michalak EE, Axler A, et al. Relief of chronic or resistant depression (Re-ChORD): a pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression. *J Affect Disord*. Jun 2010;123(1-3):243-248.
366. Nattala P, Leung KS, Nagarajaiah, Murthy P. Family member involvement in relapse prevention improves alcohol dependence outcomes: a prospective study at an addiction treatment facility in India. *Journal of studies on alcohol and drugs*. Jul 2010;71(4):581-587.
367. Navarre M, Patel H, Johnson CE, et al. Influence of an interactive computer-based inhaler technique tutorial on patient knowledge and inhaler technique. *Annals of Pharmacotherapy*. 2007;41(2):216-221.
368. Neufeld KJ, Kidorf MS, Kolodner K, King VL, Clark M, Brooner RK. A behavioral treatment for opioid-dependent patients with antisocial personality. *Journal of substance abuse treatment*. Jan 2008;34(1):101-111. Pmc2193670:
369. Ng BH, Tsang HW, Jones AY, So CT, Mok TY. Functional and psychosocial effects of health qigong in patients with COPD: a randomized controlled trial. *Journal of alternative and complementary medicine (New York, N.Y.)*. Mar 2011;17(3):243-251.
370. Nguyen HQ, Donesky D, Reinke LF, et al. Internet-based dyspnea self-management support for patients with chronic obstructive pulmonary disease. *Journal of pain and symptom management*. Jul 2013;46(1):43-55. Pmc3548968:
371. Niedermann K, de Bie RA, Kubli R, et al. Effectiveness of individual resource-oriented joint protection education in people with rheumatoid arthritis. A randomized controlled trial. *Patient education and counseling*. Jan 2011;82(1):42-48.

372. Nield M, Hoo GW. Real-time telehealth for COPD self-management using Skype. *Copd*. Dec 2012;9(6):611-619.
373. Nielsen JD, Palshof T, Mainz J, Jensen AB, Olesen F. Randomised controlled trial of a shared care programme for newly referred cancer patients: Bridging the gap between general practice and hospital. *Quality and Safety in Health Care*. 2003;12(4):263-272.
374. Niiranen TJ, Leino K, Puukka P, Kantola I, Karanko H, Jula AM. Lack of impact of a comprehensive intervention on hypertension in the primary care setting. *Am J Hypertens*. Mar 2014;27(3):489-496.
375. Nilsson BB, Westheim A, Risberg MA. Long-term effects of a group-based high-intensity aerobic interval-training program in patients with chronic heart failure. *The American journal of cardiology*. Nov 1 2008;102(9):1220-1224.
376. Noh JH, Cho YJ, Nam HW, et al. Web-based comprehensive information system for self-management of diabetes mellitus. *Diabetes technology & therapeutics*. May 2010;12(5):333-337.
377. Nothwehr FK, Guare J, Marrero DG, Hoen H. Sequencing diet and exercise programs for African American women with diabetes. *The Diabetes educator*. 2001;27(2):245-251.
378. Nyamathi A, Hanson AY, Salem BE, et al. Impact of a rural village women (Asha) intervention on adherence to antiretroviral therapy in southern India. *Nursing research*. Sep-Oct 2012;61(5):353-362. Pmc3509934:
379. Nyklicek I, Dijksman SC, Lenders PJ, Fonteijn WA, Koolen JJ. A brief mindfulness based intervention for increase in emotional well-being and quality of life in percutaneous coronary intervention (PCI) patients: the MindfulHeart randomized controlled trial. *Journal of behavioral medicine*. Feb 2014;37(1):135-144.
380. Obreli-Neto PR, Guidoni CM, de Oliveira Baldoni A, et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. *International journal of clinical pharmacy*. Aug 2011;33(4):642-649.
381. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. *The Annals of pharmacotherapy*. Mar 2005;39(3):433-440.
382. Oldenmenger WH, Sillevs Smitt PAE, Van Montfort CAGM, De Raaf PJ, Van Der Rijt CCD. A combined pain consultation and pain education program decreases average and current pain and decreases interference in daily life by pain in oncology outpatients: A randomized controlled trial. *Pain*. 2011;152(11):2632-2639.
383. Olney SJ, Nymark J, Brouwer B, et al. A randomized controlled trial of supervised versus unsupervised exercise programs for ambulatory stroke survivors. *Stroke*. 2006;37(2):476-481.
384. Omranifard V, Karahmadi M, Jannesari Z, Maracy M. Efficacy of modified compliance therapy for schizophrenia patients. *Journal of Research in Medical Sciences*. 2012;17(SUPPL.2):S258-S263.
385. Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women's Intervention Trial for Coronary Heart Disease (SWITCHD). *Circulation. Cardiovascular quality and outcomes*. Jan 2009;2(1):25-32.
386. O'Shea E, Devane D, Cooney A, et al. The impact of reminiscence on the quality of life of residents with dementia in long-stay care. *International journal of geriatric psychiatry*. 2014;29(10):1062-1070.
387. Osteras N, Hagen KB, Grotle M, Sand-Svartrud AL, Mowinckel P, Kjekken I. Limited effects of exercises in people with hand osteoarthritis: Results from a randomized controlled trial. *Osteoarthritis and Cartilage*. 2014;22(9):1224-1233.
388. Oxman TE, Hegel MT, Hull JG, Dietrich AJ. Problem-solving treatment and coping styles in primary care for minor depression. *Journal of consulting and clinical psychology*. Dec 2008;76(6):933-943. Pmc2593861:

389. Pacella ML, Armelie A, Boarts J, et al. The impact of prolonged exposure on PTSD symptoms and associated psychopathology in people living with HIV: a randomized test of concept. *AIDS and behavior*. Jul 2012;16(5):1327-1340.
390. Papaioannou A, Adachi JD, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. *Osteoporosis International*. 2003;14(8):677-682.
391. Parker JC, Smarr KL, Slaughter JR, et al. Management of Depression in Rheumatoid Arthritis: A Combined Pharmacologic and Cognitive-Behavioral Approach. *Arthritis Care and Research*. 2003;49(6):766-777.
392. Parry GD, Cooper CL, Moore JM, et al. Cognitive behavioural intervention for adults with anxiety complications of asthma: prospective randomised trial. *Respiratory medicine*. Jun 2012;106(6):802-810.
393. Passalacqua R, Caminiti C, Campione F, et al. Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients. *Journal of Clinical Oncology*. 2009;27(11):1794-1799.
394. Patterson TL, Shaw WS, Semple SJ. Reducing the sexual risk behaviors of HIV+ individuals: Outcome of a randomized controlled trial. *Annals of Behavioral Medicine*. 2003;25(2):137-145.
395. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. *Journal of acquired immune deficiency syndromes (1999)*. Oct 1 2007;46(2):238-244. Pmc4044044:
396. Penckofer SM, Ferrans C, Mumby P, et al. A psychoeducational intervention (SWEEP) for depressed women with diabetes. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*. Oct 2012;44(2):192-206. Pmc3682680:
397. Penedo FJD, J. R.:Molton, I.:Gonzalez, J. S.:Kinsinger, D.:Roos, B. A.:Carver, C. S.:Schneiderman, N.:Antoni, M. H. Cognitive-behavioral stress management improves stress-management skills and quality of life in men recovering from treatment of prostate carcinoma. *Cancer*. Jan 1 2004;100(1):192-200.
398. Perini S, Titov N, Andrews G. Clinician-assisted Internet-based treatment is effective for depression: randomized controlled trial. *The Australian and New Zealand journal of psychiatry*. Jun 2009;43(6):571-578.
399. Perneger TV, S, P.:Muntner, P.:Uldry, C.:Courteheuse, C.:Naef, A. F.:Jacquemet, S.:Nicod, L.:Rochat, T.:Assal, J. P. Effect of patient education on self-management skills and health status in patients with asthma: a randomized trial. *The American journal of medicine*. Jul 2002;113(1):7-14.
400. Petrie KJ, I.:Thomas, M. G.:Booth, R. J.:Pennebaker, J. W. Effect of written emotional expression on immune function in patients with human immunodeficiency virus infection: a randomized trial. *Psychosomatic medicine*. Mar-Apr 2004;66(2):272-275.
401. Phillips R, Schneider J, Molosankwe I, et al. Randomized controlled trial of computerized cognitive behavioural therapy for depressive symptoms: effectiveness and costs of a workplace intervention. *Psychol Med*. Mar 2014;44(4):741-752. Pmc3898729:
402. Pollack MH, Penava SA, Bolton E, et al. A novel cognitive-behavioral approach for treatment-resistant drug dependence. *Journal of substance abuse treatment*. 2002;23(4):335-342.
403. Poorkiani M, Abbaszadeh A, Hazrati M, Jafari P, Sadeghi M, Mohammadianpanah M. The effect of rehabilitation on quality of life in female breast cancer survivors in Iran. *Indian Journal of Medical and Paediatric Oncology*. 2010;31(4):105-109.
404. Pozehl B, Duncan K, Krueger S, VerMaas P. Adjunctive effects of exercise training in heart failure patients receiving maximum pharmacologic therapy. *Progress in cardiovascular nursing*. 2003;18(4):177-183.

405. Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL. Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control. *Diabetes Technology and Therapeutics*. 2013;15(SUPPL.1):S65-S66.
406. Rabow MW, Dibble SL, Pantilat SZ, McPhee SJ. The Comprehensive Care Team: A Controlled Trial of Outpatient Palliative Medicine Consultation. *Archives of Internal Medicine*. 2004;164(1):83-91.
407. Rachmani R, Levi Z, Slavachevski I, Avin M, Ravid M. Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with Type 2 diabetes mellitus - A randomized prospective study. *Diabetic Medicine*. 2002;19(5):385-392.
408. Ramanath KV, Balaji DBSS, Nagakishore CH, Mahesh Kumar S, Bhanuprakash M. A study on impact of clinical pharmacist interventions on medication adherence and quality of life in rural hypertensive patients. *Journal of Young Pharmacists*. 2012;4(2):95-100.
409. Rao R, Cruz V, Peng Y, et al. Bootcamp during neoadjuvant chemotherapy for breast cancer: A randomized pilot trial. *Breast Cancer: Basic and Clinical Research*. 2012;6(1):39-46.
410. Rapp MA, Mell T, Majic T, et al. Agitation in nursing home residents with dementia (VIDEANT trial): effects of a cluster-randomized, controlled, guideline implementation trial. *Journal of the American Medical Directors Association*. Sep 2013;14(9):690-695.
411. Ravaud EP, Flipo RM, Boutron I, et al. ARTIST (osteoarthritis intervention standardized) study of standardised consultation versus usual care for patients with osteoarthritis of the knee in primary care in France: Pragmatic randomised controlled trial. *BMJ (Online)*. 2009;338(7696).
412. Ravaud PG, B.:Logeart, I.:Larguier, J. S.:Rolland, D.:Treves, R.:Euller-Ziegler, L.:Bannwarth, B.:Dougados, M. Management of osteoarthritis (OA) with an unsupervised home based exercise programme and/or patient administered assessment tools. A cluster randomised controlled trial with a 2x2 factorial design. *Annals of the rheumatic diseases*. Jun 2004;63(6):703-708. Pmc1755039:
413. Rawl SM, Given BA, Given CW, et al. Intervention to improve psychological functioning for newly diagnosed patients with cancer. *Oncology nursing forum*. 2002;29(6):967-975.
414. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. *Addiction (Abingdon, England)*. Feb 2006;101(2):267-274.
415. Rawson RAH, A.:McCann, M.:Shoptaw, S.:Farabee, D.:Reiber, C.:Ling, W. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. *Arch Gen Psychiatry*. Sep 2002;59(9):817-824.
416. Rawson RAM-C, P.:Anglin, M. D.:Dickow, A.:Frazier, Y.:Gallagher, C.:Galloway, G. P.:Herrell, J.:Huber, A.:McCann, M. J.:Obert, J.:Pennell, S.:Reiber, C.:Vandersloot, D.:Zweben, J. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. *Addiction (Abingdon, England)*. Jun 2004;99(6):708-717.
417. Rea HM, S.:Stewart, A.:Lamont, C.:Roseman, P.:Didsbury, P. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. *Internal medicine journal*. Nov 2004;34(11):608-614.
418. Ream E, Richardson A, Alexander-Dann C. Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial. *Journal of pain and symptom management*. Feb 2006;31(2):148-161.
419. Redzuan NS, Engkasan JP, Mazlan M, Freddy Abdullah SJ. Effectiveness of a video-based therapy program at home after acute stroke: A randomized controlled trial. *Archives of Physical Medicine and Rehabilitation*. 2012;93(12):2177-2183.

420. Reid SC, Teesson M, Sannibale C, Matsuda M, Haber PS. The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial. *Journal of studies on alcohol*. Nov 2005;66(6):833-841.
421. Reif K, de Vries U, Petermann F, Gorres S. A patient education program is effective in reducing cancer-related fatigue: a multi-centre randomised two-group waiting-list controlled intervention trial. *European journal of oncology nursing : the official journal of European Oncology Nursing Society*. Apr 2013;17(2):204-213.
422. Rejeski WJ, Focht BC, Messier SP, Morgan T, Pahor M, Penninx B. Obese, older adults with knee osteoarthritis: Weight loss, exercise, and quality of life. *Health Psychology*. 2002;21(5):419-426.
423. Reynolds NR, Testa MA, Su M, et al. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. *Journal of acquired immune deficiency syndromes (1999)*. Jan 1 2008;47(1):62-68.
424. Rickheim PLW, T. W.:Flader, J. L.:Kendall, D. M. Assessment of group versus individual diabetes education: a randomized study. *Diabetes care*. Feb 2002;25(2):269-274.
425. Rickhi B, Moritz S, Reesal R, et al. A spirituality teaching program for depression: a randomized controlled trial. *Int J Psychiatry Med*. 2011;42(3):315-329.
426. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: Pilot study of an antiretroviral adherence intervention. *Journal of general internal medicine*. 2000;15(12):841-847.
427. Rodrigue JR, Mandelbrot DA, Pavlakis M. A psychological intervention to improve quality of life and reduce psychological distress in adults awaiting kidney transplantation. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. Feb 2011;26(2):709-715. Pmc3108357:
428. Rogers LQ, Hopkins-Price P, Vicari S, et al. A randomized trial to increase physical activity in breast cancer survivors. *Medicine and science in sports and exercise*. Apr 2009;41(4):935-946.
429. Rosal MC, Ockene IS, Restrepo A, et al. Randomized trial of a literacy-sensitive, culturally tailored diabetes self-management intervention for low-income latinos: latinos en control. *Diabetes care*. Apr 2011;34(4):838-844. Pmc3064037:
430. Ross CJ, Davis TM, MacDonald GF. Cognitive-behavioral treatment combined with asthma education for adults with asthma and coexisting panic disorder. *Clinical nursing research*. May 2005;14(2):131-157.
431. Rost K, Nutting P, Smith JL, Elliott CE, Dickinson M. Managing depression as a chronic disease: A randomised trial of ongoing treatment in primary care. *British Medical Journal*. 2002;325(7370):934-937.
432. Rupp CI, Kemmler G, Kurz M, Hinterhuber H, Wolfgang Fleischhacker W. Cognitive remediation therapy during treatment for alcohol dependence. *Journal of Studies on Alcohol and Drugs*. 2012;73(4):625-634.
433. Ruskin PES-A, M.:Kling, M. A.:Reed, S. A.:Bradham, D. D.:Hebel, J. R.:Barrett, D.:Knowles, F., 3rd:Hauser, P. Treatment outcomes in depression: comparison of remote treatment through telepsychiatry to in-person treatment. *The American journal of psychiatry*. Aug 2004;161(8):1471-1476.
434. Rygg LO, Rise MB, Gronning K, Steinsbekk A. Efficacy of ongoing group based diabetes self-management education for patients with type 2 diabetes mellitus. A randomised controlled trial. *Patient education and counseling*. Jan 2012;86(1):98-105.
435. Sabzmakan L, Hazavehei S, Morowatisharifabad M, Hasanzadeh A, Rabiee K, Sadeqi M. The effects of a PRECEDE-based educational program on depression, general health, and quality of life of coronary artery bypass grafting patients. *Asian Journal of Psychiatry*. 2010;3(2):79-83.

436. Sacks S, Chaple M, Sacks JY, McKendrick K, Cleland CM. Randomized trial of a reentry modified therapeutic community for offenders with co-occurring disorders: crime outcomes. *Journal of substance abuse treatment*. Apr 2012;42(3):247-259.
437. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. *Journal of consulting and clinical psychology*. Jun 2012;80(3):404-415. Pmc3365619:
438. Salacinski AJ, Kelly K, Sco FL, Megan LH, Kathryn I, Gregory M. The effects of group cycling on gait and pain-related disability in individuals with mild-to-moderate knee osteoarthritis: A randomized controlled trial. *Journal of Orthopaedic and Sports Physical Therapy*. 2012;42(12):985-995.
439. Salvetti MX, Oliveira AJ, Servantes MD, Vincenzo de Paola AA. How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease. *Clinical rehabilitation*. 2008;22(10-11):987-996.
440. Samet JH, Horton NJ, Meli S, et al. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. *Antiviral Therapy*. 2005;10(1):83-93.
441. Sawka AM, Straus S, Rotstein L, et al. Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Aug 10 2012;30(23):2906-2911.
442. Schleicher HE, Harris KJ, Campbell DG, Harrar SW. Mood management intervention for college smokers with elevated depressive symptoms: a pilot study. *Journal of American college health : J of ACH*. 2012;60(1):37-45. Pmc3373255:
443. Schlenk EA, Lias JL, Sereika SM, Dunbar-Jacob J, Kwok CK. Improving physical activity and function in overweight and obese older adults with osteoarthritis of the knee: a feasibility study. *Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses*. Jan-Feb 2011;36(1):32-42. Pmc3052988:
444. Schmaling KB, Blume AW, Afari N. A randomized controlled pilot study of motivational interviewing to change attitudes about adherence to medications for asthma. *Journal of Clinical Psychology in Medical Settings*. 2001;8(3):167-172.
445. Schmitz JM, Averill P, Sayre S, McCleary P, Moeller FG, Swann A. Cognitive-behavioral treatment of bipolar disorder and substance abuse: A preliminary randomized study. *Addictive Disorders and their Treatment*. 2002;1(1):17-24.
446. Schroeder K, Fahey T, Hollinghurst S, Peters TJ. Nurse-led adherence support in hypertension: a randomized controlled trial. *Family practice*. Apr 2005;22(2):144-151.
447. Secades-Villa R, Garcia-Rodriguez O, Higgins ST, Fernandez-Hermida JR, Carballo JL. Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: six-month outcomes. *Journal of substance abuse treatment*. Mar 2008;34(2):202-207.
448. Secades-Villa RF-H, J. R.:Arnaez-Montaraz, C. Motivational interviewing and treatment retention among drug user patients: a pilot study. *Substance use & misuse*. Jul 2004;39(9):1369-1378.
449. Sees KL, Delucchi KL, Masson C, Hall SM. Methadone maintenance was more effective for treatment retention for opioid dependence than psychosocially enriched detoxification. *Evidence-Based Medicine*. 2000;5(6):180.
450. Sen AP, Sewell TB, Riley EB, et al. Financial incentives for home-based health monitoring: a randomized controlled trial. *Journal of general internal medicine*. May 2014;29(5):770-777. Pmc4000326:
451. Sengupta S, Lo B, Strauss RP, Eron J, Gifford AL. Pilot study demonstrating effectiveness of targeted education to improve informed consent understanding in AIDS clinical trials. *AIDS care*. Nov 2011;23(11):1382-1391. Pmc3205427:

452. Serrani Azcurra DJ. A reminiscence program intervention to improve the quality of life of long-term care residents with Alzheimer's disease: a randomized controlled trial. *Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)*. Dec 2012;34(4):422-433.
453. Serrano JP, Latorre JM, Gatz M, Montanes J. Life review therapy using autobiographical retrieval practice for older adults with depressive symptomatology. *Psychology and Aging*. 2004;19(2):272-277.
454. Sharma VK, Das S, Mondal S, Goswami U, Gandhi A. Effect of Sahaj Yoga on neuro-cognitive functions in patients suffering from major depression. *Indian journal of physiology and pharmacology*. Oct-Dec 2006;50(4):375-383.
455. Sharpe L, Schrieber L. A blind randomized controlled trial of cognitive versus behavioral versus cognitive-behavioral therapy for patients with rheumatoid arthritis. *Psychother Psychosom*. 2012;81(3):145-152.
456. Shea S, Weinstock RS, Teresi JA, et al. A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. *Journal of the American Medical Informatics Association*. 2009;16(4):446-456.
457. Shearer NB, Cisar N, Greenberg EA. A telephone-delivered empowerment intervention with patients diagnosed with heart failure. *Heart & lung : the journal of critical care*. May-Jun 2007;36(3):159-169.
458. Shelledy DC, Legrand TS, Gardner DD, Peters JJ. A randomized, controlled study to evaluate the role of an in-home asthma disease management program provided by respiratory therapists in improving outcomes and reducing the cost of care. *The Journal of asthma : official journal of the Association for the Care of Asthma*. Mar 2009;46(2):194-201.
459. Shet A, De Costa A, Kumarasamy N, et al. Effect of mobile telephone reminders on treatment outcome in HIV: Evidence from a randomised controlled trial in India. *BMJ (Online)*. 2014;349.
460. Shi Q, Ostwald SK, Wang S. Improving glycaemic control self-efficacy and glycaemic control behaviour in Chinese patients with type 2 diabetes mellitus: randomised controlled trial. *Journal of clinical nursing*. Feb 2010;19(3-4):398-404.
461. Shirai Y, Fujimori M, Ogawa A, et al. Patients' perception of the usefulness of a question prompt sheet for advanced cancer patients when deciding the initial treatment: a randomized, controlled trial. *Psycho-oncology*. Jul 2012;21(7):706-713.
462. Shrier I, Zukor D, Boivin JF, et al. The feasibility of a randomized trial using a progressive exercise program in patients with severe hip osteoarthritis. *Journal of Musculoskeletal Pain*. 2008;16(4):309-317.
463. Sibitz I, Amering M, Gossler R, Unger A, Katschnig H. One-year outcome of low-intensity booster sessions versus care as usual in psychosis patients after a short-term psychoeducational intervention. *European psychiatry : the journal of the Association of European Psychiatrists*. May 2007;22(4):203-210.
464. Siddique HH, Olson RH, Parenti CM, et al. Randomized trial of pragmatic education for low-risk COPD patients: impact on hospitalizations and emergency department visits. *International journal of chronic obstructive pulmonary disease*. 2012;7:719-728. Pmc3484530:
465. Sikkema KJ, Hansen NB, Kochman A, Tate DC, Difrancesco W. Outcomes from a randomized controlled trial of a group intervention for HIV positive men and women coping with AIDS-related loss and bereavement. *Death Studies*. 2004;28(3):187-209.
466. Sikorskii A, Given CW, Given B, et al. Symptom management for cancer patients: a trial comparing two multimodal interventions. *Journal of pain and symptom management*. Sep 2007;34(3):253-264. Pmc2043403:
467. Silverman KS, D.:Wong, C. J.:Hampton, J.:Stitzer, M. L.:Bigelow, G. E. A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. *Experimental and clinical psychopharmacology*. Aug 2002;10(3):228-240.

468. Silvers MA, Savva J, Huggins CE, Truby H, Haines T. Potential benefits of early nutritional intervention in adults with upper gastrointestinal cancer: a pilot randomised trial. *Supportive Care in Cancer*. 2014;22(11):3035-3044.
469. Simoni JM, Chen WT, Huh D, et al. A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China. *AIDS and behavior*. Jul 2011;15(5):919-929. Pmc3583199:
470. Simpson J, Mapel T. An investigation into the health benefits of mindfulness-based stress reduction (MBSR) for people living with a range of chronic physical illnesses in New Zealand. *The New Zealand medical journal*. Jul 8 2011;124(1338):68-75.
471. Sloman R. Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. *Cancer nursing*. 2002;25(6):432-435.
472. Smeulders ES, van Haastregt JC, Ambergen T, Janssen-Boyne JJ, van Eijk JT, Kempen GI. The impact of a self-management group programme on health behaviour and healthcare utilization among congestive heart failure patients. *European journal of heart failure*. Jun 2009;11(6):609-616.
473. Smith PM, Burgess E. Smoking cessation initiated during hospital stay for patients with coronary artery disease: a randomized controlled trial. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. Jun 23 2009;180(13):1297-1303. Pmc2696525:
474. Smith SM, Paul G, Kelly A, Whitford DL, O'Shea E, O'Dowd T. Peer support for patients with type 2 diabetes: cluster randomised controlled trial. *BMJ (Clinical research ed.)*. 2011;342:d715. Pmc3039437:
475. Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication self-management program to improve adherence to HIV therapy regimens. *Patient education and counseling*. 2003;50(2):187-199.
476. Sobell LCS, M. B.:Leo, G. I.:Agrawal, S.:Johnson-Young, L.:Cunningham, J. A. Promoting self-change with alcohol abusers: a community-level mail intervention based on natural recovery studies. *Alcoholism, clinical and experimental research*. Jun 2002;26(6):936-948.
477. Sohn AJ, Hasnain M, Sinacore JM. Impact of exercise (walking) on blood pressure levels in African American adults with newly diagnosed hypertension. *Ethnicity & disease*. Summer 2007;17(3):503-507.
478. Sondergaard E, Moller JE, Egstrup K. Effect of dietary intervention and lipid-lowering treatment on brachial vasoreactivity in patients with ischemic heart disease and hypercholesterolemia. *American heart journal*. 2003;145(5):E19.
479. Song R, Lee EO, Lam P, Bae SC. Effects of tai chi exercise on pain, balance, muscle strength, and perceived difficulties in physical functioning in older women with osteoarthritis: A randomized clinical trial. *Journal of Rheumatology*. 2003;30(9):2039-2044.
480. Song R, Roberts BL, Lee EO, Lam P, Bae SC. A randomized study of the effects of t'ai chi on muscle strength, bone mineral density, and fear of falling in women with osteoarthritis. *Journal of alternative and complementary medicine (New York, N.Y.)*. Mar 2010;16(3):227-233.
481. Sorensen JL, Dilley J, London J, Okin RL, Delucchi KL, Phibbs CS. Case management for substance abusers with HIV/AIDS: A randomized clinical trial. *American Journal of Drug and Alcohol Abuse*. 2003;29(1):133-150.
482. Sorensen JL, Haug NA, Delucchi KL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. *Drug and alcohol dependence*. Apr 17 2007;88(1):54-63. Pmc1976289:
483. Sorensen JL, Masson CL, Delucchi K, et al. Randomized trial of drug abuse treatment-linkage strategies. *Journal of consulting and clinical psychology*. Dec 2005;73(6):1026-1035.
484. Spencer MS, Rosland AM, Kieffer EC, et al. Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled trial. *American journal of public health*. Dec 2011;101(12):2253-2260. Pmc3222418:

485. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. *Cancer*. Sep 1 2007;110(5):1130-1138.
486. Stahler GJ, Kirby KC, Kerwin ME. A faith-based intervention for cocaine-dependent Black women. *Journal of psychoactive drugs*. Jun 2007;39(2):183-190.
487. Stanton AL, Ganz PA, Kwan L, et al. Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Sep 1 2005;23(25):6009-6018.
488. Startup M, Jackson MC, Bendix S. North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: Outcomes at 6 and 12 months. *Psychological Medicine*. 2004;34(3):413-422.
489. Stein MD, Solomon DA, Herman DS, et al. Pharmacotherapy Plus Psychotherapy for Treatment of Depression in Active Injection Drug Users. *Archives of General Psychiatry*. 2004;61(2):152-159.
490. Steinberg M, Leoutsakos JM, Podewils LJ, Lyketsos CG. Evaluation of a home-based exercise program in the treatment of Alzheimer's disease: the Maximizing Independence in Dementia (MIND) study. *International journal of geriatric psychiatry*. Jul 2009;24(7):680-685.
491. Steven J, Simpson A, Carlson LE, Trew ME. Effect of group therapy for breast cancer on healthcare utilization. *Cancer Practice*. 2001;9(1):19-26.
492. Stewart A, Noakes T, Eales C, Shepard K, Becker P, Veriawa Y. Adherence to cardiovascular risk factor modification in patients with hypertension. *Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners*. Mar-Apr 2005;16(2):102-107.
493. Stiegelis HEH, M.:Sanderman, R.:Bennenbroek, F. T.:Buunk, B. P.:van den Bergh, A. C.:Botke, G.:Ranchor, A. V. The impact of an informational self-management intervention on the association between control and illness uncertainty before and psychological distress after radiotherapy. *Psycho-oncology*. Apr 2004;13(4):248-259.
494. Stone RA, Rao RH, Sevick MA, et al. Active care management supported by home telemonitoring in veterans with type 2 diabetes: the DiaTel randomized controlled trial. *Diabetes care*. Mar 2010;33(3):478-484. Pmc2827492:
495. Subramaniam P, Woods B, Whitaker C. Life review and life story books for people with mild to moderate dementia: a randomised controlled trial. *Aging & mental health*. 2014;18(3):363-375. Pmc4017276:
496. Sun HW, Wang JP, Wang SZ, et al. Effect of educational and psychological intervention on the quality of life of asthmatic patients. *Respiratory care*. Jun 2010;55(6):725-728.
497. Sun J, Wang Y, Chen X, et al. An integrated intervention program to control diabetes in overweight Chinese women and men with type 2 diabetes. *Asia Pacific journal of clinical nutrition*. 2008;17(3):514-524.
498. Sundin OL, J.:Hofman-Bang, C.:Nygren, A.:Ryden, L.:Ohman, A. Comparing multifactorial lifestyle interventions and stress management in coronary risk reduction. *International journal of behavioral medicine*. 2003;10(3):191-204.
499. Suskin NG, Heigenhauser G, Afzal R, Finegood D, Gerstein HC, McKelvie RS. The effects of exercise training on insulin resistance in patients with coronary artery disease. *European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology*. Dec 2007;14(6):803-808.

500. Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. *The journal of supportive oncology*. May-Jun 2009;7(3):101-107.
501. Swindle RW, Rao JK, Helmy A, et al. Integrating clinical nurse specialists into the treatment of primary care patients with depression. *International Journal of Psychiatry in Medicine*. 2003;33(1):17-37.
502. Szapocznik JF, D. J.:Mitrani, V. B.:Prado, G.:Smith, L.:Robinson-Batista, C.:Schwartz, S. J.:Mauer, M. H.:Robbins, M. S. Structural ecosystems therapy for HIV-seropositive African American women: effects on psychological distress, family hassles, and family support. *Journal of consulting and clinical psychology*. Apr 2004;72(2):288-303. Pmc1480817:
503. Tavakolizadeh J, Moghadas M, Ashraf H. Effect of self-regulation training on management of type 2 diabetes. *Iranian Red Crescent Medical Journal*. 2014;16(4).
504. Taylor CB, Miller NH, Reilly KR, et al. Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. *Diabetes care*. 2003;26(4):1058-1063.
505. Taylor KL, Lamdan RM, Siegel JE, Shelby R, Moran-Klimi K, Hrywna M. Psychological adjustment among African American breast cancer patients: One-year follow-up results of a randomized psychoeducational group intervention. *Health Psychology*. 2003;22(3):316-323.
506. Taylor SJC, Sohanpal R, Bremner SA, et al. Self-management support for moderate-to-severe chronic obstructive pulmonary disease: A pilot randomised controlled trial. *British Journal of General Practice*. 2012;62(603):e687-e695.
507. Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. *Journal of consulting and clinical psychology*. 2000;68(4):615-623.
508. Templeton HC, V. Evaluation of an evidence-based education package for men with prostate cancer on hormonal manipulation therapy. *Patient education and counseling*. Oct 2004;55(1):55-61.
509. The California Medi-Cal Type 2 Diabetes Study Group. Closing the gap: effect of diabetes case management on glycemic control among low-income ethnic minority populations: the California Medi-Cal type 2 diabetes study. *Diabetes care*. Jan 2004;27(1):95-103.
510. Theander K, Jakobsson P, Jorgensen N, Unosson M. Effects of pulmonary rehabilitation on fatigue, functional status and health perceptions in patients with chronic obstructive pulmonary disease: a randomized controlled trial. *Clinical rehabilitation*. Feb 2009;23(2):125-136.
511. Thoolen BJ, Ridder DD, Bensing J, Gorter K, Rutten G. Beyond good intentions: The role of proactive coping in achieving sustained behavioural change in the context of diabetes management. *Psychology and Health*. 2009;24(3):237-254.
512. Toobert DJ, Glasgow RE, Radcliffe JL. Physiologic and related behavioral outcomes from the women's lifestyle heart trial. *Annals of Behavioral Medicine*. 2000;22(1):1-9.
513. Toobert DJ, Glasgow RE, Strycker LA, et al. Biologic and quality-of-life outcomes from the Mediterranean Lifestyle Program: A randomized clinical trial. *Diabetes care*. 2003;26(8):2288-2293.
514. Torres HC, Franco LJ, Stradioto MA, Hortale VA, Schall VT. Evaluation of group and individual strategies in a diabetes education program. *Revista de saúde pública*. 2009;43(2):291-298.
515. Toth SL, Rogosch FA, Oshri A, Gravener-Davis J, Sturm R, Morgan-Lopez AA. The efficacy of interpersonal psychotherapy for depression among economically disadvantaged mothers. *Development and psychopathology*. Nov 2013;25(4 Pt 1):1065-1078. Pmc3826873:
516. Traeger L, Penedo FJ, Benedict C, et al. Identifying how and for whom cognitive-behavioral stress management improves emotional well-being among recent prostate cancer survivors. *Psycho-oncology*. Feb 2013;22(2):250-259.

517. Trento M, Basile M, Borgo E, et al. A randomised controlled clinical trial of nurse-, dietitian- and pedagogist-led Group Care for the management of Type 2 diabetes. *Journal of endocrinological investigation*. Nov 2008;31(11):1038-1042.
518. Trento M, Passera P, Borgo E, et al. A 5-Year Randomized Controlled Study of Learning, Problem Solving Ability, and Quality of Life Modifications in People with Type 2 Diabetes Managed by Group Care. *Diabetes care*. 2004;27(3):670-675.
519. Tsang HWH, Mok CK, Au Yeung YT, Chan SYC. The effect of Qigong on general and psychosocial health of elderly with chronic physical illnesses: A randomized clinical trial. *International journal of geriatric psychiatry*. 2003;18(5):441-449.
520. Tsuyuki RT, Fradette M, Johnson JA, et al. A multicenter disease management program for hospitalized patients with heart failure. *Journal of Cardiac Failure*. 2004;10(6):473-480.
521. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). *Archives of Internal Medicine*. 2002;162(10):1149-1155.
522. Tuldra A, Fumaz CR, Ferrer Ma J, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes*. 2000;25(3):221-228.
523. Turner BJ, Hollenbeak CS, Liang Y, Pandit K, Joseph S, Weiner MG. A randomized trial of peer coach and office staff support to reduce coronary heart disease risk in African-Americans with uncontrolled hypertension. *Journal of general internal medicine*. Oct 2012;27(10):1258-1264. Pmc3445668:
524. Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: A randomized controlled trial. *Journal of the American Medical Association*. 2002;288(22):2836-2845.
525. Vale MJJ, M. V.:Best, J. D.:Santamaria, J. D. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world"--randomized controlled trial. *Journal of clinical epidemiology*. Mar 2002;55(3):245-252.
526. Vallance JKH, Courneya KS, Plotnikoff RC, Yasui Y, Mackey JR. Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. *Journal of Clinical Oncology*. 2007;25(17):2352-2359.
527. van den Berg-Emons RB, A.:Bussmann, H.:Stam, H. Does aerobic training lead to a more active lifestyle and improved quality of life in patients with chronic heart failure? *European journal of heart failure*. Jan 2004;6(1):95-100.
528. Van der Gaag M, Kern RS, Van den Bosch RJ, Liberman RP. A controlled trial of cognitive remediation in schizophrenia. *Schizophrenia bulletin*. 2002;28(1):167-176.
529. van der Lee ML, Garssen B. Mindfulness-based cognitive therapy reduces chronic cancer-related fatigue: a treatment study. *Psycho-oncology*. Mar 2012;21(3):264-272.
530. Van Der Palen J, Klein JJ, Zielhuis GA, Van Herwaarden CLA, Seydel ER. Behavioural effect of self-treatment guidelines in a self-management program for adults with asthma. *Patient education and counseling*. 2001;43(2):161-169.
531. van der Peet EH, van den Beuken-van Everdingen MH, Patijn J, Schouten HC, van Kleef M, Courtens AM. Randomized clinical trial of an intensive nursing-based pain education program for cancer outpatients suffering from pain. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. Aug 2009;17(8):1089-1099. Pmc2707949:
532. van der Pompe GA, M. H.:Duivenvoorden, H. J.:de Graeff, A.:Simonis, R. F.:van der Vegt, S. G.:Heijnen, C. J. An exploratory study into the effect of group psychotherapy on cardiovascular and

- immunoreactivity to acute stress in breast cancer patients. *Psychother Psychosom.* Nov-Dec 2001;70(6):307-318.
533. van Marwijk HW, Ader H, de Haan M, Beekman A. Primary care management of major depression in patients aged > or =55 years: outcome of a randomised clinical trial. *The British journal of general practice : the journal of the Royal College of General Practitioners.* Oct 2008;58(555):680-686, I-II; discussion 687. Pmc2553526:
534. van Middendorp H, Sorbi MJ, van Doornen LJ, Bijlsma JW, Geenen R. Feasibility and induced cognitive-emotional change of an emotional disclosure intervention adapted for home application. *Patient education and counseling.* May 2007;66(2):177-187.
535. Van Os JA, A. C.:Bobes, J.:Gerlach, J.:Hellewell, J. S.:Kasper, S.:Naber, D.:Robert, P. Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. *The British journal of psychiatry : the journal of mental science.* Jan 2004;184:79-83.
536. van Vugt MK, Hitchcock P, Shahar B, Britton W. The effects of mindfulness-based cognitive therapy on affective memory recall dynamics in depression: A mechanistic model of rumination. *Frontiers in Human Neuroscience.* 2012(SEPTEMBER).
537. Velligan D, Mintz J, Maples N, et al. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. *Schizophrenia bulletin.* Sep 2013;39(5):999-1007. Pmc3756784:
538. Velligan DI, Bow-Thomas CC, Huntzinger C, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. *American Journal of Psychiatry.* 2000;157(8):1317-1323.
539. Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. *Schizophrenia bulletin.* May 2008;34(3):483-493. Pmc2632420:
540. Venmans LM, Gorter KJ, Baard KP, Rutten GE, Hak E. Acceptability and effects of an educational leaflet on infections in type 2 diabetes patients: a randomized controlled trial in primary care. *Primary care diabetes.* Sep 2007;1(3):135-142.
541. Villeneuve J, Genest J, Blais L, et al. A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.* Mar 23 2010;182(5):447-455. Pmc2842856:
542. Vitriol VG, Ballesteros ST, Florenzano RU, Weil KP, Benadof DF. Evaluation of an outpatient intervention for women with severe depression and a history of childhood trauma. *Psychiatric services (Washington, D.C.).* Jul 2009;60(7):936-942.
543. Vollmer WM, Feldstein A, Smith DH, et al. Use of health information technology to improve medication adherence. *The American journal of managed care.* Dec 2011;17(12 Spec No.):Sp79-87. Pmc3641901:
544. Volpicelli JR, Markman I, Monterosso J, Filing J, O'Brien CP. Psychosocially enhanced treatment for cocaine-dependent mothers: Evidence of efficacy. *Journal of substance abuse treatment.* 2000;18(1):41-49.
545. Vos PJ, Visser AP, Garssen B, Duivenvoorden HJ, de Haes HC. Effectiveness of group psychotherapy compared to social support groups in patients with primary, non-metastatic breast cancer. *Journal of psychosocial oncology.* 2007;25(4):37-60.
546. Vrijhoef HJ, Van Den Bergh JH, Diederiks JP, Weemhoff I, Spreeuwenberg C. Transfer of care for outpatients with stable chronic obstructive pulmonary disease from respiratory care physician to respiratory nurse--a randomized controlled study. *Chronic illness.* Jun 2007;3(2):130-144.

547. Vyas A, Haidery AZ, Wiles PG, Gill S, Roberts C, Cruickshank JK. A pilot randomized trial in primary care to investigate and improve knowledge, awareness and self-management among South Asians with diabetes in Manchester. *Diabetic Medicine*. 2003;20(12):1022-1026.
548. Waalen J, Bruning AL, Peters MJ, Blau EM. A telephone-based intervention for increasing the use of osteoporosis medication: a randomized controlled trial. *The American journal of managed care*. Aug 2009;15(8):e60-70.
549. Wagner EH, Ludman EJ, Aiello Bowles EJ, et al. Nurse navigators in early cancer care: a randomized, controlled trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Jan 1 2014;32(1):12-18. Pmc3867643:
550. Wagner GJ, Kanouse DE, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). *AIDS (London, England)*. Jun 12 2006;20(9):1295-1302.
551. Wakabayashi R, Motegi T, Yamada K, et al. Efficient integrated education for older patients with chronic obstructive pulmonary disease using the Lung Information Needs Questionnaire. *Geriatrics & gerontology international*. Oct 2011;11(4):422-430.
552. Wakefield M, Olver I, Whitford H, Rosenfeld E. Motivational interviewing as a smoking cessation intervention for patients with cancer: Randomized controlled trial. *Nursing research*. 2004;53(6):396-405.
553. Walker EA, Schechter CB, Caban A, Basch CE. Telephone intervention to promote diabetic retinopathy screening among the urban poor. *American journal of preventive medicine*. Mar 2008;34(3):185-191. Pmc2272534:
554. Walker MS, Podbilewicz-Schuller Y. Video preparation for breast cancer treatment planning: results of a randomized clinical trial. *Psycho-oncology*. May 2005;14(5):408-420.
555. Wang PS, Simon GE, Avorn J, et al. Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. *Jama*. Sep 26 2007;298(12):1401-1411. Pmc2859667:
556. Ward S, Donovan H, Gunnarsdottir S, Serlin RC, Shapiro GR, Hughes S. A randomized trial of a representational intervention to decrease cancer pain (RIDcancerPain). *Health psychology : official journal of the Division of Health Psychology, American Psychological Association*. Jan 2008;27(1):59-67. Pmc2526464:
557. Washington OG. Using brief therapeutic interventions to create change in self-efficacy and personal control of chemically dependent women. *Archives of psychiatric nursing*. Feb 2001;15(1):32-40.
558. Watkins CL, Auton MF, Deans CF, et al. Motivational interviewing early after acute stroke: A randomized, controlled trial. *Stroke*. 2007;38(3):1004-1009.
559. Watson JCG, L. B.:Stermac, L.:Kalogerakos, F.:Steckley, P. Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression. *Journal of consulting and clinical psychology*. Aug 2003;71(4):773-781.
560. Weaver T, Metrebian N, Hellier J, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. *Lancet*. Jul 12 2014;384(9938):153-163.
561. Webb DR, Khunti K, Gray LJ, et al. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial. *Diabetic medicine : a journal of the British Diabetic Association*. Apr 2012;29(4):531-540.
562. Welch G, Zagarins SE, Feinberg RG, Garb JL. Motivational interviewing delivered by diabetes educators: does it improve blood glucose control among poorly controlled type 2 diabetes patients? *Diabetes research and clinical practice*. Jan 2011;91(1):54-60. Pmc3011053:

563. Welschen LMC, Bot SDM, Kostense PJ, et al. Effects of cardiovascular disease risk communication for patients with type 2 diabetes on risk perception in a randomized controlled trial: The @RISK study. *Diabetes care*. 2012;35(12):2485-2492.
564. Wengstrom Y, Haggmark C, Forsberg C. Coping with radiation therapy: effects of a nursing intervention on coping ability for women with breast cancer. *International journal of nursing practice*. 2001;7(1):8-15.
565. Wetzel H, Szegedi A, Scheurich A, et al. Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. *The Journal of clinical psychiatry*. 2004;65(10):1406-1413.
566. Wetzels R, van Weel C, Grol R, Wensing M. Family practice nurses supporting self-management in older patients with mild osteoarthritis: a randomized trial. *BMC family practice*. 2008;9:7. Pmc2235871:
567. Weymiller AJ, Montori VM, Jones LA, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: Statin choice randomized trial. *Archives of Internal Medicine*. 2007;167(10):1076-1082.
568. Whelan T, Levine M, Willan A, et al. Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: A randomized trial. *Journal of the American Medical Association*. 2004;292(4):435-441.
569. Whittemore R, Melkus GD, Sullivan A, Grey M. A nurse-coaching intervention for women with type 2 diabetes. *Diabetes Educator*. 2004;30(5):795-804.
570. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBaIT randomised controlled trial. *Lancet*. Feb 2 2013;381(9864):375-384.
571. Willemsse GRS, F.:Cuijpers, P.:Tiemens, B. G. Minimal-contact psychotherapy for sub-threshold depression in primary care. Randomised trial. *The British journal of psychiatry : the journal of mental science*. Nov 2004;185:416-421.
572. Williams C, Wilson P, Morrison J, et al. Guided Self-Help Cognitive Behavioural Therapy for Depression in Primary Care: A Randomised Controlled Trial. *PloS one*. 2013;8(1).
573. Williams JM, Steinberg ML, Zimmermann MH, et al. Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder. *Journal of substance abuse treatment*. Jun 2010;38(4):384-393. Pmc2859987:
574. Williams JMG, Crane C, Barnhofer T, et al. Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: A randomized dismantling trial. *Journal of consulting and clinical psychology*. 2014;82(2):275-286.
575. Williams Jr JW, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. *Journal of the American Medical Association*. 2000;284(12):1519-1526.
576. Williams M, Bowen A, Atkinson JS, et al. An assessment of brief group interventions to increase condom use by heterosexual crack smokers living with HIV infection. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV*. 2012;24(2):220-231.
577. Winkens I, Van Heugten CM, Wade DT, Habets EJ, Fasotti L. Efficacy of Time Pressure Management in Stroke Patients With Slowed Information Processing: A Randomized Controlled Trial. *Archives of Physical Medicine and Rehabilitation*. 2009;90(10):1672-1679.
578. Wolf AM, Conaway MR, Crowther JQ, et al. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. *Diabetes care*. 2004;27(7):1570-1576.

579. Wolff M, Sundquist K, Larsson Lonn S, Midlov P. Impact of yoga on blood pressure and quality of life in patients with hypertension - a controlled trial in primary care, matched for systolic blood pressure. *BMC cardiovascular disorders*. 2013;13:111. Pmc4029555:
580. Wong DF. Cognitive and health-related outcomes of group cognitive behavioural treatment for people with depressive symptoms in Hong Kong: randomized wait-list control study. *The Australian and New Zealand journal of psychiatry*. Aug 2008;42(8):702-711.
581. Wong KW, Wong FKY, Chan MF. Effects of nurse-initiated telephone follow-up on self-efficacy among patients with chronic obstructive pulmonary disease. *Journal of advanced nursing*. 2005;49(2):210-222.
582. Wong SY, Lau EM, Lau WW, Lynn HS. Is dietary counselling effective in increasing dietary calcium, protein and energy intake in patients with osteoporotic fractures? A randomized controlled clinical trial. *Journal of Human Nutrition and Dietetics*. 2004;17(4):359-364.
583. Woollard J, Burke V, Beilin LJ, Verheijden M, Bulsara MK. Effects of a general practice-based intervention on diet, body mass index and blood lipids in patients at cardiovascular risk. *Journal of Cardiovascular Risk*. 2003;10(1):31-40.
584. Worden BL, McCrady BS. Effectiveness of a feedback-based brief intervention to reduce alcohol use in community substance use disorders treatment. *Alcoholism Treatment Quarterly*. 2013;31(2):186-205.
585. Wu CJ, Chang AM, Courtney M, Kostner K. Peer supporters for cardiac patients with diabetes: a randomized controlled trial. *International nursing review*. Sep 2012;59(3):345-352.
586. Wyatt GK, Donze LF, Beckrow KC. Efficacy of an in-home nursing intervention following short-stay breast cancer surgery. *Research in Nursing and Health*. 2004;27(5):322-331.
587. Xue F, Yao W, Lewin RJ. A randomised trial of a 5 week, manual based, self-management programme for hypertension delivered in a cardiac patient club in Shanghai. *BMC cardiovascular disorders*. 2008;8:10. Pmc2412838:
588. Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Sep 1 2005;23(25):6027-6036.
589. Yates PE, H.:Nash, R.:Aranda, S.:Purdie, D.:Najman, J.:Skerman, H.:Walsh, A. A randomized controlled trial of a nurse-administered educational intervention for improving cancer pain management in ambulatory settings. *Patient education and counseling*. May 2004;53(2):227-237.
590. Yeh GY, McCarthy EP, Wayne PM, et al. Tai chi exercise in patients with chronic heart failure: A randomized clinical trial. *Archives of Internal Medicine*. 2011;171(8):750-757.
591. Yildirim YK, Cicek F, Uyar M. Effects of pain education program on pain intensity, pain treatment satisfaction, and barriers in Turkish cancer patients. *Pain management nursing : official journal of the American Society of Pain Management Nurses*. Dec 2009;10(4):220-228.
592. Yoo HJ, An HG, Park SY, et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. *Diabetes research and clinical practice*. Oct 2008;82(1):73-79.
593. Yoo HJ, Park MS, Kim TN, et al. A Ubiquitous Chronic Disease Care system using cellular phones and the internet. *Diabetic medicine : a journal of the British Diabetic Association*. Jun 2009;26(6):628-635.
594. Yoon KH, Kim HS. A short message service by cellular phone in type 2 diabetic patients for 12 months. *Diabetes research and clinical practice*. Feb 2008;79(2):256-261.
595. Zanjani F, Miller B, Turiano N, Ross J, Oslin D. Effectiveness of telephone-based referral care management, a brief intervention to improve psychiatric treatment engagement. *Psychiatric services (Washington, D.C.)*. Jul 2008;59(7):776-781.

596. Zedlitz AM, Rietveld TC, Geurts AC, Fasotti L. Cognitive and graded activity training can alleviate persistent fatigue after stroke: a randomized, controlled trial. *Stroke*. Apr 2012;43(4):1046-1051.
597. Zhang Y, Shen CL, Peck K, et al. Training self-administered acupressure exercise among postmenopausal women with osteoarthritic knee pain: A feasibility study and lessons learned. *Evidence-based Complementary and Alternative Medicine*. 2012;2012.
598. Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). *Journal of general internal medicine*. Dec 2005;20(12):1091-1096. Pmc1490290:
599. Zissiadis Y, Harper E, Kearney E. Impact of more intensive written information in patients having radical radiation therapy: results of a prospective randomized phase III trial. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. Aug 2010;96(2):254-258.
600. Ziv A, Vogel O, Keret D, et al. Comprehensive Approach to Lower Blood Pressure (CALM-BP): a randomized controlled trial of a multifactorial lifestyle intervention. *Journal of human hypertension*. Oct 2013;27(10):594-600. Pmc3775127:

7. Key informant information

Key informants contacted

Amy McQueen, PhD - Assistant Professor of Medicine, Division of Health Behavior Research, Washington University School of Medicine

Kate Wolin, ScD, FACSM - Coeus Health

Wendy Demark-Wahnefried, PhD, RD – Professor and Webb Endowed Chair of Nutrition Sciences, Associate Director, UAB Comprehensive Cancer Center, American Cancer Society Clinical Research Professor

Aimee James, PhD, MPH - Associate Professor, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine

Gary Bennett, PhD – Bishop-MacDermott Family Professor of Psychology, Global Health & Medicine, Duke University

Summary of comments

GENERAL COMMENTS

- Consider commenting on exclusion of behavioral trials that don't assess/report MCC (e.g. the number excluded, how excluded trials may have affected results)
 - Could include a flow chart diagramming screening process used and exclusions w/ reasons at each stage
- Note the varied ways comorbidity is measured → use broad inclusion of chronic conditions
- Consider how to capture exclusion of MCC based on safety issue for participation
- Does the inclusion/exclusion of MCC vary by PI experience? (e.g. clinicians more likely to include)
- Consider how MCC are reported (self-report, med record extracted/confirmed)

SPECIFIC COMMENTS

- Included Studies
 - Overall study characteristics
 - Diet = 5/day fruits & veggies
 - Adherence to disease management = medication adherence, glucose monitoring, etc
 - Include: cancer screening; vaccinations (non-cancer – flu, pneumonia, child)
 - Include: sample characteristics (i.e. if the study was amply powered); the duration of the trial; delivery of intervention (e.g. face-to-face, other, etc)
 - Consider how to handle intervention components directed a multiple behaviors
 - Summary stats
 - Detail & categorize: standard measures (y/n), scale vs. single item(s), objective vs. self-report, single vs. repeated assessment
 - Study quality summary
 - Classify studies
- Patient Eligibility and Selection
 - Exclusion criteria
 - Consider studies that exclude people with a “narrowed” version of targeted condition (e.g. cancer screening studies excluding people with history of cancer)
 - Consider effect of how specific conditions are identified/confirmed (e.g. self-report MCC)
 - Include cognitive limitations in mental illness category

- Make clear what trials are excluding specified “behavioral factors” (e.g. diabetes trial excluding smokers, not smoking cessation trial requiring everyone to be smokers)
- Include age upper bound in analysis & consider range and mean/mode of upper bound
- Participant screening
 - Consider that flow chart info etc may only be included in methods paper of studies
 - Organize presence of flow chart, specific # MCC exclusion, specific condition exclusion **by time**
- Study Participants
 - Consider self-report MCC in prevalence of reporting & be aware of studies using “count” system (e.g. 1 CC, 2 CC)
 - Of those reporting prevalence, consider recruitment approach
- Outcomes
 - Include: % including comorbidity in analysis at all & reporting and effect of comorbidity on outcomes (sig, not sig)
 - Sub-group analysis include when comorbidities “controlled” in model
- Additional Variables for Stratification
 - Stratification in general → consider setting?
 - Behavioral component of intervention → more specific criteria?
 - Funding source → add government & foundation; for non-industry differentiate b/w peer reviewed and non-peer reviewed
 - Quality of study
 - Analyze each of 6 bias variables independently and the aggregate score
 - Blinding of outcome assessment includes objective data

Individual Comments

AMY MCQUEEN

- General Comments
 - Many behavioral trials that don’t assess/report MCC → comment on how excluded trials may have affected results, the # excluded
 - Potential flow chart to include:
 - Number of articles reporting on an eligible RTC of a behavioral or psychosocial intervention
 - Number of those in #1 that include any assessment of co/multimorbidity
 - a. Number of those in #2 that report measuring it but don’t report using it in analyses, and provide no data on it
 - b. Number of those in #2 that assess it and exclude anyone with co/multimorbidity
 - c. Number of those in #2 that assess it and report it in descriptive results only (either for sample as a whole or by group)
 - d. Number of those in #2 that assess it and report its association with the intervention effect
 - Comorbidity measured in variety of ways → use broad inclusion of chronic conditions to get a multimorbidity & note differences between measures and definitions used in studies

- Specific Comments (re: preliminary results)
 - Included Studies
 - Overall study characteristics → diet = 5/day fruits & veggies; adherence = medication adherence, glucose monitoring, etc; include: cancer screening, vaccination (non-cancer – flu, pneumonia, child)
 - Summary stats → detail & categorize: standard measures (y/n), scale vs. single item(s), objective vs. self-report, single vs. repeated assessment
 - Study quality summary → classify studies
 - Patient Eligibility and Selection
 - Exclusion criteria
 - Narrow condition consider those that are cancer studies that exclude people with history of cancer & consider self-reporting MCC effect
 - Age exclusion → include range and mean/mode of the upper bound (consider upper bound age in guidelines when interpreting results)
 - Study Participants
 - Consider self-report MCC in prevalence of reporting
 - For prevalence → describe recruitment approach (non-random, random selection from list/registry; non-random, random selection from community; other)
 - Outcomes
 - Add % that include comorbidity info in analysis at all & % that report any effect of comorbidity on outcomes (summarize the effect: sig or not sig)
 - Additional Variables for Stratification
 - Behavioral component of intervention → Susan Michie’s taxonomy work
 - Funding source → add government & foundation
 - Quality of study → analyze each of 6 bias variables & aggregate score

KATE WOLIN

- General Comments
 - Some trials use “standard tool” (e.g. Physical Activity Readiness questionnaire) to establish eligibility → exclude MCC b/c safety issue [how to capture this idea]
 - PI expertise make a difference in inclusion/exclusion of MCC? (Clinician = more likely?)
 - Consider how MCC are reported (self-report, medical record extracted/confirmed)

WENDY DEMARK-WAHNEFRIED

- Specific Comments (re: preliminary results)
 - Included Studies
 - Overall study characteristics → include: sample characteristics (i.e. if the study was amply powered); the duration of the trial; delivery of intervention (e.g. face-to-face, other, etc)
 - Patient Eligibility and Selection
 - Participant screening → consider the fact that flow chart info etc missing from primary outcomes paper, so may need to check methods paper to find it
 - Additional Variables for Stratification

- Quality of study → blinding of outcome data can also include objective data (e.g. accelerometer data)

AIMEE JAMES

- Specific Comments (re: preliminary results)
 - Patient Eligibility and Selection
 - Exclusion criteria
 - Include cognitive limitations in mental illness?
 - Make it clear what trials are excluding for “behavioral factors” (e.g. diabetes trial that excludes smokers, not a smoking cessation trial the requires everyone to be smokers)
 - Recommend keeping analysis of trials using upper bound of age as exclusion criteria
 - Participant screening → organize presence of flow chart, specific # MCC exclusion, specific condition exclusion **by time**
 - Outcomes
 - Subgroup analysis → does this include if they “control” for it in the model?
 - Additional Variables for Stratification
 - Funding source → non-industry: differentiate between peer-reviewed (e.g. NIH, foundation) and not peer-reviewed (e.g. internal funding)

GARY BENNETT

- Specific Comments (re: preliminary results)
 - Included Studies
 - Overall study characteristics → consider trials that are strictly behavioral w/o attention to condition & consider how to handle trials that include intervention components directed to multiple behaviors (e.g. trials where complementary behaviors are mentioned, but they aren’t the focus)
 - Patient Eligibility and Selection
 - Exclusion criteria → consideration of how specific conditions are identified
 - Consideration of how specific conditions are identified (confirmed)
 - Other conditions: pregnancy, nursing, intentions to become pregnant
 - Study Participants
 - % of trials reporting MCC details → addressing metabolic syndrome?
 - MCC prevalence → some studies may use “count” system instead of naming conditions (e.g. 1 CC, 2 CC)
 - Additional Variables for Stratification
 - Stratification → what about setting? Including feeding trials?